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In medicine, one size does not fit all. Population differences in response, 
including adverse drug reactions (ADRs) are associated with commonly 
prescribed drugs, ranging from anticancers to hormone therapies. Genetic 
diversity in the form of Single Nucleotide Polymorphisms (SNPs) has been 
reported to play a role in this phenomenon. This thesis focuses on identifying 
SNPs that are extremely population differentiated and seeks to utilize the 
genes that carry these SNPs for profiling population differentiation of drug 
response. 
Initially, I evaluated the role of coding SNPs in a multidrug resistance protein, 
the ABCB1. The potential effect of coding SNPs to the homolog 3D structure 
of ABCB1 was accessed based on residue location and conservation status. 
Nonetheless, as ABCB1 is not the only protein that plays a role in drug 
response, I then expanded the study to 750 drug-response genes that are linked 
to 41 conventional drug pharmacokinetic or pharmacodynamic pathways. The 
architecture of SNPs in these genes was elucidated and it was discovered that 
there is an abundant presence of both coding and non-coding genic SNPs. The 
latter are relatively less studied and can potentially affect gene expression, 
RNA structure or stability. Moreover, compared to coding SNPs, more of 
these regulatory SNPs are extremely population-differentiated. Subsequently, 
the next focus was on SNPs that are extremely population differentiated. 
However, the HapMap tag-SNPs data, which totaled 1.4 million SNPs, may 
not be the best representation of all SNPs in the human genome. 
XI 
 
Therefore, using the genome-wide SNP allele frequencies from the 1000 
Genomes project, I calculated pairwise FST score of 23 million SNPs. Here, 
the main focus was to identify top chromosome differentiated SNPs (tcdSNP) 
in addition to the tcdGenes containing these SNPs. Many pathways that are 
found to be enriched by tcdGenes include those that are connected with highly 
variable phenotypes, such as the olfactory transduction, antigen presentation, 
and immune system-related pathways. 
This genome-wide population genetic differentiation data was then integrated 
with an expanded collection of drug-response genes that are originated from 
four major pharmacogenomics databases. Gene sets information was available 
for a total of 1,151 drugs that are approved by the US Food and Drug 
Administration. Subsequently, tcdGene enrichment analysis with this vast 
collection of drug-response genes was conducted. With this approach, I 
identified drug clusters that are associated with strong population genetic 
differentiation profile between African and other populations, in addition to 
those that are differentiated between the East Asian and European populations. 
Whilst the former is dominated by drugs that are associated with the musculo-
skeletal system anatomical group, the latter cluster is mostly occupied by 
nervous system drugs, including psycholeptics. 
Finally, the vast knowledge that is generated in this thesis is significant as it 
can be utilized for the development of drug population-genetic profiling, 
which can be useful for early prevention of ADR. The novel approach 
employed in this thesis can be replicated in drug clinical trial. This 
information is stored in an SQL database and publicly made available through 
the PharmaSNP web resource that is accessible at http://bit.ly/pharma-snp. 
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Chapter 1. General Introduction 
 
Part of this chapter is adapted from  
Maulana Bachtiar and Caroline G. L. Lee, Current Genetic Medicine Report, 
2013, 1(3):162-170 
This thesis focuses on the study of human genetics diversity that could potentially 
affect population differences in drug response. Drug response in this case, is the 
outcome, whether positive or negative, that an individual exhibits after consuming 
medicine prescribed by a doctor. 
1.1 One size does not fit all 
 
Human diversity, particularly one that arises as a result of genetic differences, is 
manifested at various levels. This includes differential response to xenobiotic or 
external compounds such as drugs, which are not inherently produced and found 
in the human body. The long term vision for developing a personalized approach 
to medicine is to tailor drug prescription according to individual’s need so as to 
optimize outcome and prevent potential adverse drug reaction (ADR) [1]. 
ADRs cases are not uncommon and do not benefit the patient as not only do they 
worsen the clinical outcome, frequent ADR occurrence can translate to higher 
hospitalization cost and is a public health concern [2-5]. In the United States, 




Moreover, variation in the susceptibility of ADR in different populations can also 
affect drug development. At often times, clinical trial is performed in a country 
that has a different population profile to the final destination of the drug. These 
trials may employ subjects who have significant differences in genetic 
background and cultural behavior. Due to such approach in drug testing, it is 
therefore unsurprising to observe unexpected ADR cases of drug that was 
observed to be highly effective during trials. Ideally, a drug should always be 
initially tested in individuals who have similar background to the intended 
population where it is going to be marketed. This pushes for a greater 
involvement of a more diverse clinical trial subjects. However, most of the 
clinical trials are still conducted in developed economies, despite a growing 
number of clinical trials that are now organized in developing countries [6, 7]. 
One reason for this uneven global distribution in drug trial is the extraordinary 
cost that is associated with organizing clinical trials in multiple geographic 
regions. As complexity arises, so does the cost in developing the drug, which will 
have a direct impact to the end consumers, the patients. Therefore, diversity in 
population profiles can be one of the biggest hurdles in the production of effective 
medicine [8]. However, if a drug trial is conducted only with one population few 
could foresee the potential occurrence of side effects in another population. At the 
same time, there is also a concern that when an ADR is observed in one or more 
populations within a complex trial, more potentially effective drug could be 
terminated in the early phase of development. 
One potential solution is to identify the population that is more susceptible to 
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ADR early in the drug development phase. Therefore, ADR can be prevented 
even during clinical trials. In this regard, drug developers would also be saved 
from potential problem that would have surfaced in the early phase of a drug 
development pipeline such as those that are associated with “bad drug” 
candidates. At the same time, they can also expect to expedite approval of 
potential block bluster drugs that will be beneficial for the correct audience. 
Hence in drug development, the big question is: what if we can prioritize trials in 
subject population that are identified to be less susceptible to drug toxicity? And 
what if we can identify drugs that are more population-specific, hence when it 
induces toxicity in one population; we do not have to recall the drug for the other 
population? What is the best way to identify the factor that induces population 
differences in the first place? 
Motivated by these questions, my PhD thesis focuses on addressing population 
differences of drug response and attempted to attack the two above challenges 
using novel pharmacogenomic approaches, for a better medicine. The method that 
is developed throughout the course of this study is aimed to serve as a reliable 
proxy in determining the important factors that account for population differences 
in treatment response. 
1.2 Population Differentiation and Drug Response 
 
Medicine is the epicenter of healthcare. However, population differences in the 
way patients’ response to medication could complicate treatment and elevate the 
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cost associated with healthcare. This problem becomes more significant in 
especially two scenarios. The first is in countries with a strong degree of 
demographic background variation, such as in places that are populated by 
multiracial demographics carrying significant genetic and lifestyle differences. In 
this case, no same treatment can be applied to all individuals and tailoring of dug 
dosage may become a necessity. The other scenario involved drugs that had 
passed clinical trials in country(s) that has a different population profile to the 
intended market.  
Part of the reason for treatment complication is due to unforeseen ADR 
occurrence, as a result of variation in a drug response profile in different 
individuals. These inter-individual differences in drug response are often 
manifested at the population level, where it has been frequently reported that the 
outcome of treatment could be manifested differently in individuals belonging to 
different race or population background [9-12]. It is a common phenomenon and 
can significantly affect the outcome of treatment including those reported in 
anticancers, anticoagulation and beta-blockers [13-16]. Population differences in 
ADR is especially significant if such cases can lead to fatal consequences [17], 
hence it is important to be able to identify the group of patients who are more 
susceptible to this negative side effect of a drug. 
Furthermore, during literature preview, it can also be observed that there are great 
number of studies reporting population differences between the European and 
other populations, particularly Asians or Africans (Fig. 1.1). It is believed that 
there are more studies that were conducted in these population groups, owing to 
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the possibly bigger budget and accessibility of clinical trials information in these 
populations. In the course of this thesis, I had the opportunity to review some of 
the most highly-studied drugs that are associated with population differences, 





Figure 1.1 Circular plot showing population differences in response to commonly 
used drugs. The drugs shown are reported to have a different response profile in two or 
more populations. A drug response difference is shown by ribbon joining at least two 
populations. The number of population differences that are involved in a drug response 
profile can be judged by the thickness of the root of the ribbon. Drugs that are reported to 
have only two population differences are shown by thin black/grey lines. References are 
marked by the reference number as published in Maulana Bachtiar and Caroline G. L. 
Lee, Current Genetic Medicine Report, 2013, 1(3):162-170. 
  
Frequently cited to have differences in drug response in different populations, 5-
Fluorouracil (5-FU) is a widely-prescribed chemotherapy in the treatment of 
various cancers. 5-FU, which is a fluoropyrimidine-based drug that is known to be 
associated with hematologic toxicities such as leukopenia and anemia, has been 
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reported to have outcome differences between Europeans and either African 
Americans or East Asians [18-21]. The East Asians were also reported to have a 
different response compared to the Latino or African descents [19]. Individuals 
with a deficient dihydropyrimidine dehydrogenase (DPD/DPYD) were reported to 
be more susceptible to 5-FU-induced hematologic toxicities [22]. 
Another popular drug that exerts population differences in response is warfarin, 
an anticoagulant used to prevent thrombosis and embolism. Patients who are more 
susceptible to ADR are at higher risk of bleeding. Warfarin treatment is best done 
through proper optimization of dosage so that efficacy and patient’s safety can be 
ensured. Furthermore, variation in warfarin response is observed in patients of 
different ethnicities and has been reported albeit not much appreciated [11]. East 
Asians and either European or Latino populations are known to have significant 
difference in optimal warfarin dose, in addition to what is observed between the 
Europeans and either Latinos or Africans [13] (Fig. 1.1, purple ribbons). 
Besides 5-FU and Warfarin, another ‘drug’ that exhibits population difference in 
response is nicotine. Perez-Stable et al argue that ethnic differences in nicotine 
response could have accounted for the observation of ethnic differences in 
tobacco-related disease [23]. The body eliminates nicotine by initially 
metabolizing it into cotinine. Genes that are involved in this metabolism pathway 
is known to carry genetic variations, which is a possible factor of addiction to 
nicotine and tobacco-associated diseases [24]. It has been reported that East 
Asians and Europeans or Africans, in addition to those between the African and 
Latino populations, do have significant variation in their serum cotinine levels 
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[24, 25] (Fig. 1.1, red ribbons). 
Reports on ethnic or population differences in the response of other drugs such as 
codeine, vincristine and b-blockers were also observed, particularly between 
European and the Asian or African populations. Nonetheless, these reports that 
are briefly reviewed in this thesis probably over-represent those cases that are 
seen in developed countries while not highlighting the cases in developing 
economies. Lastly, Appendix 6 provides a non-exhaustive list of studies 
describing differential response to various drug treaments.  
1.3 Genetic Basis behind Population Differences in Drug 
Response 
 
Based on the assumption that any two individuals from the same population has a 
higher chance to be more similar than those from different population 
backgrounds, ‘population differences’ can been used as a proxy of 
‘interindividual differences’. As introduced above, population differentiation is a 
phenomenon that shall not be neglected in medicine as it is a factor that can 
significantly affect outcome. Ideally, no two patients are to be given equal 
treatment as they may respond differently. However economically, individual 
tailoring of treatments is extremely expensive and requires extensive investigation 
on patient’s background hence it is not a standard practice today. 
Drug or xenobiotic response is highly influenced by a number of factors which 
can be broadly categorized into inherent (which includes but is not restricted to 
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genetic predisposition, disease status, age, and weight) and external (such as 
environment condition, socioeconomic status, and education level) factors. Out of 
all these variables that may affect a person’s response to medication, the genetic 
factor is the most prevalent variable. Hypothetically, with the exception of 
somatic mutations, most if not all of our genetic material will stay the same from 
birth to adulthood. For this reason, studying the genetic components that are 
affecting drug response is the most feasible and is the primary driving force of 
pharmacogenomics, the field of study involving genes and gene variants that are 
important in drug-response pathways. 
1.3.1 Single Nucleotide Polymorphisms (SNPs) 
 
Single Nucleotide Polymorphisms (SNPs) are the most abundant form of genetic 
variants in humans, with up to 38 million validated reference SNPs that are 
recorded in the dbSNP (build 137) database [26]. To be classified as SNP, a 
genetic mutation has to be observed in a relatively high frequency (usually more 
than one percent in a particular population). The frequency elevation of these 
mutations is most probably due to natural pressures that had positively selected 
these mutations due to them producing survival or reproductive advantages to the 
organism. 
SNPs residing within genes could potentially affect gene function, depending on 
the location of the sequence variation. Coding region SNPs, particularly those that 
are associated with substitution in a protein amino acid sequence, could 
potentially pose a functional effect to a protein structure or post-translational 
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modification activity [27, 28] (Fig. 1.2). Moreover, when residing in transcription 
binding site, miRNA binding site, or exon/intron splicing regulatory site within 
gene regulatory regions, SNPs could pose functional changes to gene expression 
[29, 30]. 
 
Figure 1.2 SNPs have potential implication for gene function. Those residing in 
regulatory region such as transcription factor binding site (TFBS), miRNA binding site 
(miRBS), intronic splicing regulatory elements (ISRE), exonic splicing enhancer/silencer 
(ESE/S), may affect gene expression. On the other hand, coding SNPs may affect protein 
structure or post-translational modification (PTM), which may be important to protein 
function. 
 
Due to its abundance, SNPs play a significant role in the manifestation of 
population diversity in the human genome. Furthermore, the different 
environmental factors across various geographic regions would have acted as 
selection force throughout human migration and evolution, which could 
negatively or positively select SNPs that are associated with disadvantegous or 
advantageous traits, respectively [39]. Theoretically, these selection forces leave a 
“genomic signature” that can be measured by studying SNPs differentiation 
5’ 3’
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pattern in the genome [39]. One way to estimate genomic differentiation between 
populations is by measuring genetic diversity. This thesis utilizes FST statistics in 
estimating population differentiation, which is a measurement that takes into 
account the reduction of heterozygosity in two or more sub-populations, 
compared to the total population heterozygosity level [40]. 
Traditionally, SNP frequencies were obtained by genotyping a targeted DNA 
region that has been previously sequenced. If one is to conduct this over the entire 
genome, not only that it will be a very slow process, the approach could only give 
us a small amount of data that does not represent the overall big picture of 
variants in the genome. Moreover, this candidate-based approach required one to 
develop a prior hypothesis in localizing the region where the SNP resides, hence 
limiting the possibility of finding SNPs that reside in genomic regions that were 
thought to be of less significance. The advent of high thoroughput genotyping 
SNP technology had also enabled scientists to genotype many individuals over a 
relatively shorter period. It is for this reason that the HapMap project was 
initiated, in which a selection of representative ‘tag’ SNPs were genotyped to 
create a haplotype map of the genome [31, 32]. This created a new foundation for 
pharmacogenomics, which can particularly serve as a referral point in association 
studies that involve diverse population backgrounds. 
1.3.2 Pharmacogenomics 
 
Pharmacogenomics is an extension of pharmacogenetics. Whilst the lalter usually 
refers to a study involving a select few SNPs or genes, pharmacogenomics 
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employed a more genome-wide perspective in identifying genetic markers that are 
important in drug response.  In addition, since drug response is highly affected by 
group genes in the pharmacokinetic (PK) and pharmacodynamic (PD) pathways 
(Fig. 1.3), identifying the genes in these pathways would hypothetically give a 
good direction in pin pointing to the SNPs that can be associated with drug 
response differences.  
Following completion of the human genome sequencing, more genes were 
identified to be a component of drug-response PK and PD pathways. These genes 
range from membrane transporters, metabolizers, and drug-target genes that are 
part of a drug PK and PD process. Furthermore, next-generation sequencing 
technology had propelled genomic studies into a higher level. Genomic variants 
including SNPs can be identified by comparison of individuals’ genomic 
sequence, even without the initial mapping of these variants into gene regions 
[33]. Despite its relatively higher initial cost, this technology allows one to start 
with a hypothesis-free approach of identifying SNPs that could be population-
differentiated. These are the SNPs that have significantly different distribution of 




Figure 1.3 Genes in the Pharmacokinetic (A) and Pharmacodynamic (B) pathways 
that are associated with Warfarin. Genes are represented inside oval shape containers 
whilst drugs and drug metabolites are contained inside purple squares. Drug of significant 
interest is marked with a star. Biological intermediates are contained within green colour 
capsule boxes. In this diagram, a thick arrow indicates a primary route, whereas a thin 
arrow represents a more generic route and the dashed arrow indicates a secondary route. 
A red line indicates a repression phenomenon. This image is reproduced from 
PharmGKB [34].  
 
In 2007, the US Food and Drugs Administration decided to update the labeling for 
the anticoagulant, warfarin. The new label would put dosing recomendation based 
on the genotype of SNPs residing in the VKORC1 and CYP2C9 genes (Fig. 1.3), 
which are associated with warfarin pharmacokinetics [13, 27]. Warfarin is one of 
the best examples of a successful implementation of pharmacogenomics in the 
clinics. 
Besides the VKORC1 and CYP2C9, several other well-reported pharmacogenes 
that are potentially associated with clinical impact include the ABCB1, CYP3A4, 
DPYD, G6PD, and SLCO1B1 [34]. A more exhaustive list of well-known 
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pharmacogenomic associations is accessible at the PharmGKB website 
(www.pharmgkb.org/search/knownPairs.action).  
Nonetheles, translational application of pharmacogenomics in most if not all 
drugs are still far away from realization due to the presence of multifactorial 
components. Currently, one challenge is to find the SNPs that are not only 
associated with population differences, but also the ones affect gene functions and 
drug response. Limitations exist particularly when it comes to applying newly 
discovered pharmacogenomics knowledge to clinics, which is particularly 
associated with the complexity of drug reponse phenotypes in general. 
The vision is to be able to use these genomic variants as predictors to an 
individual’s drug response hence helping us to identify patients who are more 
susceptible to ADRs. Going forward, pharmacogenomics studies would generally 
aim to translate more newly discovered knowledge into clinical application. In 
this thesis, for the purpose of consistency, I will adopt the term 
‘pharmacogenomics’ when referring to any study that involves the genetic basis 
of drug response, regardless of its genomic scale. 
1.4 The Era of Big Data 
 
Today, not only has advancement in next-generation sequencing technology 
provided an abundant wealth of new knowledge, it also poses a new challenge on 
how to systematically catalog, mine and more importantly, study the massive 
amount of data. In the past years, there are efforts in having these data accessible 
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to the general public. Several early initiatives have embarked to provide 
population genetics data, ranging from one that genotyped SNPs in specialized 
candidate genes to one that utilized the tag-SNP approach but in a different set of 
populations. 
The International HapMap Project initially provided genotype data of individuals 
from four representative populations: CEU (Caucasian from Utah, USA), CHB 
(Han Chinese from Beijing, China), JPT (Japanese from Tokyo, Japan), and YRI 
(Yoruban from Ibadan, Nigeria) [35]. It then expanded into genotyping seven 
additional populations, covering 1.4 million SNPs that were genotyped using the 
‘tag’ or regional representative SNP coverage method [36]. As it is not feasible to 
genotype all individuals at one go, the HapMap approach of genotyping 
individual samples from representative of the diverse world populations was seen 
to be a more viable way in obtaining reference allele frequencies. Indeed, the 
HapMap is a good source of reference for allele frequency data. Moreover, it 
inspired the trend of studying global population genetics pattern and its 
relationship with human migration phenomenon. 
The Environmental Genome Project made available the genotype data of SNPs 
residing in genes that ‘interact’ with the environment. These genes have role in 
the DNA repair, metabolism, oxidative stress, apoptosis and several additional 
pathways that are important in the immune system [37]. On the other hand, the 
Singapore Genome Variation Project provided the genotype data of one million 
SNPs from representative individuals who originated from three different racial 
groups that are defined in Singapore: the Chinese, Indian and Malay [38]. 
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These initial efforts however, are faced by several limitations, including the 
unavailability of genome-wide data that can allow one to gauge the ‘true strength’ 
of population differentiation in a drug response gene, compared to other 
background genes. Moreover, the tag SNPs approach that are adopted by the 
HapMap project could have had various ‘genomic blind spots’ that are attributed 
for the lack of information that can represent many regions of the human genome.  
Nonetheless, the advent of next-generation sequencing technology, which allowed 
high-throughput sequencing, greatly expanded the coverage to a whole-genome 
level, in addition to mining sequence information from more individuals. By 
capitalizing this high-throughput platform, the 1000 Genomes Project was 
empowered to produce the whole-genome sequence data of 1,092 individuals who 
originated from the same population groups as those of the HapMap project [33]. 
Phase 1 of the project has resulted in the identification of 38 million SNPs in 
addition to insertion-deletions and structural variants that could have not been 
previously identified using the tag-SNP approach [33]. These SNPs, which have 
been deposited in dbSNP, are extremely useful in pharmacogenomics, in which it 
is now possible to identify the whole-genome SNPs that are population-







1.5 General Hypothesis and Aim 
 
My work was conducted based on the notion that population-differentiated SNPs 
are one of the determinants of population differences in drug response. This 
knowledge can serve to empower tomorrow’s medicine, particularly in advancing 
the technology that supports personalized therapy. The general hypothesis is that 
these SNPs could affect drug response variation in individuals originating from 
different background. Having said that however, this thesis does not come with an 
ideal promise that by the end of the last chapter, there will be a direct application 
of personalized medicine. Instead, I aimed to accumulate, integrate, elucidate, and 
package this novel genomic information into an accessible format for determining 
drugs population genetic differentiation profile. 
1.6 The Thesis Structure 
 
This thesis is divided into two broad categories. The initial part, which is covered 
by chapter 2 and 3, presented an attempt to understand the pattern of SNPs in 
drug-response genes. In chapter 2, I presented a detailed study of SNPs that affect 
the ABCB1 protein, an evolutionary conserved yet highly polymorphic membrane 
transporter that is associated with multidrug resistance phenomenon. Because 
drug response is affected by multiple genes, in chapter 3, I then studied the 
general architecture of SNPs in 715 genes important for drug response, which not 
only covered coding SNPs, but also SNPs residing in non-coding regions.  
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The raw data in chapter 3 was derived from the HapMap, which is based on 
microarray technology. As next-generation sequencing technology emerged, I 
then attempted to perform a whole genome calculation of population 
differentiation scores to identify SNPs that could possibly be significant in 
manifesting population differences in drug response. This is the focus of chapter 
4, where by utilizing data from the 1000 Genomes project, SNPs that are 
population-differentiated were identified. With this result, in chapter 5, I then 
specifically utilized the population-differentiated SNPs to study population 
genetic differentiation pattern of more than a thousand drugs. This ‘PharmaSNP’ 
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Differential response in drug therapies is a common clinical phenomenon with 
human genetic predisposition contributing as a major factor [1]. Single 
Nucleotide Polymorphisms (SNPs) in genes responsible for drug 
pharmacokinetics (PK) or pharmacodynamics (PD) activity are associated 
with variation in drug metabolism, transport and efficacy [2, 3]. Moreover, it 
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has been shown that SNPs could potentially exert certain functional changes to 
drug-response genes [4-6]. The potential effect to which SNPs could implicate 
relies on where they are located in genes [7]. 
This chapter focuses on studying coding SNPs in the ABCB1 multidrug 
resistance protein, a membrane transporter that plays a key role in drug 
pharmacokinetics. Coding SNPs can be categorized into non-synonymous 
(amino acid substituting) and synonymous (non amino acid substituting). The 
potential functional effect of non-synonymous SNPs in ABCB1 depends on the 
relative positioning of the affected amino acids. In this chapter, based on a 
mouse homolog crystal structure, I constructed a 3D protein model that allows 
investigation of these coding SNPs in the ABCB1 protein based on two 
perspectives: amino acid residue location and evolutionary conservation. This 
work was conducted in collaboration with Dr. Steven J. Wolf.  
 
2.2 ABCB1 is involved in multidrug resistance and altered 
drug pharmacokinetics 
 
The ATP Binding Cassette superfamily member protein, ABCB1 (P-
glycoprotein or P-gp / MDR1), has a primary role in the unidirectional 
transport of drugs from the cytoplasm to the extra cellular environment [8]. 
Due to its involvement in resistance to drugs used in treatment of cancer, heart 
disease, AIDS, and epilepsy, this trans-membrane protein is widely referred as 
a multidrug resistance (MDR) protein [9, 10]. It is a phenotype that is often 
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associated with variation in the level of drug efficacy, adverse drug reaction 
(ADR) or alteration in drug-to-drug interaction [11, 12]. 
In drug pharmacokinetic (PK) and drug resistance phenomena, the role of this 
MDR protein is complex as it is often affected by other variables that may 
affect the expression and localization of the ABCB1 protein. For instance, the 
presence of other protein such as the pregnane-X-receptor (PXR), in addition 
to an ABCB1 upregulation, may alter a drug PK [13]. Other studies also 
reported that the family of ABC proteins can be found across the membrane of 
organelles such as lysosomes or endosomes, where drug transport takes place 
for further drug processing within these organelles [14, 15].   
Genetic polymorphisms in drug transporter can potentially affect the drug PK, 
with various studies showing evidence of the impact on drug concentration 
variation in the cerebrospinal fluid or intracellular compartment [16]. 
Furthermore, ABCB1 protein structure and function have been shown to be 
important in its role in multidrug resistance [8, 17]. This role is well 
established since 1976, when the protein was first discovered [18]. Now, 
following the release of protein crystal structure of the closest ABCB1 
mammalian homolog, the mouse Abcb1a [19], the role of genetic 
polymorphisms in altering the protein function can be established further. 
There is great structural and chemical diversity of substrates that are subject to 
ABCB1 protein activity. They are usually small molecules that bind the 
ABCB1 substrate binding region, which are found on the internal surface of 
the protein. This region is a large open cavity that is surrounded by 12 
transmembrane domains (TMDs) and is integrated to the lipid-based cell 
membrane [8, 19].  
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These TMDs are connected with the nucleotide binding domains, where 
hydrolysis of ATP takes place in the cytoplasmic portion of the protein [20, 
21]. ATP binding and hydrolysis in the ABCB1 protein are done at the region 
containing conserved motifs such as the Walker A, Walker B and Signature C 
motifs. In addition, the TMD also accomodates a number of conserved loops, 
including the A-loop, D-loop, H-loop, and Q-loop [22-25] . Most of the ABC 
protein family and homologs are known to carry the same motifs, which is 
proposed to be important in binding ATP when the NBD domains dimerize 
[26]. This dimerization would eventually change ABCB1 conformation, 
resulting in substrate dissociation and efflux from the protein [26, 27]. 
Because ABCB1 is a very active transporter that handles various substrates 
[25], genetic polymorphisms can incur a potentially significant consequence. 
These polymorphisms can arise in the form of amino  acid change or alteration 
in gene expression. This will be more prominent where the sequence changes 
take place at the sites where substrate bind or at regions that are highly 
conserved, including the Nucleotide Binding Domain (NBD), which can affect 
ABCB1 function including drug efflux or small molecules pharmacokinetics. 
A comprehensive literature review summary on the involvement of ABCB1 






2.3 ABCB1 SNPs as potential contributor to variation in 
individual drug response 
 
There has been much interest surrounding the role of genetic variation in the 
ABCB1 gene in altering protein expression and function. Single Nucleotide 
Polymorphisms (SNPs) is the most common type of genetic variation. As 
introduced in the previous chapter, these SNPs can potentially affect gene 
function depending on the location where they reside. In this chapter, the focus 
is on ABCB1 coding region SNPs, which can alter the protein structure in the 
case of non-synonymous SNPs. On the other hand, non amino acid 
substituting SNP can affect an mRNA sequence, in addition to affecting the 
stability and structure of a RNA transcript. How SNPs evolved, particularly in 
a way that is relevant to ABC proteins, have previously been discussed in 
literature [28, 29]. 
SNPs influence can be apparent in the occurrence of adverse drug reaction, 
drug efficacy difference or multidrug resistance. Using the high resolution 
crystal structure of a mammalian homolog, the Abcb1a, these SNPs can now 
be mapped to the 3D structure, allowing better observation of the location of 
the residue, in addition to conserved regions information and the residues 
within close vicinities, which may also be coding SNPs. Some of these SNPs 
are also implicated with drug pharmacokinetics. The analysis in this chapter is 





2.4 Polymorphic ABCB1 is also well conserved protein 
 
The ABCB1 protein is well conserved and is 87% identical to the protein 
sequence of the mouse Abcb1a homolog (Figure 2.1). In order to perform a 
multiple sequence alignment, 11 homologous ABCB1 sequences from 
multiple organisms were obtained from the NCBI Homologene database 
(Table 2.1). Using the ClustalW algorithm, despite its half-transporter status in 
unicellular organism (Sav1866 and MsbaA), it can be observed that the 
sequence of this protein is conserved from E. coli to humans (Fig. 2.2). Here, 
the prefix ‘E’ refers to the exon location of a SNP in the ABCB1 gene 
sequence. Based on the dbSNP database (Build 131), out of 66 coding SNPs in 
total, 24 SNPs are categorized as synonymous (sSNPs – ‘s’ in the Figures and 
Tables), whereas 42 SNPs are considered to be nonsynonymous (nsSNPs – ‘ns’ 
in the Figures and Tables). These ABCB1 coding polymorphisms are 
summarized in Table 2.2 and Table 2.3. When comparing the human and 
mouse protein sequences, it can be observed that all ABCB1 sSNPs residues 
are conserved (Shaded blue in Table 2.2, Fig. 2.2). Furthermore in 11 
organisms, five residues corresponding to sSNPs are found to be conserved. 
These are R442, L554, T558, S565 and I598; which correspond to #s8, #s11, 
#s12, #13 and #s14 respectively in Fig. 2.3C. 
In addition, out of 42 ABCB1 nsSNPs, there are 37 that can be mapped to the 
residues in the mouse crystal structure, which is in accordance with the pair-
wise sequence alignment that was performed with ClustalW (Table 2.2, Fig. 
2.1) [30, 31]. Based on this alignment, it was observed that out of 37 nsSNPs, 
the major amino acid alleles of 31 nsSNPs or 83.7%, are similar between 
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mouse and human (Table 2.2 and Fig. 2.2). In 11 organisms that were 
examined, only two residues from this total of 37 nsSNPs are conserved, 
whilst 12 residues are observed to be similar in 7 or more organisms (Table 
2.2). 
Globally, most of the coding SNPs are perceived to be located in the ABCB1 
NBDs, are located in close vicinity to conserved regions such as the Walker A, 
Walker B and signature motif C (Fig. 2.2, Fig. 2.3B and Fig. 2.3C). One 
nsSNP, E26/3222A>C or the C1074W (ns#27 in Fig. 2.3B) is located inside 
the Walker A motif at the C-terminal NBD (Table 2.2, Fig. 2.2). For every 100 
residues, there are around 6.2 SNPs in the NDBs, whereas in the TMDs, the 
number is almost half, which is 3.7 SNPs. Furthermore, out of a total of 14 
SNPs that are located outside of the NBDs, there are five that are found at the 
protein external surface, while three SNPs are found within the internal 






Table 2.1 ABCB1 homologous proteins. 
  






1 ABCB1 (Homo sapiens) 1280 NP_000918.2 
2 ABCB1 (Canis lupus familiaris) 1280 NP_001003215.1 
3 Abcb1a (Mus musculus) 1276 NP_035206.2 
4 ABCB1 (Gallus gallus) 1288 NP_990225.1 
5 pgp-1  (Caenorhabditis elegans) 1321 NP_502413.1 
6 Mdr50 (Drosophila melanogaster) 1313 NP_523740.3 
7 PGP18 (Arabidopsis thaliana) 1225 NP_189480.1 
8 pmd1 (Schizosaccharomyces pombe) 1362 NP_588265.1 
9 Sav1866 (Staphylococcus aureus) 578 NP_372390   
10 MsbA (Escherichia coli) 582 NP_415434 
11 PFMDR1 (Plasmodium falciparum) 1419 XP_001351787.1 
 
 
Figure 2.1 Pairwise sequence alignment of the ABCB1 human and mouse 
homologous protein sequences. The SNP numbering is identical to the ones 
used in Table 2.2 . Red and blue indicate position of nonsynonymous and 
synonymous SNPs, respectively. The purple boxes indicate residues 























Figure 2.2 (next page): Homology map derived from the multiple 
sequence alignment of 11 ABCB1 homologs. Black bar height indicates the 
number of identical residues between the 11 homologous sequences at the 
respective amino acid site (between 11 and 0 identical residues may occur). 
sSNPs and nsSNPs whose corresponding residues can be mapped into the 
mouse protein are represented with blue and red dots,  respectively. The C-
terminal portion of the alignment where the bacterial half transporter 
sequences of Sav1866 and MsbA were repeated to produce a full sequence is 
marked with an arrow. This map also depicts the putative P-gp secondary 
structure shown in a linear chain format modified from the Protein Database 
(PDB). Conserved regions essential for protein function are highlighted both 







Table 2.2 Genetic conservation of amino acids corresponding to ABCB1 coding region SNPs. 
 
1 - rs28381804 E3/49T>C (F17L) F17 W16 S16 Y17 Y35 F39 - A42 - - G11 - -
2 - rs41304191 E3/55C>T (L19L) L19 M18 M18 I19 G37 P41 - E44 - - L13 - -
3 - rs76199854 E3/57G>A (L19L) L19 M18 M18 I19 G37 P41 - E44 - - L13 - -
4 - rs9282564 E3/61A>G  (N21D) N21 K20 K20 N21 N39 K43 - H46 - - I15 - -
5 ns1 rs1202183 E5/131A>G (N44S) N44 N43 G43 S55 T70 T81 D16 D88 K10 A21 P50 18.2 38.7
6 ns2 rs41315618 E5/178A>C (I60L) I60 I59 I59 A71 I86 A97 G32 G104 K26 N37 L66 27.3 46.6
7 ns3 rs9282565 E5/239C>A (A80E) A80 A79 A79 V91 I106 I117 G52 Y124 N46 G57 N86 36.4 29.1
8 - rs35810889 E5/266C>T (M89T) - M89 F89 S85 T96 I112 - - - - - - - -
9 ns4 rs61607171 E7/431T>C (I144T) TM2 I144 I145 I140 V152 N168 I176 A98 A172 L93 V97 L124 36.4 40.9
10 ns5 rs61122623 E7/502G>A (V168I) V168 V169 V164 A176 S192 S200 T122 A196 V117 T121 G148 54.5 46.2
11 s1 rs1128500 E8/540C>T (S180S) S180 S181 S176 S188 E204 S212 L136 N208 E129 E133 E160 27.3 42.0
12 ns6 rs60419673  E8/548A>G (N183S) N183 N184 N179 N191 K207 E215 Q139 Q211 K132 A136 S163 27.3 39.9
13 ns7 rs1128501 E8/554G>T (G185V) G185 G186 G181 G193 G209 G217 F141 G213 F134 S138 G165 45.5 40.9
14 s2 rs1128502 E8/555A>T (G185G) G185 G186 G181 G193 G209 G217 F141 G213 F134 S138 G165 45.5 40.9
15 s3 rs2235022 E9/729A>G (E243E) E243 E244 E239 E251 E267 E275 I199 Q271 R192 M196 S223 18.2 33.3
16 s4 rs28381867 E9/738G>A (A246A) A246 A247 A242 A254 R270 M278 E202 V274 A195 T199 Y226 9.1 34.5
17 ns8 rs36008564 E9/781A>G (I261V) C-NBD (Internal) I261 I262 I257 V267 I285 I293 V217 I289 I210 H214 I241 36.4 50.3
18 s5 rs80153317 E10/879T>C (I293I) TM5 I293 I294 I289 I301 L317 M325 L249 I321 R242 S246 F273 18.2 36.3
19 ns9 rs2229109 E12/1199G>A (S400N) N-NBD (Internal) S400 S401 S396 N408 T424 Q439 T355 V428 Q348 T350 H386 18.2 60.7













































Table 2.2. Genetic conservation of amino acids corresponding to ABCB1 coding region SNPs (con’t). 
  
 
21 s7 rs35068177 E13/1308A>G (T436T) T436 T437 T432 T44 I460 C475 V391 I464 L383 I385 I422 54.5 64.6
22 s8 rs41311775 E15/1326G>A (R442R) R442 R443 R438 R450 R466 R481 R397 R470 R389 R391 R428 100.0 54.5
23 s9 rs35633772 E15/1617C>T (I539I) I539 I540 I535 I547 I563 I578 I494 I576 L486 I489 I571 90.9 65.8
24 s10 rs60247941 E15/1632C>T (A544A) A544 A545 A540 A552 A568 A583 A499 A581 I491 A494 A576 63.6 65.1
25 s11 rs2235012 E15/1662G>C (L554L) L554 L555 L550 L562 L578 L593 L509 L591 L501 L504 L586 100.0 73.6
26 s12 rs56871767 E15/1674G>A (T558T) T558 T559 T554 T566 T582 T597 T513 T595 T505 T508 T590 100.0 78.7
27 s13 rs59697741 E15/1695C>T (S565S) S565 S566 S561 S573 S589 S604 S520 S602 S512 S515 S597 100.0 75.4
28 ns10 rs28381902 E15/1696G>A (E566K) E566 E567 E562 E574 E590 E605 E521 E603 E513 E516 E598 100.0 76.6
29 ns11 rs28381914 E16/1777C>T (R593C) R593 R594 R589 R601 R617 R632 R548 R630 T540 E543 R627 54.5 67.3
30 ns12 rs56107566 E16/1778G>A (R593H ) R593 R594 R589 R601 R617 R632 R548 R630 T540 E543 R627 54.5 67.3
31 s14 rs28381915 E16/1794C>T (I598I) I598 I599 I594 I606 I622 I637 I553 I635 I545 I548 I632 100.0 65.5
32 ns13 rs2235036 E16/1795G>A (A599T) A599 A600 A595 A607 I623 V638 C554 V636 V546 V549 F633 54.5 63.6
33 ns14 rs57001392 E16/1837G>T (D613Y) N-NBD (External) D613 D614 D609 S621 R637 Q652 E568 N650 R560 N563 D677 45.5 60.5
34 - rs35657960 E17/1985T>C (L662R) L662 L663 L658 E671 M694 K698 E615 A708 - - E736 0.0 -
35 - rs35023033 E17/2005C>T (R669C) R669 R670 R665 R678 I702 D705 S662 T715 - - N743 0.0 -
36 - rs59340265 E17/2037C>T (D679D) D679 D680 D675 N688 D712 N715 S632 N725 - - E753 9.1 -
37 ns15 rs41316450 E18/2207T>A (I736K) TM7 I736 I737 V732 I745 M779 I771 V682 I820 I37 L48 V814 72.7 36.7
38 ns16 rs77144566 E19/2281A>C (A761S) TM8 A761 V763 I757 A769 V802 I796 G706 I844 I647 G655 L836 63.6 42.1
39 ns17 rs41305517 E21/2398G>A (D800N) C-NBD (Internal) D800 D801 D796 D808 H841 D835 E745 D883 S108 P112 E875 9.1 45.4
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Table 2.2. Genetic conservation of amino acids corresponding to ABCB1 coding region SNPs (con’t). 
  
41 ns19 rs2032581 E22/2485A>G (I829V) I829 I830 T825 T837 I870 T864 V744 S912 I135 S139 L904 45.5 30.2
42 s15 rs28381966 E22/2505A>G (V835V) V835 V836 V831 L843 T876 T870 L780 T918 N141 T145 F911 45.5 33.0
43 ns20 rs28381967 E22/2506A>G (I836V) I836 I837 I832 I844 V877 I871 L781 V919 I142 V146 F911 63.6 28.5
44 ns21 rs36105130  E22/2547A>G (I849M) I849 I850 I845 I857 I890 D884 I794 L932 I155 M159 M924 81.8 44.7
45 s16 rs9282563 E22/2650C>T (L884L) L884 L885 L880 K892 V925 M919 R829 E967 R190 K194 I959 27.3 31.2
46 ns22 rs2032582 E22/2677G>T/A (S893A/T) S893 A894 S889 A901 S934 C928 S838 S976 V199 V203 P982 45.5 35.7
47 ns23 rs56849127 E25/2975G>A (S992N) S992 S993 S988 S1000 T1035 L1027 G937 F1075 V298 T302 M1081 36.4 38.4
48 ns24 rs72552784 E25/2995G>A (A999T) A999 A1000 A995 A1007 A1042 Q1034 V944 T1082 T305 Q309 E1089 27.3 36.5
49 s17 rs2235044 E26/3084G>A (P1028P) P1028 P1029 P1024 P1036 - P1063 P973 V1111 P332 V334 I1117 0.0 33.0
50 ns25 rs28401798 E26/3151C>G (P1051A) P1051 P1052 P1047 K1059 E1093 Q1086 I996 K1135 P355 P357 P1142 18.2 57.6
51 ns26 rs2707944 E26/3188G>C (G1063A) G1063 G1064 G1059 G1071 G1105 G1098 G1008 G1147 G367 G369 K1154 45.5 53.8
52 s18 rs2707943 E26/3189C>G (G1063G) G1063 G1064 G1059 G1071 G1105 G1098 G1008 G1147 G367 G369 K1154 45.5 53.8
53 ns27 rs74755520 E26/3222A>C (C1074W) C-NBD (Internal) C1074 C1075 C1070 C1082 C1116 C1109 S1019 C1158 G378 S380 S1165 63.6 67.8
54 ns28 rs57521326 E26/3262G>A (D1088N) D1088 D1089 D1084 D1096 D1130 D1123 D1033 D1172 D392 D394 D1179 100.0 53.9
55 ns29 rs41309225 E27/3295A>G (K1099E) K1099 K1100 K1095 I1107 S1141 C1134 R1044 V1183 H403 H405 I1237 18.2 38.5
56 ns30 rs55852620 E27/3320A>C (Q1107P) Q1107 Q1108 Q1103 Q1115 E1149 T1142 R1052 N1191 G411 A413 R1245 27.3 43.7
57 ns31 rs35730308 E27/3322T>C (W1108R) W1108 Q1109 W1104 Q1116 H1150 N1143 S1053 D1192 S412 S414 D1246 27.3 43.5
58 s19 rs34748655 E27/3396C>T (A1132A) C-NBD (Internal) A1132 A1133 A1128 A1140 I1174 S1167 M1077 V1216 L436 A438 K1270 27.3 56.8
59 ns32 rs41309228 E27/3410G>T (S1137I ) S1137 S1138 S1133 S1145 P1179 A1172 S1082 S1220 P440 E443 - 18.2 41.8
60 ns33 rs2229107 E27/3421T>A (S1141T) S1141 S1142 S1137 S1149 T1183 T1176 D1086 S1224 D444 R447 T1277 45.5 50.9
61 s20 rs1045642 E27/3435C>T (I1145I) C-NBD (Internal) I1145 I1146 I1141 I1153 V1187 I1180 I1090 M1228 V447 I450 V1281 72.7 57.6
62 ns34 rs59241388 E28/3502A>G (K1168E) K1168 R1169 R1164 R1176 R1210 R1203 C1113 L1251 E470 V473 N1304 27.3 61.9
63 ns35 rs41309231 E29/3669A>T (E1223D) E1223 E1224 E1219 E1231 E1265 E1258 V1168 Q1306 K525 K528 D1359 27.3 60.2
64 s21 rs2235051 E29/3747C>G (G1249G) C-NBD (Internal) G1249 G1250 G1245 G1257 G1291 G1284 G1194 G1332 G551 G554 T1392 63.6 63.0
65 ns36 rs45456698 E29/3751G>A (V1251I) V1251 V1252 V1247 V1259 I1293 V1286 V1196 I1334 I553 I556 V1394 81.8 59.2















































Table 2.2 (previous page) Note. ^The conservation of residues corresponding to all coding regions SNPs was obtained following multiple 
sequence alignment of 11 confirmed ABCB1 homolog protein sequences. For each species the amino acid, as well as its position in the 
corresponding sequence, is indicated. Corresponding ends of each of the row containing ABCB1 SNPs of a particular pharmacogenomics interest 
are marked by the same colour that were used to highlight their names in Figure 2.3. Highlighted in faded blue are the rows containing 
synonymous SNPs. Shaded in green is the sequence alignment obtained after re-using the same bacterial half-transporter sequence that were 
used for the first half of the alignment. The SNP nomenclature (i.e. ns# (non-synonymous) or s# (synonymous)) is similar to what were used 







Figure 2.3 (previous page): (A) A global view of residue conservation 
following the multiple sequence alignment of 11 ABCB1 homologs using 
the ClustalW algorithm (see Table 2.1 and Table 2.2). A heat map with 
differing colors depending on the residue conservation score is shown (blue: 
low conservation, red: high conservation). (B) Global view of amino acid 
residues corresponding to non-synonymous SNPs (prefixed as ‘ns’) and (C) 
synonymous SNPs (prefixed as ‘s’) within the human ABCB1 gene mapped to 
the mouse Abcb1a crystal structure (PDB: 3G5U). Identical residues between 
human and mouse are represented as Blue (sSNPs) and Red (nsSNPs) 
balls/fonts. Those residues that are not homologous are represented as green 
balls/fonts. The conserved Walker A (light blue), Walker B (pink) and  
signature C motifs (dark blue) are also highlighted as coloured lines. Number 
labels correspond with the data/labels in Table 2.2. The residue housing SNPs 
of pharmacogenomics interest are consistently highlighted by the same colours 
in Tables 2.2 and 2.3. 
 
2.5 SNPs associated with protein function or expression 
 
Based on literature review, there are two sSNPs and 12 nsSNPs that are 
associated with the ABCB1 protein function or expression variation (Table 
2.3). However, because they are located outside of the crystalized region of 
the Abcb1a protein, four of the twelve nsSNPs could not be located in the 




Table 2.3 ABCB1 coding SNPs and their allele frequencies. 
# rsNo SNP (Amino Acid Substitution) 






 1 - rs28381804 E3/49T>C  (F17L) 2.5 0 0 b No   
 2 - rs41304191 E3/55C>T  (L19L) - No   
 3 - rs76199854 E3/57G>A (L19L)     -     No   
 4 - rs9282564 E3/61A>G   (N21D) 
0 0 10 0 a 
Yes   0 19 0 b 
- - 6.5 2.1 c 
 5 ns1 rs1202183 E5/131A>G  (N44S) 
0 0 0 0 a 
No   
- - 0 0 c 
 6 ns2 rs41315618 E5/178A>C  (I60L) - No   
 7 ns3 rs9282565 E5/239C>A  (A80E) 
0 0 0 0 a 
No   
- - 0 2.1 c 
 8 - rs35810889 E5/266C>T (M89T) - Yes   
 9 ns4 rs61607171 E7/431T>C (I144T) - No   
 10 ns5 rs61122623 E7/502G>A (V168I) - No   
 11 s1 rs1128500 E8/540C>T  (S180S) - No   
 12 ns6 rs60419673  E8/548A>G (N183S) - No   
 13 ns7 rs1128501 E8/554G>T  (G185V) - Yes   
 14 s2 rs1128502 E8/555A>T  (G185G) - No   
 15 s3 rs2235022 E9/729A>G  (E243E) 0 0 0 0 a No   
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 16 s4 rs28381867 E9/738G>A  (A246A) 0 0 0 b No   
 17 ns8 rs36008564 E9/781A>G (I261V) - No   
 18 s5 rs80153317 E10/879T>C (I293I)     -     No   
 19 ns9 rs2229109 E12/1199G>A  (S400N) 
0 0 3.3 0 a 
Yes   0 2.3 0 b - - 3.2 2.1 c 
0 - 2.1 0 d 
 20 s6 rs1128503 E13/1236C>T  (G412G) 
68.9 57.8 39.2 12.3 a 
Yes   68.8 38.6 25 b - - 46.8 18.7 c 
66.7 - 47.7 13.6 d 
 21 s7 rs35068177 E13/1308A>G (T436T) - No   
 22 s8 rs41311775 E15/1326G>A  (R442R) - No   
 23 s9 rs35633772 E15/1617C>T (I539I) - No   
 24 s10 rs60247941 E15/1632C>T (A544A) - No   
 25 s11 rs2235012 E15/1662G>C  (L554L) 
0 0 0 2.5 a 





 26 s12 rs56871767 E15/1674G>A (T558T) - No   
 27 s13 rs59697741 E15/1695C>T (S565S) - No   
 28 ns10 rs28381902 E15/1696G>A  (E566K) 
0.6 0.6 1.3 0.5 a 
No   
0 0 0 b 
 29 ns11 rs28381914 E16/1777C>T  (R593C) 0 0 0 b No   
 30 ns12 rs56107566 E16/1778G>A (R593H) - No   
 31 s14 rs28381915 E16/1794C>T  (I598I) - - 0.9 - a No   
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0 2.3 0 b 
 32 ns13 rs2235036 E16/1795G>A  (A599T) 0 0 0 0 a No   
 33 ns14 rs57001392 E16/1837G>T  (D613Y) - No   
 34 - rs35657960 E17/1985T>C (L662R) - Yes   
 35 - rs35023033 E17/2005C>T (R669C) - Yes   
 36 - rs59340265 E17/2037C>T (D679D) - No   
 37 ns15 rs41316450 E18/2207T>A  (I736K) - No   
 38 ns16 rs77144566 E19/2281A>C (A761S)           No   
 39 ns17 rs41305517 E21/2398G>A  (D800N) - No   
 40 ns18 rs2235039 E21/2401G>A  (V801M) 0 0 0 0 a No   
 41 ns19 rs2032581 E22/2485A>G  (I829V) 0 0 0.9 0 a No   
 42 s15 rs28381966 E22/2505A>G  (V835V) 
- - 0.4 - a 
No   
0 2.4 0 b 
 43 ns20 rs28381967 E22/2506A>G  (I836V) 0 0 4.2 b No   
 44 ns21 rs36105130  E22/2547A>G (I849M) - No   
 45 s16 rs9282563 E22/2650C>T  (L884L) 
- - 1.6 0 c 
No   
0 2.3 0 b 
 46 ns22 rs2032582 E22/2677G>T/A (S893A/T) 52.2/15.2 38.6/0 0/0 b Yes   - - 43.5/0 12.5/2.1 c 
 47 ns23 rs56849127 E25/2975G>A (S992N) - No   
 48 ns24 rs72552784 E25/2995G>A (A999T) - No   
 49 s17 rs2235044 E26/3084G>A  (P1028P) 0 0 0 0 a No   
 50 ns25 rs28401798 E26/3151C>G  (P1051A) 0 0 0 b Yes   
 51 ns26 rs2707944 E26/3188G>C  (G1063A) - No   
 52 s18 rs2707943 E26/3189C>G  (G1063G) - No   
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 53 ns27 rs74755520 E26/3222A>C (C1074W)           No   
 54 ns28 rs57521326 E26/3262G>A (D1088N) - Yes   
 55 ns29 rs41309225 E27/3295A>G  (K1099E) - No   
 56 ns30 rs55852620 E27/3320A>C (Q1107P) - No   
 57 ns31 rs35730308 E27/3322T>C (W1108R) - Yes   
 58 s19 rs34748655 E27/3396C>T  (A1132A) - - 0 2.1 c No   
 59 ns32 rs41309228 E27/3410G>T  (S1137I) - No   
 60 ns33 rs2229107 E27/3421T>A  (S1141T) 
0 0 0 4.5 a 
Yes   
0 - 0 13.6 d 
- - 0 10.4 c 
0 0 4.2 b 
 61 s20 rs1045642 E27/3435C>T (I1145I) 
40 47.8 54.2 11.7 a 
Yes   52.3 54.5 20.8 b - - 53.2 20.8 c 
37.5 - 62.5 15.2 d 
 62 ns34 rs59241388 E28/3502A>G (K1168E) - No   
 63 ns35 rs41309231 E29/3669A>T  (E1223D) - No   
 64 s21 rs2235051 E29/3747C>G  (G1249G) - - 0 1.4 c No   
 65 ns36 rs45456698 E29/3751G>A  (V1251I) 0 0 0 b Yes   
 66 ns37 rs35721439 E29/3767C>A (T1256K) - No   
~The corresponding ends of each of the row containing ABCB1 SNPs of a particular pharmacogenomics 
interest are marked by the same colour that were used to highlight their names in Figure 2.3. Highlighted in 
faded blue are the rows containing synonymous SNPs. Minor allele frequency source: HapMap (a), EGP SNPs 




2.6 In 3D structure E13/1236C>T, E22/2677G>T/A and 
E27/3435C>T are located in distant regions and have 
varied conservation 
 
The E13/1236C>T, E22/2677G>T/A and E27/3435C>T are among the SNPs 
that are most extensively studied in ABCB1 pharmacogenetics [32-37]. Not 
only are they present at diverse frequencies across different populations (Table 
2.3), it is also reported that these three SNPs are in high linkage disequilibrium 
[35]. Whilst the E22/2677G>T/A is categorized as nsSNPs (#ns22 in Fig. 
2.3B), the other two SNPs are synonymous in nature (#s6 and #s20 in Fig. 
2.3C). Interestingly, unlike the conventional biallelic SNPs, nsSNP #22, which 
is located at residue 893, exists with three different alleles conferring a Serine 
to Alanine or Threonine substitution. 
By using the 3D structure, the two sSNPs are observed to be located in 
different protein regions (Fig. 2.3C and flash movie at 
http://pfs.nus.edu.sg/demo_src/abcb1.html)), which are located more than 50 
Å apart. They also have a very dissimilar evolutionary conservation level. To 
calculate regional conservation score, amino acid residues within 10 Å of the 
SNP were fetched from the Abcb1a crystal structure. Subsequently, an average 
score of all the individual conservation scores of these residues, in addition to 
the scores of five residues adjacent to them were calculated and assigned to 
the residue of interest. This score was then referred as the regional 
conservation score. Table 2.2 presents the regional conservation scores of the 
ABCB1 coding SNPs. The reason for choosing five amino acids  that are 
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located on either side of each residue was to obtain a finer spread of data, in 
demarcating the regions that have a big difference in conservation scores. 
Synonymous SNP #s6 or the E13/1236C>T, which corresponds to a glycine, is 
located on the external surface within the NBD that is closer to the N-terminal 
(Fig. 2.2 and Fig. 2.3C). This residue is found inside a beta-sheet, between the 
Walker A and A-loop motif, which are separated by 15 and 10 amino acids, 
respectively. In this study, it is observed that the individual conservation score 
of this residue is relatively low (28%), which suggests that there is a 
considerable degree of tolerance for variation in this residue during the protein 
evolution (Table 2.2, Fig. 2.4A). Furthermore, this notion is supported by the 
presence of lysine, aspartic acid and asparagine in residues of the same 
position that is found in other homologous sequences (Table 2.2). They only 
differ from glycine in term of polarity and charge of side chain, in addition to 
being less hydrophobic (-3.5 to -3.9 in compared to -0.4). Because #s6 is 
likely to have an impact at mRNA level, this variation of tolerance is 
postulated to be important in nature. 
The second highly studied sSNP was the E27/3435C>T or #s20, which 
corresponds to I1145I in the protein (Fig. 2.3C). The residue that corresponds 
to this SNP is observed to be highly conserved (73%) in all 11 ABCB1 
homologous protein sequences (Table 2.1 and Table 2.2). Except in C. elegans, 
S. aureus and P. falciparum, which has a valine residue, all other ABCB1 
homologs have isoleucine at the corresponding site to SNP #s20 (Fig. 2.2, 
Table 2.2). In the 3D structure, it can be observed that Ile 1145 is located 
within the internal structure of the NBD that is closer to the C-terminal (Fig. 
2.3B). Because both isoleucine and valine have neutral side chains with non-
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polar and hydrophobic residues, it suggested that these properties are 
important for this site of the protein throughout its evolution. 
Theoretically, E27/3435C>T is similar to E13/1236C>T in term of variability 
as it is at the transcript level that they may exert influence. And it could be 
predicted that in S. pombe, methionine 1228 could have been the result of a 
mutation that took place at the isoleucine codon, from ATC to ATG. Residue 
1145 is located right next to the signature C (Fig. 2.4C), a highly conserved 
motif and functionally important for ATP binding and hydrolysis [38, 39]. The 
regional conservation scores of E13/1236C>T and E27/3435C>T are highly 
similar, 56% and 58%, respectively, despite the variation in their conservation 
level and their opposite NBDs placement. Furthermore, these regions are more 
conserved than the average conservation of other SNPs, with regional 







Figure 2.4 Location and conservation of (A) E13/1236C>T (G412G), (B) E22/2677G>T/A (S893A/T) and (C) E27/3435C>T (I1145I). 
Individual residue scores are mapped to the ribbon model with each colour representing a percentage of conservation where 100% is equal to 11 
species expressing the same residue at the corresponding position. A heat map with differing colors depending on the conservation score is 
shown (blue: low conservation, red: high conservation). 
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The E27/3435C>T polymorphism (#s20 in Fig. 2.3C), which corresponds to 
the I1145I is a highly studied SNP of the ABCB1 protein, which is highly 
suggested to affect the protein 3D structure, stability or expression following 
the occurrence of a ribosomal stall during mRNA translation. This ribosomal 
stall is proposed to occur due to the presence of rare codon that changes the 
speed of mRNA translation and protein folding that is facilitated by chaperone 
[6, 40, 41]. This intriguing hypothesis however, is still supported by limited 
evidence. Moreover, rather than focusing on this SNP alone, most of the 
studies had largely been focusing on the SNPs haplotype consisting of #s6, 
#ns22, in addititon to the #s20 itself. 
 
Similar to the #s20, the #ns22, which corresponds to E22/2677G>T/A has a 
higher conservation score than the residues in its vicinity (#ns22 in Fig. 2.3B). 
It is a non-synonymous SNP that is associated with substitution of amino acids 
at residue 893, from Serine to either Alanine or Threonine. Based on the 
regional conservation score of 36% and individual conservation score of  46%, 
the SNP probably lies in a region that was subjected to sequence variation 
throughout the protein evolution (Table 2.2, Fig. 2.4B). Moreover, several 
homologous residues are different to Serine in the polarity of side chains and 
hydrophaty index [42]. These are the Alanine in C. l. Familiaris and G. gullus, 






There have been enormous efforts that focus in studying the role of these three 
ABCB1 SNPs in drug response, many of them often yielded conflicting 
conclusion (See Supplementary Table 3 in the published manuscript version). 
Where some studies concluded on the causative role of a single ABCB1 SNP, 
the majority of other studies have reported on the role of the SNP haplotypes. 
With many contradictory conclusion, the real evidence surrounding the 
significant role of the E13/1236C>T, E22/2677G>T/A and E27/3435C>T 
SNPs have therefore been largely controversial. Moreover, reviews on the 
association between ABCB1 polymorphisms and drug pharmacokinetics or 
protein functions have also carried mixed perspectives [10, 16, 43]. 
 
Because inferring a conclusion from many of these studies is not easy, 
especially in terms of ABCB1 pharmacogenetics, the availability of the 3D 
crystal structure provided an opportunity. With the mouse structure, we can 
now evaluate the potential effect of ABCB1 SNPs on the protein structure and 
function. This could complement the design of future functional studies, 











2.7 3D structure reveals that classic G185V polymorphism is 
in close proximity to two other non-synonymous SNPs in 
less evolutionary conserved region 
 
Besides the E13/1236C>T, E22/2677G>T/A and E27/3435C>T SNPs, there 
are several nsSNPs that are associated with drug responses. The majority of 
these SNPs could be mapped to the mammalian Abcb1a crystal structure. 
The E8/554G>T (#ns7), which is a G185V substitution (Fig. 2.3B) is one of 
the non-synonymous SNPs that have been reported to be associated with drug 
response. It is a “classic” polymorphism that induce an amino acid substitution 
from Glycine to Valine at residue 185, and is associated with vinblastine and 
colchicine drug specificity [44]. It is reported that glycine 185 is an important 
component in the alteration of ABCB1 conformation between the drug binding 
and catalytic sites [45]. Atomic detail homology modeling coupled with 
combining dynamics simulation predicted an improved drug efflux as a result 
of non-polar van der Waals force reduction that were supposed to bind 
colchicine near residue 185. Because Valine is bulkier than Glycine, this 
interaction would have been prevented, which increases efflux and 
dissociation [45, 46]. 
As can be observed in the crystal structure (Fig. 2.5 and 2.6), G185V is 
located within a close 3D vicinity to two other nsSNPs, the I144T (#ns4 in Fig. 
2.3B) and N183S (#ns6 in Fig. 2.3B). With the #ns4, the G185V is located 
10.9 Å apart, whilst with the N183S, it is 5.2 Å apart. However, because 
ABCB1 is known to have more than one structural confirmation [19], there is 
a concern that this close proximity may not be observed in a different 
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conformation. To address this, the same SNPs were mapped to the Sav1866 
ADP-bound structure, which is a half transporter found in Staphylococcus 
aureus. Here, it can be observed that the 3D distance between these nsSNPs 
are roughly similar, with 11.3 and 5.3 Å, respectively (Fig. 2.5 and Fig. 2.6). 
With an average score of around 40% for the I144, N183 and G185, the 
individual conservation scores are 36%, 27% and 45%, respectively. Within 
10 Å region, there are only three residues that have conservation score of 80% 
or more. It can therefore be suggested that throughout the protein evolution, 
some degree of variation of residues are tolerated. One should evaluate the 
influence of I144T and N183S on ABCB1 conformation in addition to their 
influence on the role of G185V in protein functional change. 
 However, few studies focus on the role of these three SNPs in drug 
response. In fact, no genotype information is available (Table 2.3). Therefore, 
in order to determine whether drug specificity is influenced by these SNPs, the 
next focus should be in obtaining the genotype information, in addition to the 





Figure 2.5 Three homologous residues housing I144T, N183S and G185V 
in mouse Abcb1a structure (ATP/ADP free form). The homologous SNP 
amino acid sites are identical between human and mouse. Distances are 
indicated with yellow dashed lines. 
 
 
Figure 2.6 Three homologous residues housing I144T, N183S and G185V 
in Staphylococcus aureus Sav1866 structure (ADP-bound conformation). 
The homologous SNP amino acid sites are non-identical between human and 






























Figure 2.7 (next page) Location and conservation of (A) E8/554G>T 
(G185V), (B) E12/1199G>A (S400N), (C) E26/3151C>G (P1051A), (D) 
E27/3322T>C (W1108R), (E) E27/3421T>A (S1141T), (F) E29/3751G>A 
(V1251I). Individual residue scores are mapped to the ribbon model with each 
colour representing a percentage of conservation where 100% is equal to 11 
species expressing the same residue at the corresponding position. A heat map 
with differing colors depending on the conservation score is shown (blue: low 






2.8 E12/1199G>A (S400N) is evolutionary non-conserved, but 
resides in an evolutionary conserved region  
 
The E12/1199G>A (#ns9 in Fig. 2.3b) nsSNP, which induces an S400N 
residue substitution, has a frequency of less than 4% in Asians. This SNP has 
been previously reported to be influential in drug responses [47-53]. With the 
mouse protein structure, it can be observed that S400N is similarly located as 
Gly 412, which houses the synonymous SNP, E13/1236C>T (Fig. 2.7B and 
see flash movie at http://pfs.nus.edu.sg/demo_src/abcb1.html). It lies within 
the NBD, next to the A-loop (Fig. 2.2 and Fig. 2.8B) at the same turn region as 
Gly 412, in between two beta-sheets. Based on this analysis however, the 
S400 residue is observed to have a relatively low individual conservation 
score (18%), which indicates poor evolutionary conservation that may tolerate 
variation at this position (Table 2.2). At this position, serine is observed only 
in three species: human, canine and mouse. In other species, substitution takes 
place with amino acids having polar side chain, except in yeast where there is 
an occurrence of valine, which is hydrophobic in property. Furthermore, there 
is an interesting observation that this S400 residue is flanked by two residues 
that are completely conserved, with a score of 100% (Fig. 2.7B), in a region of 






2.9 Four SNPs that are associated with drug response are 
mapped to the outer surface of C-terminal NBD 
 
Using pair-wise protein sequence alignment, there are four out of eight SNPs 
that are reported to be associated with drug response that could be mapped to 
the crystal structure of the mouse Abcb1a protein (Fig. 2.1) [30, 31]. These 
SNPs are the P1051A, W1108R, S1141T, and V1251I, which corresponds to 
#ns25, #ns31, #ns33, and #ns36, respectively (Fig. 2.3B). These SNPs, which 
reside in the C-terminal Nucleotide Binding Domain, may affect protein 
function if they are reside in close vicinity to the protein surface that is 
important for ATP binding. The outer protein surface may also be important in 
NBDs dimerization, either during ATP binding and hydrolysis or opposing 
NBDs interaction. 
Here, the SNP E26/3151C>G, which corresponds to a P1051A (#ns25) 
substitution is highlighted (Fig. 2.3B and Fig. 2.7C). It is a relatively well 
conserved amino acid substitution, affecting only protein hydropathy. In the 
3D structure, #ns25 is mapped to the C-terminal NBD, at the surface forming 
the ATP binding pocket. The SNP is found to be located between two beta-
sheets, within a turn region, in a fashion that is similar to the S400N 
polymorphism (Fig. 2.7B). SNP P1051A is located close to the A-loop and 
Walker A motif, which are both very conserved and important for ATP 
activity [22, 25]. Moreover, the individual conservation score of the P1051 is 
only 18.2%, albeit residing in a region with around 60% of conservation score 
(Table 2.2, Fig. 2.7C). This suggests that at this residue, variation was well 
tolerated during the protein evolution despite it not being equally tolerated at 
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the neighboring residues. In a yeast-based experiment, it was shown that the 
P1051 polymorphism affects valinomycin resistance, when it occurred in 
diplotype with E22/2677G>T/A [54]. 
Another SNP that has previously been reported to play a role in drug response 
is SNP E27/3421T>A (S1141T) (#ns33) and the E27/3322T>C (W1108R) 
(#ns31) [54, 55]. Based on the assessment using the 3D crystal structure, 
S1141T and W1108R are found at the C-terminal NBD. S1141 resides at the 
external surface, whilst the W1108R is found within the NBD interior (Fig. 
2.3B, 2.7D, 2.7E, and flash movie http://pfs.nus.edu.sg/demo_src/abcb1.html).  
Meanwhile, the E27/3421T>A (S1141T, #ns33) polymorphism, which has a 
relatively high minor allele frequency of more than 4% in Africans, is not 
associated with highly conserved residue and protein region. The individual 
conservation and regional conservation score for this residue is 45.5% and 
50.9%, respectively (Table 2.2). This suggests that throughout the protein 
evolution, there was a good tolerance for a change of residue properties. 
Another non-synonymous polymorphism, which is less conserved than 
S1141T, is the E27/3322T>C (W1108R). This SNP, which is also referred as 
#ns31, corresponds to a less conserved residue (individual conservation score 
= 27.3%) compared to its surroundings (regional conservation score = 43.5%) 
(Table 2.2, Fig. 2.7E). Interestingly, both #ns31 and #ns33 are poorly 
evolutionary conserved and reside in the C-terminal NBD. These SNPs have 
previously been proposed to be associated with ABCB1 substrate 
discrimination [54].  
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Lastly, #ns36 is a non-synonymous polymorphisms that correspond to the 
V1251I substitution (E29/3751G>A) and has been reported to affect 
BODIPY-FL-paclitaxel pharmacokinetics [55]. Using the mouse crystal 
structure, it can be seen that the V1251I is located at the outer side of the C-
terminal NBD (Fig. 2.3B and Fig. 2.7F). The individual conservation score of 
81.8% signifies a highly conserved residue, which is also associated with 
conservative amino acid changes in 4 out of 11 species (Table 2.2). This SNP 
however, is located in a less conserved protein region, with regional 
conservation score of 59.2%, which suggests a relatively high tolerance level 
of change in the neighboring residues. 
Generally, with the exception of E27/3322T>C (W1108R) (#ns31), most of 
these SNPs, which have been reported to have association with ABCB1 
function alteration, are found at the external surface of the protein, specifically 
at the C-terminal NBD. These SNPs are #ns25, #ns33 and ns36, which 
correspond to E26/3151C>G (P1051A), E27/3421T>A and E29/3751G>A 
(V1251I), respectively (Table 2.2, Fig. 2.3B and flash movie at 
http://pfs.nus.edu.sg/demo_src/abcb1.html). Furthermore, all of these SNPs 
have relatively low average conservation scores (below 46%), except for 
#ns36 that has a relatively high individual conservation score of more than 
80%. With the structure information, we can now deduce that all these SNPs 
are located in a region that have a moderate degree of evolutionary 




2.10 More inclination for nsSNPs to be located at less 
conserved residues 
 
In this chapter, it can be observed that there is some correlation between the 
degree of conservation and SNPs. There is a higher percentage of non-
synonymous SNPs (12%) versus synonymous SNPs (7%) that are associated 
with low individual conservation score (20-30%) (Fig. 2.8A). Based on this 
observation, it can be deduce that there is a tendency for nsSNPs to reside in 
amino acids that are less conserved. Nonetheless, because SNPs are found 
throughout both the non-conserved and conserved protein regions, no clear 
correlation can be deduced between regional conservation scores and the 
overall presence of SNPs in ABCB1 protein (Fig. 2.8B). Here, it is found that 
most of the SNPs (39%) that could be mapped to the protein structure 







Figure 2.8  Distribution of conservation scores in ABCB1 protein. (A) The distribution of SNP individual conservation scores. (B) Presence 































































































































In conclusion, out of a total of 66 coding SNPs in the ABCB1 protein, there 
are two sSNP and 12 nsSNPs that have been reported to be associated with 
protein function variation. There are ten SNPs that could be mapped into the 
mouse crystal structure and none of these SNPs are found at the region 
important for substrate binding as illustrated by Aller et al [19]. Here, it was 
observed that the only one of these SNPs that possibly resides within the lipid 
bilayer region is #ns7 or the E8/554G>T (G185V) polymorphism. In addition, 
although residing in a residue that is part of TM10, #ns22 or the 
E22/2677G>T/A (S893A/T) is located between the cytosolic N-terminal NBD 
and the membrane region (Fig. 2.3). The NBD can further be suggested to play 
a significant role in the functioning of ABCB1. This is based on the 
observation that most of the SNPs that are associated with function differences, 
are located at the external surface of the C-terminal NBD, not within the 
internal surface where ATP hydrolysis take place. 
From these 14 SNPs, the genotype data of 8 SNPs indicated diverse frequency 
across various populations. In fact, #ns33 or the E27/3421T>A (S1141T) is 
only observed in the African American population (Table 2.3). Furthermore, 
whilst the conservation scores of these 14 SNPs (except for #ns36 and #ns28) 
are well below average (less than 46%), their regional conservation score only 
reached average level (40-60%). This indicates that variability is somewhat 
tolerated in these regions of ABCB1, which may facilitate the variation of 
substrate specificity of ABCB1 polymorphs. 
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In recent years, studies involving ABCB1 SNPs have grown in number. Many 
of them focus on studying the SNPs association with drug pharmacokinetics. 
However, there has been little clarification of the role of these SNPs over 
variation of drug response. The field is becoming more saturated as 
differences in methodologies and approaches of various group further 
confounded the issue. For instance, the difference in populations that are 
involved in the different studies would add an extra challenge in comparing 
the results of these studies. Hence, such variable must be addressed in future 
study design. 
Moving forward, structural information of a drug response protein will be 
extremely useful, especially to enable more understanding of the potential 
effect of coding SNPs to the protein function. As illustrated in this chapter, 3D 
localization of the nsSNPs to the protein can aid the generation of a more 
knowledge-based hypothesis in functional studies. Moreover, using the 
evolutionary conservation methodology, one is also able to get more insight 
not only on the potential role of these non-synonymous SNPs, but also the 
synonymous SNPs that may exert impact in the mRNA level. Therefore, 
deducing the SNPs location and residue conservation in the 3D crystal 
structure can arguably provide a more accurate and realistic approach in 
visualizing the SNPs, in comparison to using the conventional 2D schematic 
diagram. The study elaborated in this chapter therefore highlighted the 
feasibility of using this approach in other proteins, given 3D crystal structure 
is available. It can also extend interpretation of results that are derived from 




Nonetheless, this analysis was limited to only protein-coding SNPs in the 
ABCB1, which is only part of the general breath of polymorphisms that can 
affect drug response. Hence, in the next chapter, I present the general 
architecture of SNPs in drug-response pathways, which not only include the 
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Drug response variation is affected by individual's genetic background [1-3]. 
Elucidating the role of SNPs residing in drug-response genes is a central theme in 
many pharmacogenomics studies [4-7]. Moreover, as shown in the previous 
chapter, coding SNPs could affect protein 3D structure, which can potentially 
affect the protein function. There have been studies supporting the potential 
importance of protein-coding region SNPs (cSNPs) in drug response [5-6, 8-10]. 
However more recently, there has been an increasing awareness of the impending 
potential consequence of SNPs that reside on non-coding or regulatory regions 
despite their lack of effects on protein structure [11-13]. The potential functional 
effect of non-coding polymorphisms can be exerted in gene expression level (for 
regulatory SNPs - rSNPs) such as by affecting transcription factor (TF) binding or 
miRNA binding; or in RNA structural level (for structural RNA SNPs - srSNPs) 
by affecting splicing. 
In this chapter, utilising the potentially functional SNPs (pfSNPTM - 
http://pfs.nus.edu.sg/) resource [14], the architecture of rSNPs and srSNPs in 
addition to that of cSNPs in genes responsible for drug response were elucidated. 
In addition, the correlation pattern between SNPs genotype and changes of drug-
response gene expression level was also investigated. 
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The relationship between drug response variation and population differentiation in 
SNP allele frequency has been discussed extensively [2, 15-16]. International 
consortiums that have publicized genotype data of major world populations 
include the HapMap, which genotyped SNPs in 11 populations and the Singapore 
Genome Variation Project (SGVP), which genotyped SNPs in three Asian 
populations in Singapore, a multiracial city-state [17-18]. Using this publicly 
available information, this chapter also reports the pattern of population genetics 
differentiation across conventional drug-response genes. This approach is 
arguably effective in studying the genetic background that is important in drug 
responses, especially when a clinical trial was done in populations that constitute 
a different genetic background. 
Moreover, it is important to note that in many drugs, the PK/PD is a multigenic 
process [19-20]. However, many studies were conducted based on a candidate 
gene or candidate SNP approach, which could disregard other potentially 
important genetic factors affecting the drug response. Nonetheless, there has been 
an effort to systematically organize drug-response genes into biological pathways 
where their specific role on the drug PK/PD is well annotated [20-21]. These 
drug-response pathways (DRPs) represent diverse networks of PK/PD genes that 
are associated with various drug responses. Genes within a DRP may interact and 
regulate the overall therapeutic outcome through various roles such as in drug 
absorption, distribution, metabolism, and excretion.  
In this chapter, I designed a systematic analysis of SNPs in the DRPs using a gene 
functional region-directed approach, one that could reliably detect pattern of 
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SNPs distribution in genes that belong to various DRPs. To my knowledge, at the 
time this study was initiated, a systemic investigation of the pattern of SNP 
architecture such as the gene regional distribution and predicted functional effect 




3.2.1 Drug-response genes & pathways 
 
The drug pathways in this study were mined from the PharmGKB database 
(http://www.pharmgkb.org) [21]. Sixty six pathways that contain genes 
information in the PharmGKB database were used to assemble the set of 715 
drug-response genes that were used for analysis. Pathways that are associated 
with similar drugs were combined, which made up the 41 drug-response pathways 
(DRPs) used in this analyses (Appendix 2). 
3.2.2 Mapping of SNPs to gene region 
 
The SNPs data were obtained from the NCBI dbSNP (build 131) database [30]. A 
total of 10,512,313 SNPs from 22,333 genome genes were extracted for this 
purpose. Out of this total, 497,736 SNPs belong to the 715 drug-response genes. 
The work in this chapter employed the gene functional region-directed approach 
in mapping SNPs to the gene sets, in accordance to NCBI Genome build 37. SNPs 
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are categorised based on their location in genes. For SNPs in non-coding regions, 
the following classification was applied: Promoter for SNPs residing within 
5.5Kb upstream of a gene transcription start site; Intronic for SNPs residing in 
introns; as well as  5’ UTR and 3’ UTR for SNPs residing in the 5’ or 3’ un-
translated mRNA regions. In the coding region (i.e. exons), SNPs that cause 
amino acid substitution during mRNA translation is classified as non-synonymous 
SNPs (nsSNPs). On the other hand, silent or non-amino acid-substituting SNPs 
are referred as synonymous SNPs (sSNPs). SNP density was calculated on 
transcript level and its average was used to define the gene SNP density. 
Using the gene functional region-directed approach the SNP density of 
each gene transcript was calculated according to the following formula: 
 
3.2.3 Potentially Functional SNPs 
 
In studying the SNPs potential functional implication, the information in the 
Potentially Functional SNPs database (pfSNPTM - http://pfs.nus.edu.sg/) was 
utilized [14]. The pfSNP reseource integrated SNPs functional prediction tools 
into a one-stop portal of SNPs predicted functional anottation. The predicted 
functional features in this resource was used to define a SNP into different 
functional categories: Transcription factor (TF) binding sites, miRNA binding 
sites, 3’ UTR conserved regions, splicing regulatory sites, nonsense-mediated 
 73 
 
decay (NMD), codon usage differentiation, protein deleterious, post-translational 
modification sites, and protein domains. These are summarized in Table 3.1. 
Using the gene functional region-directed approach of SNP mapping, the SNPs’ 
potential functional effect could be derived and the proportion of potentially 
functional SNPs in each gene were calculated. 
 
Table 3.1 Description of tool used for SNP functional categories. 
 
Functional category Tools Description 
TF Binding Sites TF binding site changes 
miRNA Binding Sites miRNA binding site changes 
3' UTR Conserved 3' UTR conserved regions 
Splicing Regulatory Sites 
Exonic splicing enhancer/silencer 
(ESE/ESS), intronic splicing regulatory 
element (ISRE), abberrant splice sites 
Nonsense-mediated Decay Nonsense-mediated decay (NMD) sequence changes 
Codon Usage Differentiation Codon usage differentiation sequence changes 
Protein Deleterious Polyphen/SNP34/LS-SNP predicted deleterious amino acid substitution 
Post-translational Modification 
Sites Glycosylation and phosphorylation sites 
Protein Domains Transmembrane domain, Interpro Scan 
 
3.2.4 eQTL analysis 
 
Gene expression data was obtained from the Gene Expression Omnibus (GEO) 
database. The study in this chapter utilised lymphoblastoid cell line (LCL) 
expression data from 144 (43 CEU, 59 CHB-JPT, and 42 YRI) unrelated HapMap 
 74 
 
individuals performed by Stranger et al (Series GSE6536) [31]. In order to 
capture as many SNPs that could be correlated with differential gene expression, a 
linear regression was performed involving the expression data and their matched-
individuals genotype from three populations (CEU, CHB-JPT and YRI) of the 
1000 Genomes Project pilot phase [32]. The analysis of eQTL was then 
performed with 2.9 million, 2.4 million and 3.6 million SNP-mRNA probe pairs 
in the CEU, CHB-JPT and YRI, respectively. A SNP is categorised as expression-
associated or eQTL if its false discovery rate (FDR)-corrected P-value is less than 
0.05 after performing linear regression. The eQTL variants (n = 37,756) were 
subsequently mapped according to the gene functional region-directed method 
employed in this study. 
 
3.2.5 Population differentiation estimation 
 
The allele frequency was calculated using genotype data from two sources. The 
first originated from the HapMap (Release 27), consisting of 1.4 million SNPs 
that were genotyped from more than a thousand individuals in 11 populations 
[17]. The second came from the Singapore Genome Variation Project (SGVP), 
which genotyped approximately 1.4 million SNPs in 292 individuals from three 




The allele frequency data was used to calculate the estimate measure of SNP 
population differentiation using FST statistics [22]. Only common SNPs that have 
been genotyped in unrelated individuals from all populations were used in the 
calculation of FST, which for this chpater, measure population differentiation 
estimates across all populations. In this analysis, a total of 10 populations from 
the two genotyping sources were combined into four continental groups: Africans 
(consisting of LWK and YRI), Europeans (consisting of CEU and TSI), East 
Asians (consisting of CHB, CHD, CHS and JPT), and South Indians (consisting 
of GIH and INS). Pairwise FST scores within populations belonging to the same 
continental group are all 0.01 or less. An extremely differentiated SNP is defined 
as one having FST score within the top 5% of the whole-genome overall 
population FST distribution. The pathway population differentiation was analyzed 
by determining the proportion of genes that carry one or more extremely 
differentiated SNP in the DRP. 
 
3.2.6 Random sampling simulation 
 
The statistical random sampling simulation was performed in the ‘R’ environment 
(http://www.r-project.org/). For each DRP, the same number of genes was 
sampled and the sampling criteria were set such that only genes having 
approximately similar length (size of transcripts are within the range of what is 
observed in the pathway genes set) to the DRP genes were considered. 
Simulations were run independently for the analysis involving SNP density, 
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proportion of potentially functional SNPs, proportion of genes with eQTL, and 
proportion of genes with high-FST SNPs. 
Each simulation required 10,000-time random sampling repeats before an 
empirical distribution was formed in the individual DRP. Using these results; the 
percentile (Pc) value of each DRP was calculated using the following equation: 
 
Where: 
h = number of sampling observations higher than expected  
l = number of sampling observations lower than expected 
e = number of sampling observations equal to what expected   
 
A Pc value < 0.05 determined significantly non-random observation where 95 
percent of the sampling results fall below the observed value of the DRP. 







3.2.7 Drug pathway priority score 
 
For each DRP, the ‘Py score’ was calculated using their SNP architecture 
signatory parameters that were gathered in this study (Table 3.2). The Py score 
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Table 3.2 Features used for calculating drug pathways prioritization (Py) 
scores. 
Variable Description Weight 
a Potentially Functional SNPs                                             - No. of significant categories 1 
b Expression SNPs                                                               - No. of significant categories 1 
c Population Differentiation                                                - No. of significant categories 1.5 
d Expression-associated Potentially Functional SNPs        - No. of categories with SNPs 2 
e Highly-differentiated Potentially Functional SNPs          - No. of categories with SNPs 2 




Highly-differentiated Expression-associated SNPs          
- No. of categories with SNPs 3 
  Highest FST 3.5 
g 
Highly-differentiated & Expression-associated 
Potentially Functional SNPs                                                 
- No. of categories with SNPs 
4 





The Py score was derived based on the following rationale. The first three 
variables: a, b and c were derived based on the question whether a pathway is 
associated with one or more SNP category enrichment that is above the statistical 
threshold (Pc value < 0.05). Variable a recognizes the presence of enrichment of 
potentially functional SNPs in up to nine pfSNP categories (Table 3.1), which 
also explained the use of 9 as denominator. The subsequent variable, b, takes into 
account the observed enrichment of expression-associated SNPs in up to 6 SNP 
categories (Promoter, 5’ UTR, 3’UTR, Intron, Non-synonymous, and 
Synonymous). Variable c recognizes the presence of enrichment of extremely 
population-differentiated SNPs in up to 6 SNP categories. Whilst variables a and 
b carried an equal weightage of 1, variable c, due to its association with 
population differentiation, was given a heavier weightage of 1.5. 
In addition to recognizing the presence of SNP enrichment in the above variables, 
the subsequent part of the equation accounted the presence of SNPs that can be 
categorized into two or more categories, hence were given twice the weightage of 
the above variables. These are the potentially functional SNPs that are associated 
with variation in gene expression (variable d) or high population differentiation 
FST scores (variable e). Variable f, which was given a greater weightage, 
recognizes the presence of potentially functional SNPs that are also associated 
with gene expression variation. Moreover, the rarity of potentially functional 
SNPs that are also associated with gene expression and extreme population 
differentiation was given an even higher weightage of 4 in variable g. 
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The last three variables, ê, f ̂ and ĝ accounted the highest FST score for SNPs that 
are predicted to be potentially functional (ê) and associated with gene expression 
(f )̂, in addition to expression-associated SNPs that are predicted to be potentially 
functional (ĝ). In taking into account the relevance of their population 
differentiation status, greater weightages were given for these variables. 
3.3 Results 
 
3.3.1 SNP enrichment in drug-response pathways (DRPs) 
 
To evaluate the general distribution of SNPs in 715 drug-response genes retrieved 
from the PharmGKB database, the SNP densities were calculated based on gene 
functional region-directed approach (see methods). Each SNP is mapped to their 
respective genes and classified according to the gene functional region where they 
are located. SNPs in the non-coding region are classified as Promoter (if it is 
located within 5.5 Kbp upstream of the transcription start site), 5’ un-translated 
region (UTR), 3’ UTR, or intronic. SNPs in coding regions are categorized as 
either non-synonymous (nsSNPs, amino acid-substituting) or synonymous 
(sSNPs, non-amino acid-substituting). Table 3.3 presents the SNP densities of 
drug-response genes most commonly found in the DRPs. 
The whole-genome median SNP densities are 7.6, 3.1, 7.6, 6.9, 3.7, and 2.2 
SNPs/Kbp in the Promoter, 5' UTR, Intronic, 3' UTR, nsSNPs and sSNPs 
categories, respectively. When compared to these values, we observed that the 
coding and non-coding regions of the drug-response genes are equally SNP-
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enriched (Fig. 3.1A). In fact, SNPs enrichment in the 5’ UTR and synonymous 
SNP categories are more than 1.5 fold (P-value < 0.001, Mann-Whitney U test). 
SNP enrichment is therefore a widespread occurrence that occurs not only in the 




Table 3.3 SNP density of the most common genes in drug-response pathways. 












25 12.55 28.85 10.72 18.23 22.49 2.65 
CYP3A5 1577 17 8.91 68.97 8.01 27.03 11.93 1.99 
ABCB1 5243 Transporter 15 10 19.14 7.94 29.46 12.23 5.98 
CYP2C19 1557 
Metaboliser 
14 11.09 0 10.6 0 23.08 6.11 
CYP2C9 1559 14 14.18 0 12.79 22.04 22.4 7.47 
CYP2D6 1565 10 22.36 22.22 36.01 0 54.25 16.9 
ABCG2 9429 Transporter 10 21.82 18.26 9.66 4.06 8.13 3.05 
CYP1A2 1544 Metaboliser 9 9.09 0 16.41 11.9 19.34 7.09 
ABCC2 1244 Transporter 8 10.36 14.39 13.25 7.3 8.41 4.74 
UGT1A1 54658 
Metaboliser 
8 14.36 0 13.21 13.51 21.85 1.87 
CYP2C8 1558 7 7.64 10.53 10.06 11.24 12.22 1.36 
CYP2B6 1555 6 9.09 0 17.01 36.33 24.39 7.45 
ABCC1 4363 
Transporter 
6 7.09 0 12.15 14.5 4.66 7.16 
ABCC3 8714 6 5.09 0 7.45 6.81 6.18 3.89 
MAPK1 108 Cellular Signalling 5 4.36 0 8.21 4.98 1.53 3.36 
ADCY2 5594 cAMP formation 5 7.82 8.33 7.96 6.79 1.85 5.54 
UGT2B7 7364 Metaboliser 5 11.45 0 10.12 35.86 6.92 10.06 
^SNP density is in SNPs/Kbp. The whole-genome median SNP densities are 7.6, 3.1, 7.6, 6.9,  3.7, and 2.2 SNPs/Kbp in 




Figure 3.1 SNP enrichment in drug-response pathways (DRPs) is seen 
extensively across all gene functional regions. As shown by the median (fold 
versus genomic median) SNP density, genes taking part in drug-response (n = 
715) are generally highly polymorphic from the promoter and intron to the coding 
and un-translated (UTR) regions (A). This enrichment of SNPs is also seen in the 
DRPs (B) where each bar represents DRP SNP enrichment in the gene functional 
region of interest. A heat map of DRP Pc values showed that many DRP Pc 
values are inclining towards zero, which signifies non-random enrichment of 
SNPs (C). In each DRP, the numbers in the blocks represent the enrichment rank 
associated with the specific SNP categories (ie. Syn, NonSyn, 3'UTR, 5'UTR, 
Intron, and Promoter). 
 
As different drugs may target different tissues, metabolized and transported by 
diverse genes, we questioned whether the general SNPs enrichment observed in 
these genes could translate into significant projections of polymorphisms in the 
DRPs that are specific to certain drug types. In order to reduce background noise, 
the 66 PharmGKB PK/PD pathways information was summarized into 41 DRPs 
(Appendix 2). Out of 715 drug-response genes found in the DRPs collection 17 -
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tioare associated with more than 5 pathways (Table 3.3). In fact the drug 
metabolizing enzyme, CYP3A4, is commonly associated with 25 pathways, 
whereas 15 pathways conceal the influential ABCB1 transporter. The individual 
DRP average SNP densities were calculated using the same gene functional 
region-directed approach (Appendix 3). The result indicates that in general, the 
DRPs are SNP-enriched in both the expression regulatory and protein coding SNP 
categories.   
Because of the involvement of multiple genes and pathways, an early concern was 
that such observation could be affected by statistical randomness. Hence for each 
DRP, a 10,000-time statistical sampling simulation was performed using random 
genes. An evaluation if the same SNP enrichment was also observed in the DRP 
random sampling data set (see methods) was then carried out. The results showed 
that in the majority of DRPs, such SNP-enrichment was not observed in the 
random sampling set (Fig. 3.1C). This suggests that the SNP enrichment in the 
DRPs is not a random observation. Out of 41 DRPs, 27 pose a significant Pc 
value in one or more SNP categories representing SNP-enrichment. The DRP Pc 
values – the percentile score of which an observed pathway SNP density falls 
within its own empirical distribution – across all gene functional regions are well 
cumulated into the significant range (Fig. 3.2). Highly polymorphic pathways 
include those associated with taxane, antiplatelet, irinotecan and etoposide drugs, 






Figure 3.2 10,000-time statistical sampling simulation with random genes of 
comparable size showed that SNP enrichment across the DRPs are not 
random. 
 
3.3.2 Potentially functional SNPs in DRPs 
 
In order to elucidate the architecture of SNPs potential functional effect, the 
detailed distribution of SNPs in the DRPs were analyzed based on their predicted 
implication for gene functions. Figure 3.3A shows the proportion of potentially 
functional SNPs in the DRPs based on three functional levels of a SNP’s effect: 
expression regulatory (rSNPs), structural RNA (srSNPs) or protein level (cSNPs). 
The result shows the apparent multi-level functional role of SNPs in drug-
response, with potential effects exerted in all levels of the central dogma of 
molecular biology; from gene expression and RNA structure levels to protein 
structure and function levels. 
In this detailed SNP architecture, the relatively high proportion of potentially 
functional SNPs in the DRPs was also revealed (Fig. 3.3A). For the regulatory 































sites is highly prominent compared to that of miRNA binding sites. In the 
structural RNA SNPs (srSNPs) category, a potentially strong influence is exerted 
in RNA splicing regulatory sites, but not in the other functional prediction 
categories (codon usage, 3’ UTR conservation or nonsense-mediated RNA 
decay). Furthermore, 10,000-time statistical sampling simulation showed that the 
high proportion of DRP SNPs in the two functional categories, TF binding and 
splicing regulatory sites alteration, are among the ones with the lowest trend of 
statistical Pc values (Fig. 3.3B). This suggests that the high proportion of TF 
binding and splicing regulatory site SNP categories is not due to random chances. 
On the other hand, in the protein structure and function level, where it is possible 
to observe coding SNPs (cSNPs), a substantial presence of non-synonymous 
SNPs was observed to be associated with protein domains or deleterious sites, but 
not post-translational modification sites (Fig. 3.3A and 3.3B). 
This result suggests for the high prominence of regulatory polymorphisms in drug 
response, which was traditionally less popular than coding SNPs in 
pharmacogenomics. Furthermore, it also signifies a novel pattern of pharmaco-
SNPs functionality, which is now attributed not only by protein variants, but also 






Figure 3.3 Potentially functional SNPs in DRPs. (A) The signature of SNPs 
with potential function in drug-response is marked by the relatively large scale of 
regulatory (rSNPs) and structural RNA-affecting SNPs (srSNPs), in addition to 
coding SNPs (cSNPs). In general, the DRPs carry substantial proportion of SNPs 
that are predicted to affect gene functional sites. (B) Among the most significant 
and non-random enrichments (Low Pc values) are in SNPs that could affect 
transcription factor (TF) binding, gene splicing and deleterious amino-acid 
substitutions.  
 
3.3.3 Expression quantitative loci (eQTL) is linked to rSNP and srSNPs in the 
DRPs 
 
This part seeks to evaluate whether potentially functional SNPs in DRPs are 
associated with actual differences in gene expression, a cellular phenotype that 
can be attributed to genetic variations. A correlation analysis between genotype 
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data was obtained from gene expression microarray of lymphoblastoid cell lines 
(LCLs) (Series GSE6536 of the Gene Omnibus Database). The matching 
genotype of the same individuals was obtained from the 1000 Genomes pilot 
phase data. A SNP that is associated with differential local gene expression or 
eQTL is defined as one with false discovery rate (FDR) corrected P-value of less 
than 0.05 following linear regression analysis. 
When taking into account SNPs potential function, it was observed that the 
proportion of SNPs that are associated with gene expression is highest in the 
rSNPs and srSNPs categories (Fig. 3.4). In addition, we also observed a relatively 
higher proportion of genes carrying expression-associated rSNPs that alter TF 
binding sites and srSNPs that alter splicing regulatory sites (Fig. 3.5 and Fig. 3.6). 
This result further accentuates the raising importance of rSNPs and srSNPs in 
drug-response. Among the DRPs that carry substantial proportion of this type of 
genes are those that are responsible for drugs such as the methotrexate, thiopurine 






Figure 3.4 Higher proportion of DRP genes carrying TF binding and splicing 
regulatory site SNPs that are associated with differential gene expression. 
(Upper panel) The bar represents the collection of 715 drug-response genes. 





Figure 3.5 Proportion of genes carrying SNPs as expression quantitative loci 
(eQTL) in  DRPs. 
 
Figure 3.6 Pc values for the proportion of genes carrying SNPs as expression 




The result also suggested on the possible co-regulation of drug response by 
regulatory SNPs that are associated with gene expression. It can presumably take 
place in DRPs that are unrelated, yet carrying common drug transporters or 
metabolisers. Out of 41 DRPs, 28 (68%) and 20 (49%) have – in their common 
genes – contained one or more TF-affecting and splicing-affecting SNPs that are 
also eQTL in nature, respectively (Appendix 4). Figure 3.7A presents a schematic 
view of a presumed DRPs co-regulation phenomenon by variants in the two most 
common genes having expression-associated SNPs in their TF binding sites. 
eQTL functional SNPs in the promoter of multi-drug resistance gene, ABCB1 
(rs3747802), as well as phase II metabolising enzyme, UGT1A1 (rs10929302), 






Figure 3.7 Co-regulation of drug response by common regulatory variants in 
drug transporters and metabolizers. Expression-associated promoter TF 
binding site SNPs in ABCB1 and UGT1A1 (A) as well as extremely population-
differentiated splicing SNPs in ABCG2 and CYP3A5 (B) serve in regulating 
multiple DRPs (encapsulated by ovals). These are the most co-shared genes with 
prospective functional SNPs associated to either differential gene expression or 
extreme population difference in the DRPs.  
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3.3.4 High population differentiation in rSNPs and srSNPs of the DRPs 
 
Response to drug therapies are known to vary between different people, especially 
when they originate from populations of different genetic backgrounds. Hence the 
subsequent question was whether there is a distinct population differentiation 
pattern of SNPs within genes of the DRPs. In analyzing the pattern of population 
differentiation in the DRPs, SNP allele frequencies were derived from the 
HapMap (Phase 3) and Singapore Genome Variation Project (SGVP) genotype 
data. The allele frequency data were compiled into four major continental groups: 
Africans, Europeans, East Asians, and South Asians (see methods). For each SNP, 
the FST score was calculated and used to estimate the degree of population 
differentiation using all the available populations [22]. Based on this data, the 
extremely population-differentiated SNPs, are the SNPs in the top 5% of the 
whole-genome FST distribution. These SNPs in the top 5% are observed to have 






Figure 3.8 The distribution of FST scores of SNPs in the human genome. 
 
It could be observed that the majority (78%) of DRPs carry a substantial 
proportion of genes that house one or more extremely population-differentiated 
SNPs, higher than the genome-wide average (proportion genome-wide genes with 
high-FST SNPs = 0.27) (Fig. 3.9A). Following 10,000-time statistical random 
sampling, 11 of the 41 DRPs pose a Pc value of less than 0.05. This includes 
DRPs responsible for the beta-agonist/blocker, antiarrhythmic, bisphosphonate, 


























Figure 3.9 Population differentiation in the DRPs. (A) The proportion of genes 
(blue line) carrying one or more highly differentiated SNPs (in top 5% of 
distribution) and their Pc values (black line) across the DRPs. (B) High 
magnitude of highly population-differentiated TF binding and splicing regulatory 
sites-affecting SNPs in DRPs. 
 
Furthermore at the SNP functional level, the magnitude of highly population-
differentiated potentially functional SNPs in the DRPs are more pronounced in TF 
binding site-affecting rSNPs and splicing regulatory site-affecting srSNPs (Figure 
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antiarrhythmic and statin drugs. However, the gene functional region-directed 
random simulation showed that the pattern of population differentiation in many 
DRPs is less uniform (Fig. 3.10). This is despite the relatively more prominent 
population differentiation in the non-coding category (i.e. Intronic SNPs), but not 





Figure 3.10 High population differentiation can be more obviously seen in 
the non-protein coding regions such as the Intron and UTR categories. A heat 
map of DRP Pc values obtained from 10,000-time statistical sampling. Pc value 
approaching 0 indicates a significant and non-random proportion of genes 
carrying highly differentiated SNPs. In each DRP, the numbers in the blocks 
represent the enrichment rank associated with the specific SNP categories (ie. 
Syn, NonSyn, 3'UTR, 5'UTR, Intron, and Promoter). 
 
Furthermore, the question whether highly-differentiated regulatory variants in 
common drug-response genes could serve to co-regulate unrelated drug pathways 
was also assessed. Common genes that are shared in 32 (78%) of the DRPs are 
shown to carry extremely population-differentiated ‘splicing SNPs’, which 
suggest the potentially high influence of this functional SNP category in drug 
response (Appendix 5). On the other hand, 17 (41%) of the DRPs carry one or 
more high-FST TF binding site variants in their shared common genes. In contrast, 
only 3 (0.07%) DRPs share highly differentiated SNPs affecting protein 
deleterious substitution sites. Highly population-differentiated srSNPs in common 
metabolising enzyme, CYP3A5 (rs776746), as well as the transporter, ABCG2 
(rs2231164 and rs2725267), could co-regulate 20 different DRPs through their 
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3.3.5 Potential translational application and the antiarrhythmic drug as a 
case 
 
To investigate a possible clinical application of using SNPs architecture 
information, a pilot DRP priority scoring strategy (see methods) was designed. 
This score was used to estimate the probable occurrence of drug-response 
variation in a pathway using the features listed in Table 3.2. 
Figure 3.11 showed Py scores of all 41 DRPs in this study sorted from highest to 
lowest. A high Py score would signify a higher potential of having a drug-
response variation event. In addition, several studies that report on events relating 
to drug-response variation among different population groups were also mined 
(Appendix 6). These reports were used to corroborate the Py scores. The result 
demonstrated that as Py score increases, the number of pathway without a 
recognized report on therapy variation decreases (Fig. 3.11). DRP with relatively 
high Py scores would have had reports that indicate on experiencing a response 
difference, except for one DRP (the VEGF pathway) where literature evidence is 





Figure 3.11 The potential implication of human genetic variation to 
differences in drug response. The graph is sorted from high-to-low potential of 
having a drug-response difference based on the DRP Py scores. (Inset) The 
number of pathways with literature evidence that corroborate for the presence of 
drug response variation across different population groups. Red (Y): evidence 
found or green (N): no evidence found. 
 
A highly potential candidate for clinical application would be in the 
antiarrhythmic pathway, where Py score is the highest (Py = 0.29), and where 
previous studies have reported on population differences in response [23-24]. 
Table 3.4 provides the list of antiarrhythmic pathway SNPs that might be useful 
for future pharmacogenetics-based testing. These are SNPs that are relevant for 
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clinical study not only because of their potential functional implication to altering 
gene expression and splicing regulatory sites, but also because of the extreme 
population differentiation signature within them. Four eQTL regulatory SNPs in 
three genes are also present within the antiarrhythmic pathway (Table 3.5). 
Interestingly, SNP rs8022091 in SLC8A3 is the only high-FST SNP that is 





Table 3.4 Highly population-differentiated potentially functional SNPs in the 
Antiarrhythmic pathway. 













ATP1A1 rs1407716 0.50 TF Site 
CACNA1D rs6766988 0.57 Splicing 
KCNJ5 rs10790976 0.31 AF-SA/EU TF Site 
KCNQ1 
rs10798 0.33



















Table 3.5 Potentially functional SNPs in the Antiarrhythmic pathway that are associated with differential 
local gene-expression. 
Gene SNP Functional Category r
2 p-value FDR Associated transcript Population
HCN2 
rs34830716 
TF Site 0.444393 1.06E-06 0.00094 NM_198591 (BSG) CEU 
rs35926953 
RYR2 rs2275288 ISRE 0.352726 3.38E-05 0.016806 NM_001035 (RYR2) YRI 






In this chapter, the global SNP architecture of pathway genes important in drug 
therapies was deeply analyzed. Using the gene functional region-directed 
approach, this study reveals the high polymorphic property of the DRPs. 
Furthermore, it suggests for the prominence of SNPs with potential implication to 
TF binding, RNA splicing and protein deleterious site. The high presence of 
regulatory and RNA SNPs was also highlighted, in addition to those of coding 
SNPs in the DRPs. 
Clinical variations in therapy are well attributed to differences in the patients’ 
genetic background [1-2]. Using population genotype data, it has been shown that 
the drug-response genes are more differentiated than other genes in the human 
genome [16]. However up to the point when this study was conducted, no report 
described the relevance of population differences to the global architecture of 
SNPs functionality in these genes. In this chapter, it is shown that when 
population differentiation is considered, the magnitude of functional cSNPs in the 
DRPs is lower. The low frequency diversification of functional cSNPs could 
suggest that population differences in drug response may less be affected by SNPs 
acting on a protein structural level. Instead, there is a higher plausibility that these 
population differences in drug response are more affected by SNPs acting on gene 
regulation, as shown by the high prevalence of extremely population-
differentiated rSNPs residing in TF binding sites as well as rsSNPs residing in 
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splicing regulatory regions. This result therefore implies the importance of these 
rSNPs and rsSNPs in drug response. 
Gamazon et al has previously shown that chemotherapeutic drug susceptibility-
associated SNPs are enriched in expression quantitative trait loci (eQTL) [25]. 
This is aligned with the results obtained in this chapter, as it was also observed 
that there are many more DRP genes that house rSNPs and srSNPs associated 
with changes in gene expression profile. In fact, the result presented in this 
chapter could further extend the knowledge that was reported by Gamazon et al, 
by providing a layer of SNPs potential functionality in mind. This implicates the 
rSNPs and srSNPs and their probable significance in regulating the expression of 
genes in the DRP. It is valuable for designing future studies because the insight 
provided here could put more weight on these rSNPs and srSNPs, highlighting 
their equally important role compared to the cSNPs. In fact, my argument is 
parallel to the discussion that was presented by Sadee et al [12]. 
Furthermore, a drug PK/PD process is not an isolated event [19-20], yet many 
pharmacogenetics studies focused only on certain candidate genes in studying the 
role of SNPs in inducing drug response variation. This traditional approach would 
isolate other genes or SNPs within the same pathway, which may be equally 
crucial as the candidate gene or the candidate SNP itself. Here using the DRP-
based approach, it can be shown that the pathways responsible for drug therapies 
are not only highly polymorphic in nature; but also have high magnitude of 
expression-associated or population-differentiated rSNPs and srSNPs. Many of 
these SNPs could have been missed out if one is to use the traditional candidate 
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gene- or SNP-based approach in pharmacogenetics. Hence in this chapter, it is 
shown that the PK/PD pathway-based approach in analyzing the genetic basis of 
drug response is arguably effective, allowing one to gain a deeper understanding 
of the genetic pattern in these drug-response genes. In another word, this gives 
ability to have a ‘helicopter view’ of the polymorphisms residing in these genes 
before we narrow down to study a particular SNP in detail. 
Moreover, with this pathway-based approach, a potential phenomenon in which 
several unrelated DRPs are possibly being regulated by a selected gene could also 
be observed. An rSNP in the ABCB1 transporter (rs3747802) and another one in 
the UGT1A1 metabolizer (rs10929302) are found to be involved in multiple 
DRPs. Respectively, these SNPs are potentially functional in the TF binding on 
the promoter region, in addition to being associated with differential gene 
expression. Furthermore, the rs10929302 or UGT1A1*93 (5’ UR -3136G>A) 
polymorphism has previously been shown to be associated with the different 
susceptibility of Irinotecan-induced toxicity [26-28]. Based on this result, it is 
suggested that this same rSNP could also functionally affect pathways associated 
with other drugs such as etoposide, statin and losartan.  
In addition, this phenomenon is also observed in rSNPs that are population-
differentiated. One high-FST rSNP in the CYP3A5 metaboliser (rs77646) and two 
high-FST rSNPs in the ABCG2 transporter (rs2231164 and rs2725267) have 
potential functional impact on RNA splicing. The SNP significance is supported 
by Zeng et al, who in 2011 reported a candidate gene-based study of 211 
pancreatic cancer patients (137 of whom have had chemotherapy), where the 
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rs2231164 (ABCG2 Intron 14 -46A>G) variant was found to have been associated 
with survival [29]. 
Moving forward, it can therefore be expected that when performing functional 
studies involving a SNP or gene that is commonly involved in multiple drug 
pathways, one could also expect to also see the SNP effect in several different 
drug pathways. The reason is because this SNP is involved in multiple DRPs. 
There is a potential application from this pathway-based potentially functional 
SNPs analysis. Hence, the last part of this chapter presented an attempt to 
prioritize drug pathways based on their potential therapeutic differences. A 
scoring method was developed, taking account of the DRP SNPs potential 
functional and population differentiation status. The different weight applied on 
the variables could assist prioritization using extremities (such as extremely high 
FST SNP in a gene) as an underlying factor. As Py score increases, there are more 
pathways that could be corroborated by reports that support on the presence of 
clinical difference in therapeutic response. In the case of the antiarrhythmic 
pathway, where Py score is the highest, a list of extremely population-
differentiated rSNPs and srSNPs was provided, in addition to those that are 
associated with differential gene expression. Therefore the clinical utility of these 
SNPs can be explored further. 
However, because both the HapMap and Singapore Genome Variation projects 
employed the tag-SNP approach to genotyping SNPs, limitations exist, 
particularly whether these 1.4 million SNPs could serve as the best representative 
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of other SNPs in the drug-response genes, or more, the human genome. In fact, no 
representative SNP method is ideal in pharmacogenomics except one method: by 
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Chapter 4. Population Differentiation Pattern in 





The previous chapter highlighted the result of studying population differentiation 
pattern of SNPs in conventional drug-response genes. However, there is a 
limitation that these HapMap tag-SNPs may not be the best representatives of all 
SNPs in our genome. Hence in this chapter, with available genome-wide data 
from the 1000 Genomes Project, which at that time had just released its Phase 1 
data, I expanded the analysis to a genome scale. This data would cover all SNPs 
that could be identified from genome sequencing results of thousands of 
individuals. In addition, the data would eventually cover novel genes that may be 
important in drug response, in addition to the ‘conventional’ drug-response genes 
and SNPs that were covered in the previous chapter. 
In this chapter, the main focus is to articulate the novel pattern of genetic 
differentiation in addition to elucidating their potential functional relevance in the 
genomes of individuals that participated in the 1000 Genomes project. During the 
initiation of this thesis, few had deeply investigated this potentially intriguing 
pattern of population differentiation in our genome as prior to the advancement of 
DNA sequencing technology, such data was sparse. The effort that is focused here 
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is based on a novel approach, which to the best of my knowledge, had not been 
adopted in previous studies. Here, using the 1000 Genomes project (Phase 1) data, 
a genome-wide scan of pattern of genetic differentiation is conducted in 14 global 
populations that originated from four different continents: Latin America, Europe, 
Africa, and East Asia.  
I present the identification of ‘top chromosome differentiated SNPs’ (tcdSNPs) 
and the genes that house these SNPs, the ‘tcdGenes’. Many of these SNPs are also 
predicted to have a functional significance. The identification of tcdSNPs had also 
allowed a significant expansion of work that was done in chapter 3 of this thesis, 
whereby using this data, we can now better elucidate the potential routes in which 
population genetic differentiation can contribute to population differences in drug 
response. 
Furthermore, it is intriguing to investigate the biological pathways that are 
affected by population-differentiated genes. Hence towards the last part of this 
chapter, tcdGenes enrichment in biological pathways was investigated. Because 
human phenotype differences are determined by the variation of pathways activity, 
this approach would be extremely relevant in determining the connection between 
differentiation in population genetic architecture with that of phenotype variation 
seen across different populations. By identifying pathways that are enriched by 
tcdGenes, we could point to a possible population differentiation determinant that 




4.2.1 Estimating Population Differentiation from 1000 Genomes Data 
 
In this chapter, genome-wide population differentiation was estimated from 
publicly available data that was released by the 1000 Genomes project (Phase 1) 
[1]. This encompasses allele frequency data from 1,092 individuals who are 
originated from 14 different populations, which was derived by the use of the 
VCF tool (version 0.1.9). Based on their geographic origins and genetic 
relatedness, these diverse populations could broadly be clustered based on four 
different continental origins: Africa, East Asia, Latin America, and Europe. 
The African cluster encompasses the ASW (African ancestries from Southwest 
United States), LWK (Luhya individuals in Kenya) and YRI (Yoruba individuals 
in Nigeria). The East Asian populations are CHB (Han Chinese in Beijing, China), 
CHS (Han individuals in Southern China) and JPT (Japanese individuals in Tokyo, 
Japan). Three populations belong to the Latin American group including the CLM 
(Columbian in Medellin, Columbia), MXL (Mexicans in Los Angeles, United 
States) and PUR (Puerto Rican in Puerto Rico). The IBS (Iberian in Spain) lies 
somewhere between the Latin American and European cluster. Lastly, the 
European groups consisted of individuals from the CEU (Northern and Western 
European ancestries in Utah, United States), FIN (Finish in Finland), GBR 
(British in England and Scotland, Great Britain), TSI (Toscani in Italy). 
The SNP allele frequency data was used for the estimation of population 
differentiation using FST statistics [2, 3]. The FST score calculation method 
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employed in this chapter is identical to the one utilized in the previous chapter, 
albeit performed in a significantly bigger data size. Here, FST scores were 
calculated based on population pair comparisons. This was performed using an ‘R’ 
script that was originally constructed for the course of this thesis. The ‘R’ script 
was deployed in the LCFG high performance work stations, in addition to the 
NUS high performance computing cluster across multiple processing nodes. 
4.2.2 Identifying maximum-differentiated SNP clusters in the human genome 
 
The greater SNPs coverage in the 1000 Genomes Project Data has opened the 
possibility of performing a genome-wide analysis of SNPs population-
differentiation, in investigating the population differentiation pattern of the human 
genome. By identifying SNP clusters that contain the ‘maximum-differentiated’ 
SNPs, we could identify chromosome regions that could have been subjected to 
population differentiation or selection process. Here, I have developed a novel 
approach in identifying tcdSNPs that are located within the SNP clusters that are 
assosciated with the maximum FST scores in a given population pair comparison 
across 23 human chromosomes. An algorithm that is based on a ‘roll mean’ 
method was developed to compute the moving average spanning a window size of 
15,000 SNPs, which corresponds to the size of the cluster (Fig. 4.1). A cluster 
carrying SNP associated with the maximum average FST score could be identified 
by reading maximum peak region. The algorithm then mined the top 5% of SNPs 
in this cluster, which carry the highest FST scores in the respective cluster. These 
SNPs are then classified as the 'top chromosome differentiated SNPs' (tcdSNPs). 
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The distribution of FST scores across the SNP gene functional region that is 
presented in this chapter was analysed based on two population pairs from 





Figure 4.1 Algorithm for finding maximum-differentiated SNP clusters 
 
4.2.3 Genome-wide SNPs mapping to functional gene regions 
 
SNPs that reside within functional gene region are labelled ‘genic’ SNPs whilst 
those outside of genes are labelled ‘intergenic'. SNPs classification was performed 
using the functional region-directed approach as explained in the previous chapter. 
However, unlike what was performed in the previous chapter, mapping the 1000 
Genomes SNPs to the functional gene regions is more challenging, which is 
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used as reference, a significant upgrade of SNPs collection to that of build 131. 
The ‘top chromosome differentiated genes’ (tcdGenes) are defined as genes that 
house one or more tcdSNPs. 
4.2.4 tcdGenes enrichment in biological pathways 
 
Population-differentiation in genes in biological pathways could potentially result 
in the variation of phenotypes seen in different population, including drug 
response variation. To investigate this potential impact of population genetic 
differences, several enrichment analyses using a diverse collection of biological 
pathways were performed. In this chapter, the curated pathways information was 
obtained from the Ingenuity Pathway Analysis (IPA), KEGG [4] and Gene 
Ontology (GO) [5] databases. With the exception of the IPA pathway analysis, all 
enrichment analyses were done in the ‘R’ environment by utilising the 
clusterProfiler package (version 1.10.0) [6]. The enrichKEGG function was 
selected for analysing population-differentiated genes enrichment in the KEGG 
pathways, whilst the enrichGO function was used for the analysis involving the 
GO database. For each pathway in the database, all functions will compute the 
enrichment of population-differentiated genes. The ‘enrich’ functions are 
modelled based on the hypergeometric distribution. Enrichment is defined when a 
pathway achieves P-value less than 0.00005, a very stringent cut-off that take 
account the Bonferroni multiple tests error correction. The QIAGEN’s Ingenuity® 
Pathway Analysis (IPA®, QIAGEN Redwood City, www.qiagen.com/ingenuity) 
was used to conduct the IPA analysis. 
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4.2.5 Population differentiation in pharmacogenomics pathways  
 
In this thesis, my work encompasses the integration of drug pathways or gene sets 
from multiple resources, which will be mainly utilized in the next chapter. Briefly 
for this chapter, the drug-response genes collection was significantly expanded as 
compared to the previous chapter. In addition to annotated genes information 
from the PharmGKB database [7], drug-response genes collection were also 
obtained from the DrugBank [8], ChEMBL (version 13) [9], and the Comparative 
Toxicogenomics Databases (CTD) [10]. Genes in these pharmacogenomics 
pathways were previously curated based on their association with a drug and/or 
other compounds. 
Furthermore, a subset of the tcdGenes are linked to these pharmacogenomic 
pathways. These tcdGenes were then used in pathway enrichment analysis. Each 
pathway is associated with drugs or compounds that were approved by the US 
food and Drug Authority (FDA) and the proportion of such genes in all the 
pharmacogenomics pathways was calculated. 
For each pathway, tcdGenes enrichment analysis was performed using random 
sampling statistical exercise. As performed in the previous chapter, this random 
sampling simulation involved a 10,000 time iterations of random samples from 
the genome, with the same number of genes as found in the pathway. These genes 
would also have to fall within the same size range as the pathway or drug gene set. 
Subsequently, the multiple sampling iterations allowed the formation of an 
approximately normal empirical distribution that is unique for each drug gene sets. 
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Using this distribution, a ‘Z-score’ was derived according to the following 
equation. 
Z	score ൌ p‐ePeSD  
Where: 
p       = proportion of tcdGenes in drug-response gene set 
eP     = average proportion of tcdGenes in empirical distribution of the 
respective drug 
eSD  = standard deviation of empirical distribution of the respective drug 
A high Z-score, particularly one that is higher than 1.96, signifies a non-random 
observation of high proportion of tcdGenes in the drug-response gene set, whereas 









4.3.1 Population differentiation in different world regions 
 
In this chapter, the SNP data that were utilized mostly originated from the 1000 
Genomes Project. A total of 31,953,064 SNPs are annotated in the NCBI dbSNP 
database (build 137). FST calculations were successful for 22,866,661 SNPs, 
accounting for 71.56 percent of the total number of SNPs mined from the 1000 
Genomes Project. In 28.44 percent of the SNPs, the FST algorithm encountered 
computation error which could possibly be attributed to the presence of mono 
allelic SNPs or variant call error. In comparison to the HapMap SNPs that were 
utilised in chapter three, which publicised up to 1.4 million SNPs, the 1000 
Genomes Project data is 16 times more vast and covered significantly more part 
of the human chromosomes. 
To estimate pairwise differentiation across 14 populations, which equates to 91 
population pairwise combinations, the Weir FST statistics were calculated using 
SNPs allele frequency. The average FST between populations that are originated 
from a more similar geographic region tend to be lower than those that are 
separated by a further geographic distance (Fig. 4.2). For instance, in the 
European population groups, average FST lies between 0.001 and 0.0062. 
Moreover, not only that the CEU-GBR pair is the least differentiated among the 
European population, it is also the most similar population pair of all the other 
populations in the 1000 Genomes Project. On the other extreme, the highest 
differentiation is observed between the East Asian and African populations. The 
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CHS-YRI pair has an average FST of 0.037 and is the most differentiated 
population pair (Fig. 4.2A). Moreover, the results presented in this thesis suggest 
the closer genetic distance between the European populations and the Latino 





Figure 4.2 Population differentiation pattern in 14 global populations that 
participated in the 1000 Genomes Project. (A) The average pairwise FST scores 
computed from SNPs in the top 5% of the population pair FST distribution. (B) 
Population differentiation as seen using a phylogenetic tree that was constructed 
using the average pairwise FST scores of the SNPs within the top 5% of the 
population pair FST distribution. 
  
A




FIN 0.0022 0.0022 0.0033
IBS 0.0049 0.0045 0.0049 0.0062
MXL 0.008 0.008 0.0083 0.008 0.0094
CLM 0.0048 0.0048 0.0049 0.0055 0.0056 0.0032
PUR 0.0047 0.0048 0.0046 0.0058 0.0051 0.0053 0.0028
JPT 0.0189 0.0189 0.0189 0.0177 0.0267 0.0134 0.0159 0.0182
CHB 0.0185 0.0185 0.0184 0.0173 0.0264 0.0132 0.0157 0.0181 0.002
CHS 0.0191 0.0191 0.019 0.0179 0.0277 0.0139 0.0164 0.0187 0.0025 0.001
ASW 0.0239 0.0241 0.0244 0.025 0.0183 0.0203 0.0169 0.0146 0.0308 0.0312 0.0319
LWK 0.0305 0.0306 0.0305 0.0313 0.0291 0.0276 0.0246 0.0224 0.0347 0.0349 0.0354 0.0048
YRI 0.0324 0.0326 0.0324 0.0332 0.032 0.0295 0.0266 0.0244 0.0362 0.0364 0.037 0.0043 0.004
0.001 0.01 0.019 0.028 0.037
Average FST
Average FST score of 

























Furthermore, within similar geographic region, the African populations (ASW, 
LWK and YRI) are more diversified, suggesting the stronger presence of ‘local 
differentiation’ that leads to more diversification in Africans. On the other hand, 
there is less local differentiation within the East Asians, Latinos and Europeans 
populations (Fig. 4.2A and 4.2B). This shows high diversity within the African 
populations, in addition to the further genetic separation of this populations group 
compared to the Europeans, Latinos and East Asians. Furthermore, the East Asian 
group of populations, as shown by the shorter branch length, is less diversified 
than the other population groups (Fig. 4.2B). This result suggests the presence of 
lesser genetic diversity in the East Asian populations as compared to that of the 
Africans. In this study, the IBS population is considered as a ‘standalone’ 
population because it is not grouped to any one of the continental population 
cluster due to its relatively low similarity with the other populations. 
 
4.3.2 FST scores distribution in human genes 
 
The underlying hypothesis in this chapter is that outside of gene region, there is 
less potential functional impact that DNA sequence variation could potentially 
exert, hence intergenic SNPs are more susceptible to population differentiation. 
To address this hypothesis, this chapter compared the average population 
differentiation scores between genic and non-genic SNPs, in two most extreme 
population-pairs. The first one is in CHS-YRI, the two most genetically different 
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population (average FST = 0.037), whilst the other pair is the two most genetically 
similar populations CEU-GBR (average FST = 0.001) (Fig. 4.2A). 
In CHS-YRI, the average FST score of non-genic SNPs is significantly higher than 
those in the genic region (P-value < 2.2 x E-16) (Fig. 4.3A). Similarly, in the two 
most similar populations (CEU-GBR), non-genic SNPs also have a significantly 





Figure 4.3 Population differentiation across gene functional regions. (A) 
Significant difference in average FST scores between the genic and intergenic 
regions in both CHS-YRI and CEU-GBR population pairs (P-value < 2.2 x E-16). 
The FST scores distribution across different gene functional regions in these two 
population pairs are shown in (B).  
 
In gene regions, the SNPs are classified based on their location such as promoter, 
5’ UTR, 3’ UTR, intron as well as the coding non-synonymous and coding 
synonymous SNPs. In the CHS-YRI pair, the overall distribution of FST scores 
across these different categories seems to be no different (Fig. 4.3B). A t-test 
performed between the average FST scores of the SNPs in the 5’ UTR and 3’UTR 
yielded a P-value of 0.039 in the CHS-YRI population pair. In the CEU-GBR pair, 
where overall FST scores are much lower than the CHS-YRI pair, significant 
differences in the FST scores distribution is observed between SNPs in the 
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promoter versus 5’ UTR, promoter versus coding non-synonymous, in addition to 
the 5’ UTR versus intron comparison. 
 
4.3.3 Genomic signature of ‘maximum population differentiation’ 
 
Since the 1000 Genomes SNPs data is vastly distributed across the spectrum of 
the human genome, we could perform a genome-wide scan to find the SNPs that 
are associated with ‘maximum population differentiation’. These SNPs were 
identified using an algorithm that was constructed based on a roll-mean function. 
It first computed the moving average FST scores using 15,000 SNPs sliding 
window, which provided a significant noise reduction as compared to smaller 
window size. Subsequently, using these moving average values, group of SNPs 
with the highest moving average were identified. These groups of SNPs are 




Figure 4.4 The roll mean or moving average analysis of population-pair FST scores in chromosome 6. Each graph represents the 
population-pair differentiation pattern of SNPs in chromosome 6. The graphical summary was arranged in accordance to the FST tree 
branching (centre), which represents the average degree of differentiation between one population and another population. Here, the 
population pairwise comparisons were clustered into subgroups based on their general differentiation pattern in the whole genome. 
The y-axis is the moving average value that was calculated from a sliding window of 15,000 SNPs, whilst the x-axis is the index of 
SNPs from the 5’ to the 3’ end of the chromosome. 
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Within these maximum-differentiated SNPs cluster, the algorithm then fetched 
SNPs in the top 5% of the FST distribution of the respective cluster. These SNPs 
are referred as the ‘top chromosome differentiated SNPs’ (tcdSNPs). Figure 4.4 
displays the results of this analysis in chromosome 6, and figure 4.5 presents the 
result across eight representative population pairs. Four pairs represent the 
populations from close (CEU-GBR, CHB-CHS, ASW-LWK, and MXL-CLM) 
and distant (CHS-YRI, IBS-YRI, GBR-YRI, and YRI-JPT) geographical origins, 
respectively. In the former group, there is a consistent occurrence of maximum 
differentiation in the SNPs cluster that is located around the 30 millionth base 
region, which is approximately at locus 6p21 in chromosome 6 (shown as region 
between 400,000 and 600,000 SNP indices in Fig. 4.4 and 4.5).  
However, in the group of population pairs that are originated from  geographically 
distant location (with average FST of more than 0.03), this pattern is not observed. 
This is due to the presence of other high peak regions at these distant population 
pairs. Hence, this 'signal' is stronger in genetically more similar individuals but is 
masked by the presence of other genetic differentiation in more distant population 
groups.  
The result may suggest the potential significance of population genetic 
differentiation in genes located at the 6p21 locus. Morever, because the 
population differentiation pattern is only seen across populations that are 
genetically similar, but not in genetically more different individuals, the result 
could suggests for the presence of population-differentiated genes or chromosome 




Figure 4.5 The roll mean or moving average analysis for FST scores in 
chromosome 6 across representative population pairs. The y-axis is the 
moving average value that was calculated from a sliding window of 15,000 SNPs, 
whilst the x-axis is the index of SNPs from the 5’ to the 3’ end of the 
chromosome. 
 
4.3.4 Genes in the maximum-differentiated SNPs clusters 
 
The maximum-differentiated SNPs clusters that are unique to the different 
chromosomes and 91 population-pair combination consisted of 15,000 SNPs. 
Since these genic SNPs are mapped to NCBI genes, the genes that can be 
associated with SNPs in these maximum differentiation clusters could be 
extracted. Through this work, a total of 579,291 tcdSNPs are found to reside 
within the maximum-differentiated SNPs clusters. On average, a human 
chromosome contains 25,186.57 tcdSNPs that are located within maximum-
differentiated SNPs clusters. Chromosome X has the smallest number of tcdSNP 
(17,776 SNPs) whilst Chromosome 16 has the highest number of such SNPs 
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(30,057 SNPs) (Fig. 4.6A). These SNPs have the potential to affect phenotypic 
variation that we can observe in different human populations. 
Out of 579,291 tcdSNPs, 236,679 (41%) can be mapped to a total of 4,355 NCBI-
annotated genes, which are referred to as ‘top chromosome differentiated genes’ 
(tcdGenes). For chromosome 6, there are 181 annotated genes which carry 
tcdSNPs, 35 of them are differentiated between the CEU and GBR in 
chromosome 6 (Appendix 7). For this case, it is observed that there is a high 
number of tcdSNPs in HLA-C, a chromosome 6 gene that encode the MHC class 
I heavy chain receptor type of protein. Depending on its mRNA splice form, the 
HLA-C is potentially affected by ~60 tcdSNPs for the CEU-GBR population pair. 
And these SNPs are scattered on the 5’ upstream and 3’ downstream regions, in 
addition to that of the Exon, Intron and 3’ UTR regions. Another interesting 
observation in chromosome 6 is in the case of the TRIM genes family. Out of 8 
TRIM members in this chromosome, 6 genes carry tcdSNPs. These are TRIM 10, 
TRIM15, TRIM26, TRIM31, TRIM39, and TRIM 40, which could be potentially 
affected by these high FST SNPs. 
Chromosome 6 however, contains relatively lower proportion of tcdGenes. As 
shown in Figure 4.6B, it is the smaller chromosomes that have the highest density 
of such genes. For instance in chromosome 22, there are 257 out of 629 genes 
(41%) that are classified as tcdGenes (Fig. 4.6B). The larger chromosomes, such 
as chromosomes 1, 2 and 3, are less dense in tcdGenes with 261, 224 and 165 
tcdGenes, respectively (Fig. 4.6B). 
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To elucidate the genomic population differentiation pattern, the work in this 
chapter then focused on accessing its significance in three important gene 
functional regions: the regulatory Promoter and 3’ UTR, as well as the protein 
coding region. Subsequently, in investigating the potential functional significance 
of such SNPs, the next step was to filter the tcdSNPs that are predicted to be 
functionally important including in sites that are crucial for transcription factor-
binding, miRNA-binding and protein functional domain. By utilizing the 
potentially functional SNPs (pfSNP) database, it is identified that 48% or 5,394 
out of 11,245 tcdSNPs could potentially be functionally important in the coding 
region (Fig. 4.6C). In the promoter region, there is a higher absolute count of 
tcdSNPs that could be functionally important such as in affecting transcription 
factor binding sites, numbering 22,999 SNPs out of a total number of 78,104 
promoter tcdSNPs (29%). Moreover in the 3’UTR region, 28% or 4,745 out of 





Figure 4.6 SNPs in the maximum-differentiated SNPs clusters. (A) Total number of tcdSNPs residing in the 
maximum differentiated SNPs clusters in different chromosomes. (B) The proportion of tcdGenes carrying tcdSNPs is 
displayed by the line chart (primary y-axis). The bar-chart displays the total number of tcdGenes (secondary y-axis). 
(C) tcdSNPs that are potentially functional in the promoter, 3’ UTR and coding gene regions. (D) The proportion of 
tcdSNPs that is potentially functional across the top 10 population pairs. The top three population pairs involved the 
Japanese and African populations. 
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Furthermore, the subject was further examined in different population pairs. With 
16.5% of tcdSNPs that are predicted to be functional, the JPT-YRI is associated 
with the highest proportion of tcdSNPs that are potentially functional (Fig. 4.6D). 
Furthermore as shown in Figure 4.6D, the JPT-LWK and ASW-JPT, which are 
both Japanese-African pairs, respectively have 16.4 and 16.2% of the tcdSNPs 
that are predicted to be functional. The subsequent population pairs with relatively 
high percentage of potentially functional tcdSNPs are the CHB-YRI (16.3%) and 
CHS-LWK (16%), which belong to the Chinese-African pair combination (Fig. 
4.6D). 
In addition, based on the result of this analysis, in East Asians, there is a higher 
proportion of tcdSNPs that are predicted to affect the promoter region as 
compared to the other populations (Fig. 4.7). The top seven population pairs with 
relatively higher proportion of tcdSNPs that are potentially functional in the 
promoter are the combination between East Asians (CHB, CHS and JPT) versus 
any of the European (FIN and GBR), Latin American (PUR and CLM) or African 
(ASW) populations (Fig. 4.7). Furthermore in the 3’ UTR region, with the CLM-
YRI on top, the proportion of potentially functional tcdSNPs are more uniform in 
the top 20 population pairs. For the coding SNPs, the top two populations that 
carry a relatively higher percentage of potentially functional tcdSNPs are the 




Figure 4.7 The top 20 population pairs based on the proportion of tcdSNPs 




4.3.5 Does size matter? 
 
So far in this chapter, it is observed that there is a high proportion of tcdGenes in 
chromosomes that is releatively smaller in size. This prompted the question 
whether there is a correlation between chromosome size and the prevalence of 
population differentiation in the different chromosomes. 
To address this question, an estimate measurement of the prevalence of 
population differentiation was established. This was done using the 'Differentiated 
Population-Pairs Ratio' (DPPR).  DPPR was obtained by counting the total 
number of population-pair differentiation that is observed in a chromosome. The 
raw count was then normalised by the maximum number of differentiated 
population pairs that could have been possibly observed in that chromosome. 
Hence, chromosome with large DPPR is postulated to be more susceptible to 
population differentiation.  
As observed in Figure 4.8A, there is a tendency that the smaller chromsomes have 
relatively high DPPR score. In contrast, it is observed that the larger chromsomes, 
such as chromosomes 1, 2, 3, 4, and 5, have releatively smaller DPPR scores. 
Furthermore, in comparison to the other chromosomes, the smallest chromosome 
22 has the highest DPPR. This signifies higher prevalence of population-pairs that 




Figure 4.8 Population differentiation and chromosome size - does size matter? Differentiated Population Pairs 
Ratio (DPPR) is the proportion of the count of observation of highly-differentiated population pairs in a chromosome, 
normalized by the total number of population-pair differentiation that could have been possibly observed. (A) Smaller 
chromosomes tend to have larger DPPR as compared to the larger chromosomes. (B) Plotting chromosome size against 




In addition, to eventually look into the possible correlation between chromosome 
size and the DPPR, a x-y plot was constructed. A negative exponential correlation 
(R2 = 0.3934) is observed when plotting chromosome size against the DPPR (Fig. 
4.8B). Here, it is observed that chromosome 9, which is 141 million basepairs in 
size, has a DPPR of 0.0025409, the lowest of all chromosomes. In comparison, 
chromosome 22 is the chromosome with the highest DPPR (0.0256643), which 
signifies for the more prevalence of population pairs that are affected by the 
tcdGenes. Chromosome 22 is 51 million basepairs in size. 
Figure 4.9 presents the tcdGenes carrying SNPs that are extremely differentiated 
in 30 or more population pairs, which include the OCA2, GABRG3, HERC2, 
HLA-DBR1, and HLA-DBR6. The OCA2 and HERC2 genes especially, are 
known to have been associated with eye colour determination in human. 
4.3.6 Enrichment of tcdGenes in pathways 
  
One method for deducing the potential functional significance of population 
differentiation is to explore the biological pathways that are affected by the 
tcdGenes. In figure 4.10, the KEGG pathways that are enriched by these tcdGenes 
are presented. The analysis had taken into account the grouping of populations 
based on their continental origins. Since the IBS population does not belong to 
any particular continental cluster (Fig. 4.2B), this population is excluded in this 
analysis. In Figure 4.10, the African population group is noted to be associated 
with the highest number of pathways that are significantly enriched by the 
presence of tcdGenes that are extremely differentiated against the other 
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populations. These pathways range from one that is associated with 
Staphylococcus aureus infection to autoimmune thyroid disease pathway. One 
pathway with a significant percentage of tcdGenes only in the African population 
is the Leishmaniasis pathway. Enrichment of tcdGenes in the cell adhesion 
molecules (CAMs) pathway on the other hand, is only significant in the Latin 
Americans. In addition, the data also suggest for the significant enrichment of 
tcdGenes in olfactory transduction pathways in East Asians, Europeans and Latin 











Figure 4.10 Enrichment of tcdGenes in KEGG pathways. Each column 
represent the significant presence of tcdGenes that are extremely differentiated 
between one group of populations and the rest of the population groups. The 
population groups are AF (Africans - ASW, LWK and YRI); EA (East Asians - 
JPT, CHB, and CHS); EU (Europeans - CEU, GBR, TSI, and FIN); and LA 
(Latin Americans - MXL, CLM and PUR). The size of the circle corresponds to 
the proportion of tcdGenes in the pathway whereas the color signifies the 
enrichment P-value.  
  
Continental Population Group 
AF   EA  EU  LA
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In addition, Figure 4.11 shows the results of GO molecular functions enrichment 
analysis. Based on this observation, there are two molecular function groups 
which are differentiated only in one continental population group. In East Asians 
for instance, the nucleoside and antigen binding-related molecular function 
categories are significantly enriched by tcdGenes (shaded purple). For the Latin 
Americans group, such enrichment can be observed in the molecular functions 
categories that are relevant to carbohydrate binding; transferase activity; 
transferring acyl groups; serine-type endopeptidase activity; transferase activity; 
transferring acyl groups other than amino-acyl groups; protein C-terminus binding; 
and serine-type peptidase activity (shaded brown). Some if not all of the genes in 
these group of molecular functions were previously thought to have been more 
conserved, rather than extremely population-differentiated. Several additional GO 
annotations that are generally enriched by tcdGenes include the MHC class II 
receptor and the general umbrella of the molecular function GO annotation itself 
(shaded green).  
The next part of the enrichment analysis takes account canonical pathways 
collection that are available at the Ingenuity Pathway Analysis (IPA) platform. 
Here, the antigen presentation pathway, with more than 60 percent of it genes 
associated with tcdSNPs, is observed to have the lowest statistical P-value (Fig. 
4.12A). This is followed by the allograft rejection and OX40 signalling pathways. 
Another notable observation is that in this study, most (8 out of top 10) of the top 
pathways with significant enrichment of tcdGenes, are relevant to the immune 
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system. This suggests the importance of population differentiation in these 
‘immune genes’. 
To further assess the pathways enrichment, a deeper stratification based on the 
three SNPs functional gene region categories were conducted. These are SNPs 
that are predicted to be functional in the promoter, 3’ UTR and coding region, 
including their potential functional significance in the respective category. The 
result presented in this part of this chapter suggests a constant enrichment of the 
Antigen Presentation Pathway, OX40 Signalling Pathway and Allograft Rejection 
Signalling Pathway by tcdGenes carrying potentially functional tcdSNPs in the 
promoter (Fig. 4.12B), 3’ UTR (Fig. 4.12C) and coding regions (Fig. 4.12D). 
There is a consistent enrichment pattern, regardless of the SNPs functional 
categories, suggesting the potential importance of population differentiation in 
this group of pathways, which is typically relevant to the immune system and is 










Figure 4.12 Enrichment of tcdGenes in canonical pathways. The bars signify the enrichment P-value (primary y-
axis) and the line depicts the proportion of such genes in the pathway (secondary y-axis). The analysis was performed 
with pathways that are made available by the QIAGEN’s Ingenuity® Pathway Analysis using all genes carrying 
tcdSNPs (A), in addition to genes carrying tcdSNPs that are also predicted to be functional in the promoter (B), 3’ UTR 
(C) and coding (D) regions.  
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4.3.7 Pharmacogenomics utility 
 
The results obtained in this chapter provided a backbone data for the subsequent 
part of this thesis, in attempting to identify SNPs that are relevant for population 
differentiation of drug response. In this section of the chapter, I would like to 
present a pilot project that can bring us closer towards translational 
pharmacogenomics. 
Here, the focus was to investigate population differentiation of genes that are 
central in pharmacogenomics. In doing so, the first step was to explore whether 
there are any drug-response gene sets that are associated with high presence of 
tcdGenes. Therefore, the pilot work involved investigation of the tcdGenes 
enrichments in a wide array of drug-response gene sets. For each set, a statistical 
random sampling with 10 thousand times iteration was conducted. The 
background genes were obtained from the genome, which consisted of 22.5% 
tcdGenes. In Figure 4.13, drugs/compounds with z-score of more than 1.96, which 
are enriched by tcdgenes are displayed. A drug with high z-score is implied to 
have a non-random enrichment of tcdGenes. Top scoring dugs/compounds (z-
score > 3) include selenium, vitamin E, bortezomib, arsenic trioxide, vorinostat, 
cisplatin, decitabine, pentagastrin, and eight additional drugs. In these drugs, the 
proportion of tcdGenes range from 25 to 100 percent of the drug-response gene 
set. This is relatively higher than the percentage of tcdGenes in the genome 








The top scoring compound, selenium, has a central role in a number of enzymatic 
reactions in which it acts as a cofactor. Among the sources of this essential 
micronutrient include yeast breads, meats, poultries, fishes, eggs, and milk [11]. 
In this study, out of 1,394 genes that can be associated with selenium, 414 are 




The presence of genetic polymorphisms is an important factor that determines 
variation in phenotype. Having a substantial knowledge of  the population 
differentiation pattern of the human genome is essential, before applying this 
genomic architecture for pharmacogenomics purposes. One of the main focuses of 
this chapter was to obtain genome-wide population differentiation data, which can 
be utilized for multiple purposes, including pharmacogenomics. Unlike other 
study predecessors, this thesis chapter did not focus on using the tag SNPs or 
candidate genes approaches in finding population genetic differentiation signature 
in human. Instead, the focus was to elucidate the differentiation pattern using 
most SNPs that have been identified in the human genome. This was achieved by 
computing the FST scores of almost 23 million SNPs in the human genome, based 
on allele frequency data that has been released by the 1000 Genomes Project. 
In addition, because the 1000 Genomes project employed a next-generation 
genome sequencing technology, it allowed the examination of most if not the 
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entire SNPs list from the thousands individuals who participated in this study. 
This is a significant improvement over the tagging SNPs approach as every SNP 
could now ‘democratically represent itself’, rather than be represented by a 
sample of tag SNPs. Hence, with the exception of mono-allelic SNP or those that 
are associated with variant call error, no SNP is left out in this study. This would 
then open up more possibility in finding SNPs that contribute to population 
differentiation. In general, these SNPs are scattered all around the genome, both 
within functional genes and non-genic regions. 
Moreover, in studying the population genetics factor behind drug response 
variation, having an in depth knowledge of the human genome background would 
ensure that no single gene is neglected. Traditionally, pharmacogenomics focuses 
in conventional genes list that are believed to have been associated with drug 
response. However, with the availability of the genome sequences of thousands of 
individuals, we are entering a new era in science and medicine, in which there is a 
potential translational utility of personal genomic information that may have 
arisen from non conventional drug-response genes, which are genes that have not 
been traditionally included in pharmacogenomics studies. In achieving this, the 
initial step was therefore to first elucidate the whole genome genomic pattern that 
contributes to population differences in phenotype. This chapter of my thesis 
examined human population differentiation in the genetic level, and it opened 
more paths for further examinations on the specific genes, pathways or networks 




One important contribution of this chapter is in the discovery of novel knowledge 
surrounding population diversity. Here, it is observed that there is relatively less 
differentiation within the East Asian or European populations. In contrast, this 
‘local differentiation’ is greater among the Africans as compared to the other 
population groups. Furthermore, the approach that was adapted in this chapter is 
hypothesis free, which involved a non-guided process of scanning the entire 
genome for SNPs clusters that contain the maximum population-differentiation. A 
significant advantage of this approach is the non-biased identification of the 
chromosome regions that are extremely differentiated in the respective population. 
It also has the potential to decrease false negative rate, as tcdSNPs were identified 
in all chromosomes. In this chapter, the 30 millionth base region of chromosome 
6 or a region surrounding loci 6p21 is identified to be a hotspot of population 
differentiation, particularly between populations that are closely related. The 
presence of population-differentiated SNPs in closely related populations suggests 
that it potentially has more significance in determining differentiation in 
individual level, but not in the population level. In population pairs that are more 
genetically different, this extreme differentiation signature is probably masked by 
the presence of other high FST SNPs that would eventually be differentiated 
anyway, due to natural selection that takes place in parallel with geographic 
divergence during early human migration. Here, the most genetically similar 
population pair, the CEU-GBR, was used as a representative in studying the genes 
that are potentially affected by tcdSNPs in this 30 millionth base region of 
chromosome 6. In this study, 35 genes were identified, including the HLA-C and 
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TRIM gene families, which highlight the possible importance of these genes in 
determining inter-individual differences. 
Moreover, a comparison of the population differentiation pattern of SNPs 
between the genic and intergenic regions could support the existing knowledge in 
the field. It is observed that the intergenic region, which does not affect protein 
structure, is more inclined to carry greater magnitude of population genetic 
differentiation as compared to the gene region. This supports the result of the 
previous chapter (see 3.3.4) where a high population differentiation in regulatory 
regions was observed. Nonetheless, it is worth noting that the statistical 
significance could possibly been achieved as a result of the relatively large sample 
size that was involved in the statistical t-test calculation. 
It is noted that the results presented in this chapter suggest that there is a generally 
higher proportion of tcdSNPs that are potentially functional in the coding region 
despite the lower number of SNPs compared to that of the non-coding region. 
And because they can potentially affect protein function, through the variation in 
protein 3D structure, domain functional and post-translational modification, the 
finding could further suggests on the potential bridge between genetic 
differentiation and the variation that could be seen in phenotype. However, a 
general conclusion on this phenomenon is not advisable at this current stage 
because as shown by the subsequent result, the routes at which these genetic 
differences are translated to variation in gene functions can vary depending on the 
population. For example, East Asians have more potentially functional tcdSNPs in 
the promoter region, such as those residing on transcription factor binding sites. In 
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comparison, the Latin Americans, including the MXL and CLM, have higher 
proportion of potentially functional tcdSNPs in the coding region. 
There is also a possible link between population differentiation and chromosome 
size. Using the differentiated population-pairs ratio (DPPR), it is observed that the 
smaller chromosomes are subjected to more population differentiations. This 
could be related to the chromosome recombination rate, which could be 
dependent on chromosome size [12].  Nonetheless, at the current phase, deducing 
a biological scenario from this observation will be too premature as we need to 
further investigate on the potential causal-and-effect relationship between the 
population differentiation phenomenon and chromosome size. 
Enrichment of tcdGenes in pathways that contribute to human phenotype would 
open up the link between genetic differences and phenotype variation. The 
pathways for olfactory transduction and immune system-related functions, which 
are associated with inter-individual differences in smell and defence mechanism, 
respectively, are enriched by tcdGenes. The identification of olfactory 
transduction and immune system-related pathways is not unexpected because 
these pathways are already known to have great genetic variability [13-15]. And 
this finding could indeed act as a ‘positive control’ that the approach employed 
here is effective in finding tcdGenes. Intriguingly, during the course of work in 
this chapter, it is also observed that pathways that have been traditionally thought 
to be associated with conserved genes were indeed found to be enriched by 
tcdGenes. These enrichments are observed in the cellular mechanism- and 
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metabolic-related pathways including the Cell Adhesion Molecules (CAMs), 
Nucleoside Bindings and Transferase Activities.  
Alleles that pose greater reproductive and/or survival advantage in different 
geographical regions would overtime be positively or negatively selected. In this 
thesis, using population differentiation pattern, it is possible to elucidate more 
patterns that corroborate this assumption. SNPs in the maximum-differentiated 
clusters can potentially determine differences of phenotypes in different 
population. In this chapter, OCA2 is identified as the gene that has the greatest 
number of observation of population-pair differentiation. Its role in the production 
of skin colour determinant is well-studied [16]. Because skin colour is a 
phenotype that is highly differentiated between human populations, this finding 
serves as a concrete example on the effectiveness of the hypothesis-free approach 
in identifying tcdSNPs that are extremely differentiated between diverse 
populations. Furthermore, another gene that is identified to have a high number of 
population-pair differentiations is the HERC2. Similar to OCA2, this gene is 
involved in determining skin colour, in addition to hair and eye pigmentation, 
which are phenotypes that are associated with population or racial differences [17, 
18]. The effectiveness of this approach in identifying tcdSNPs is further 
strengthened by the identification of such SNPs in the HLA loci, which contain 
important immune system genes and is well known for its highly variable nature. 
As a matter of fact, most pathways that are enriched by tcdGenes, including those 




It is important to note however that despite this intriguing observation of 
population differentiation in human genes, phenotype differences are attributed to 
multifactorial components. Besides inherent factor such as genetic 
polymorphisms, external factors such as socio-economic influence, culture and 
other environmental factors are known to affect human differences. Studying all 
these factors at the same time however, is challenging, hence it is best to answer 
this question a single factor at the time [19, 20]. Due to this reason and because it 
is a more constant variable, studying the genetic factors behind phenotype 
difference is therefore still the most viable option. Genetic polymorphisms are 
known to have been associated with differences in foetal development, immune 
system and environmental response [21]. It is therefore in the interest of my thesis 
to deeply investigate the novel pattern of population differentiation in the human 
genomes. 
Theoretically, the differences in SNPs allele frequency are caused by the variation 
selection pressures during human migrations. This phenomenon contributed to the 
allele frequency differentiation of human populations [21-23], which have been 
associated with the variation of phenotype in different individuals. Hence, 
everyone is different. We carry different traits that are manifested in differences 
of phenotype, including our physical shape, disease susceptibility and drug 
response. The differences that we see across individuals are in turn seen on a 
population level, where population differentiation in human phenotype is seen as 
a common phenomenon.  
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Based on the findings that are presented in this chapter, we could observe the 
complexity of population genetic variation in our genome. As also shown in the 
previous chapter, decoding the genome is not a one layer effort as it involves a 
multilayer work with imagination as the limit. Therefore currently, many of our 
efforts in understanding the pattern of population differentiation in the genome 
would raise more questions for future studies. The strategy is not to bring too 
much complexity as with current limitation, it is not possible to tackle all layers at 
the same time. In this chapter of my thesis, it is possible to discover a novel 
pattern of population genetic differentiation using a simplified strategy of 
scanning the genome for maximum population-differentiated SNPs cluster. This 
contributes one significant foundational layer to the field, which can serve as a 
module for another layer. I envision that in the not-so-distant future, genetic 
polymorphisms can be used as an individual’s molecular identity, which include 
early recognition of drug response profile of a person based on SNPs information. 
The pilot pharmacogenomics work was conducted to serve this purpose, where 
the data that is generated in this chapter was brought forward closer to 
translational impact. As drug therapy often yielded a highly varied clinical 
outcome, identifying drug-response gene sets or pathways that are enriched by 
tcdGenes could provide a new method of prioritizing drugs that have higher 
potential to be associated with response differences. It has been reported in many 
drugs that SNPs are a factor that contribute to the variation of drug metabolism, 
transport and efficacy [24]. 
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For the last part of this chapter, the pilot pharmacogenomics work had 
preliminary identified enrichment of tcdGenes in several widely-used drugs or 
compounds. This include selenium, vitamin E, bortezomib, cisplatin, and 
decitabine. Cisplatin has particularly been reported to be associated with inter-
individual or population differences in response [25-27]. This shall therefore 
bring a spotlight on the potential of this population genomics approach in finding 
the genes that would eventually contribute to exerting phenotype differences 
across populations. And it will be especially significant in pharmacogenomics 
where population differentiation is a major concern. In the next chpater, I will 
utulize the knowledge that has been generated in this chapter to elucidate the 
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Chapter 5. Elucidating the Genomic Basis of Drug 





As introduced in the initial part of this thesis, drug response variation is common. 
A drug that is effective in one population may not be equally beneficial when 
prescribed to a population with different background; or worse if it could pose 
adverse drug reaction (ADR). Moreoever as seen in previous chapters, population 
differentiation in the human genome could manifest as a factor that contribute to 
population differences in drug response. 
Using the 1000 Genomes Project data, the results of scanning for genomic 
population differentiation patterns were presented in Chapter 4. These patterns are 
derived from the identification of top chromosome differentiated SNPs (tcdSNPs) 
and the corresponding top chromosome differentiated genes (tcdGenes). These 
tcdSNPs when found in genes that are responsible for drug response, are potential 
factors that could affect drug response variation. Hence in this chapter, using the 
tcdGenes that was obtained from the previous chapter, the focus is narrowed 
down to the genes that have been reported to be associated with drug response. 
The work in this chapter aimed to unleash this potential benefit by utilizing these 
tcdGenes information and developing a prototype pharmacogenomics application. 
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In doing so, drugs that potentially have strong population differentiation profile 
will be identified using their respective gene sets. 
The work in this thesis chapter involves massive integration work of various data 
types. Among them are tcdSNPs and tcdgenes information, in addition to 
pharmacogenomics annotation that allow linking population differentiation 
information of SNPs and genes to various drugs/compounds. In general, the first 
type of information consisted of ‘big-data genomics’. This includes SNPs 
population differentiation scores, which is measured by the FST statistics [1] that 
was derived from individuals who participated in the 1000 Genomes Project. The 
second breadth of information contains drug/compound names that were mined 
from four major databases namely: the PharmGKB [2], DrugBank [3], ChEMBL 
[4], and Comparative Toxicogenomics Database (CTD) [5]. In addition to 
drug/compound names, this information includes annotation of drug 
classifications which was derived from the WHO Anatomical Therapeutic 
Classification (ATC) system. The drug-response gene sets were then created by 
inter-linking these datasets, which allowed the formation of an integrated resource 
called the ‘PharmaSNP’. 
This knowledge integration could serve as a connecting bridge between 
population genomics and pharmacogenomics, in delivering its potential 
translational application. With this approach, it is possible to identify the drugs 
that are linked to significant number of population-differentiated genes (tcdGenes) 
and elucidate the gene sets that could possibly affect drug response variation in 
different populations. The subsequent part of this chapter hence presented the 
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result of drugs clustering based on their population differentiation profile. This 




5.2.1 The ‘next generation’ pharmacogenomics genes and the PharmaSNP 
resource 
 
In this chapter, in addition to using conventional drug-response genes that are 
annotated by the PharmGKB database, the gene-drug association information 
were also obtained from data mining of three other databases namely: DrugBank 
[3], Comparative Toxicogenomics Database (CTD) [5], and ChEMBL [4]. This 
has resulted in the production of ‘next generation’ pharmacogenomics genes that 
encompasses a much greater number of genomic genes and variants that could 
possibly play important role in pharmacogenomics. 
This next generation pharmacogenomics genes collection is stored in the SQL 
database engine and is publicly available in the PharmaSNP resource that was 
constructed in the course of producing this thesis. The PharmaSNP, a PHP-based 
web portal, contains information on genes that have been reported to be 
associated with drug activities such as its pharmacokinetic, pharmacodynamic, 
toxicity and other cellular effects. It is accessible at http://bit.ly/pharma-snp and 
will be elaborated further in the next chapter. 
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In addition, the drug data mining that was performed for the purpose of this 
chapter yielded an extensive list of drugs and compounds. Here, in order to be 
closer towards its translational application, it was decided to adopt an inclusion 
criteria. Only drugs or compounds that have been approved by the U.S. Food and 
Drug Administration (FDA) were included in the analysis. The list of approved 
drugs was obtained from the FDA Approved Drug Products with Therapeutic 
Equivalence Evaluations, which is also referred as the Orange Book [6]. For 
classification purposes, drug names were also associated with the various drug 
types in accordance to the WHO Anatomical Therapeutic Classification (ATC) 
system. These drugs are classified based on the relevant organ or system 
localization of the drug, in addition to other properties including chemical, 
pharmacological and therapeutic information. 
5.2.2 Population genetic differentiation in drug-response genes 
 
Population genetic differentiation was estimated using SNPs allele frequency data 
that have been presented in Chapter 4, which was obtained from the 1000 
Genomes Project (Phase 1) [7, 8]. In this study, the SNPs allele frequency is 
derived from 1,092 unrelated individuals who are originated from 14 global 
populations as described in the previous chapter. For each SNP, pairwise 
population differentiation scores were calculated by the use of FST statistics [1]. 
In this analysis, SNPs that are considered to be extremely population-
differentiated were identified. These SNPs, which are referred as top chromosome 
differentiated SNPs (tcdSNPs), were identified using an algorithm that detects 
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SNPs clusters carrying the highest moving average pairwise FST score across 
chromosomes as of conducted in the previous chapter. Moreover as explained in 
the previous chapter, top chromosome differentiated genes (tcdGenes) are defined 
as those that carry one or more tcdSNPs. Subsequently, a subset of these tcdGenes 
is found in the PharmaSNP database and these would be the drug-response genes 
that are defined as extremely population-differentiated. 
5.2.3 Random sampling enrichment analysis 
 
For all FDA-approved drugs/compounds that can be associated with one or more 
drug-response genes, the enrichment of tcdGenes was analyzed. The drug z-score 
was obtained by performing a 10,000 time random sampling iterations with 
genome genes that are within similar size range. Briefly, for each sampling set, 
the proportion of tcdGenes found in the random sample was recorded. The 
process was repeated 10,000 times, and based on these iterations, an empirical 
distribution specific to the drug in question was generated. The drug z-score was 
derived from the relative position of the observed tcdGenes proportion in this 
empirical distribution, which can be calculated with the following equation.  
Z	score ൌ p‐ePeSD  
Where: 
p = proportion of extremely population-differentiated genes in drug-
response gene set 
eP = average proportion of tcdGenes in empirical distribution of the 
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respective drug  
eSD = standard deviation of empirical distribution of the respective drug 
A drug that is significantly enriched by tcdGenes typically has a z-score of more 
than 1.96 or within the 0.05 percentile of its empirical distribution. On the other 
hand, a drug that is absent by the presence of such genes will typically have low 
z-score. 
5.2.4 Drugs and population cluster analysis 
 
The population genetic data is potentially useful in pharmacogenomics, where a 
drug population differentiation in response could possibly be predicted using the 
enrichment z-scores obtained in the above random sampling exercise. 
Subsequently, a two dimensional matrix was produced using the z-scores of 
multiple drug-response gene sets in 91 population pairs. With this matrix, a 
heatmap that is ordered based on hierarchical clustering of both the drug z-scores 
and population pair differentiation was generated. This was done by utilizing the 
heatmap.2 function available in the gplots R package [9]. 
In order to optimize the method, the heatmap and cluster generation was 
performed in drugs that have no null z-score value. Furthermore, because these z-
scores are derived from a standardized empirical distribution that was generated 
from each set of random samples, no additional scaling was conducted for the 
heatmap generation.  
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The word cloud visualization was performed in wordle.net by utilizing the non-
duplicated names of the drug classes. 
5.3 Results 
5.3.1 Drug-response genes repertoire 
 
The drug and drug-response genes collection were obtained from mining four data 
sources namely Chembl 13, PharmGKB, Comparative Toxicogenomics Database 
(CTD), and DrugBank. Figure 5.1 shows the results of this data mining, in which 
we obtained 10,902 unique drug/compound names in total. In descending order 
the CTD, DrugBank, Chembl 13, and PharmGKB contained 5,900; 4,184; 2,863; 
and 194 drugs or compounds information, respectively (Fig. 5.1). With 997 drug 






Figure 5.1 Drug names obtained from mining four major databases: Chembl 13, 
PharmGKB, Comparative Toxicogenomics Database (CTD), and Drug Bank. 
 
Out of 10,902 drugs in total, 1,511 are approved by the US FDA. These ‘approved 
drugs’ were utilized for analysis of population differentiation pattern in this study. 
From this drug data mining, we were able to collect 16,357 genes that are 
somewhat associated with drugs or compounds available at the four data sources. 
Similarly, the majority of these genes (16,185) are available at the CTD.  
As shown in Figure 5.2, the top 10 compounds with the most number of gene sets 
are cyclosporine (4,188 genes), tretinoin (2,681 genes), estradiol (1,899 genes), 
calcitriol (1,755 genes), arsenic trioxide (1,733 genes), copper (1,427 genes), 
valproic acid (1,426 genes), selenium (1,394 genes), vitamin E (1,369), and 




Figure 5.2 Drugs with the highest number of gene sets. 
 
5.3.2 Enrichment of tcdGenes in drug response gene sets 
 
Population differentiation in drug-response genes were estimated by using the FST 
scores of SNPs in these genes. Drug-response genes are considered to be 
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genes are referred as ‘tcdGenes’. Out of 14,166 drug-response genes that were 
successfully mined from the four databases, 3,108 (21.9%) are considered to be 
extremely population-differentiated. Furthermore, with 91 populations that were 
involved in the 1000 Genomes project, it is possible to calculate differentiation 
across 91 pairs of population. Because population differentiation was calculated 
based on a population pair approach, it is possible to identify the genes that are 
extremely population-differentiated in a specific population pair. 
In order to access the significance of tcdGenes in the drug-response gene sets, a 
random sampling simulation was performed. In the previous chapter, the CHS-
YRI and CEU-GBR pairs were identified as the two most distant and most similar 
populations, respectively. Figure 5.3 presents the top 20 drugs-response gene sets 
that are enriched by tcdGenes that are extremely differentiated in the two extreme 
population pairs CHS-YRI and CEU-GBR. In the CHS-YRI pair, where 
population genetic differentiation is the greatest, sincalide, azithromycin, nalidixic 
acid, levofloxacin, and menthol are among the drugs or compounds that are 
enriched by population-differentiated genes. 10,000 times random sampling 
analysis in these five drugs yielded a z-score between 5.07 and 8.21 in menthol 
and sincalide, respectively.  
On the other hand, random sampling analysis with tcdGenes that are extremely 
differentiated in the CEU-GBR population pair yielded different conclusion. In 
this population, enrichment of extremely population-differentiated genes is 
highest in phytonadione, bacitracin, consyntropin, alprostadil, and ammonium 
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chloride (Fig. 5.3). The z-scores of these five drugs range from 4.24 in 






Figure 5.3 The top 20 drugs that are enriched by extremely population-
differentiated genes in the two most distant and most similar populations of CHS-
YRI and CEU-GBR, respectively. The proportion of extremely population-
differentiated genes is presented by the shaded area that corresponds to the primary y-
axis. The enrichment z-score is presented by the dotted line that corresponds to the 
secondary y-axis. A z-score greater than 1.96 typically signifies an enrichment of 
extremely population-differentiated genes in the particular drug. 
 
5.3.3 Drugs clustering based on population differentiation profile 
 
In identifying the drugs or group of drugs with similar population differentiation 
profile, this part of my thesis presents a hierarchical cluster analysis. The first step 

































































































ASW, LWK and YRI were grouped into Africans (AF), whilst the JPT, CHS and 
CHB were categorized as East Asians (EA); CEU, GBR, TSI, and FIN as 
Europeans (EU); in addition to the MXL, CLM and PUR which are grouped into 
Latin Americans (LA). The IBS population, due to its relatively low similarity to 
any of the continental group (as seen in section 4.3.1), was excluded in this 
analysis.  
Following categorization of these populations into four continental groups, a 
matrix was constructed, with the continental population pairs and drugs 
positioned as the matrix’s columns and rows, respectively. Figure 5.4 shows a 
heatmap that was generated by utilizing this matrix data as input. Drugs with null 
z-score value in one or more population pair, which could be due to insufficient 
population genetics data, would automatically be excluded from analysis. In this 






Figure 5.4 A clustered heat-map generated using the enrichment z-scores of 141 
drugs. Each row in the heat-map represents a drug population differentiation profile, with 
z-scores corresponding to a drug name. These z-scores represent the degree of 





From this result, it can be observed that within continental group comparisons, 
which are consisted of closely related population pairings, most if not all drugs 
are observed to have relatively low z-scores (green colour cells inside yellow 
colour box in the heatmap). With the exception of few compounds such as lithium, 
auranofin and corticotropin, most drugs are not found to be enriched by tcdGenes 
that are differentiated among the EU-EU, AF-AF, LA-LA, and EA-EA within 
continental population pair comparisons. On the other hand, comparisons between 
population pairs that originate from two different continents, such as the EA-EU, 
EA-LA, EU-LA, AF-EA, AF-LA, and AF-EU, showed a number of drugs that are 
significantly enriched by tcdGenes (outside of yellow colour box in heatmap). 
Notably, this enrichment is more frequent in the comparisons involving the 
African populations, such as in the AF-EA, AF-LA and AF-EU group 
comparisons. 
By taking the above observation into consideration, a second clustering step was 
performed. In this step, the hierarchical clustering took account only of the data 
involving different continental pairs, which resulted in the inclusion of 173 drugs. 
As observed in Figure 5.5, cluster analysis with six continental population groups 
(EA-EU, EU-LA, EA-LA, AF-EA, AF-LA, and AF-EU), yielded two distinct 





Figure 5.5 A heat-map generated after a second step of cluster analysis. This 
clustered heat-map was generated by including only the z-scores representing enrichment 




As shown in Figure 5.5 (inside red colour box), the first cluster consisted of 34 
drugs having a strong differentiation profile between the Africans and other 
continental groups, which are the AF-EA, AF-LA and AF-EU pairs (Fig. 5.6). 
Among the drugs that have extreme population differentiation profile between 
Africans and other continental populations are valdecoxib, atorvastatin, catechin, 
and docetaxel. Furthermore, it can also be observed that when comparing the 
African populations with East Asians, Europeans or Latin Americans, there are 
more drugs that are associated with tcdGenes enrichment between the African and 
European populations (Figure 5.6A, AF-EU column inside yellow box). Such 
population differentiation affect a number of frequently prescribed drugs such as 
imatinib, amiloride, morphine, fluvastatin, olanzapine, dexamethasone, as well as 
the four drugs mentioned above.  
Furthermore, using these 34 drug names, it is possible to observe the frequency of 
drug class that is linked to these drugs. Drug class information is in accordance to 
that of the WHO drug Anatomical Therapeutic Chemical (ATC) classification 
system. Here, the frequency of which a drug class appears in the data is presented 
using a "word cloud" visualization. In this diagram, the bigger the word size the 
more frequent the drug class appears in the data. As can be observed in Figure 
5.6B, in the first level of the ATC classification system, which categorizes drugs 
based on their anatomical main group, drugs that play role in the musculo-skeletal 
system are the most frequently observed in the cluster that shows population 
difference between Africans and other populations. In the therapeutic (Level 2) 
and chemical (Level 3) subgroup classification, the Antiinflammatory and 
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Antirheumatic Products drug category are more dominant than other drugs such 





Figure 5.6 Drugs with a strong differentiation profile between the Africans and 
other continental groups. This cluster is consisted of 34 drugs that are differentiated 
between either the AF-EA, AF-LA or AF-EU continental population pair (A). The right 
panel (B) is a word cloud that is used to visualize the frequency of appearance of the drug 
classes that are associated with these 34 drugs. The word size is influenced by frequency 
of appearance of the drug class. 
 
As shown in Figure 5.5 (inside green colour box), in addition to the drug-response 
gene sets with tcdGene enrichment in Africans, it is also observed that there is a 
second cluster, which consisted of 28 drug-response gene sets that are enriched by 
tcdGenes differentiated between East Asians and Europeans (Figure 5.7A). This 
drug cluster includes several benzodiazepine derivatives (oxazepam, flurazepam, 
temazepam, lorazepam, triazolam, clonazepam, alprazolam, and midazolam) and 
other drugs such as simvastatin, pravastatin, capecitabine, ethanol, pentobarbital, 
carbamazepine, and corticotropin. In the WHO ATC level 1 anatomical main 
group classification, the majority of drugs in this cluster are categorized under 
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Nervous System category, which is then followed by the Antineoplastic and 
Immunomodulating agents. Figure 5.7B also shows that the Psycholeptics as well 
as the Hypnotics and Sedatives drug class are shown to be prominent in the level 






Figure 5.7 Drugs that are enriched by tcdGenes differentiated between East Asian 
and European. This cluster is consisted of 28 drugs (A), many of them are categorized 
under Nervous System drug category (B). 
 
Outside of these two clusters, there are 72 drugs with low population 
differentiation profile (Figure 5.5, inside blue colour box). As a matter of fact, the 
majority of drugs involved in this analysis belong to this group (Figure 5.8A). In 
this cluster, with an exception of low differentiation between Africans and East 
Asians, no significant population differentiation profile is observed in any of the 
other continental populations. This cluster is dominated by drugs acting under the 
Antineoplastic and Immunomodulating Agents in the level 1 WHO ATC 
anatomical main group classification. The presence of Antineoplastic Agents 
therapeutic class further dominates the level 2 and level 3 drug classifications, 
respectively. Among the chemical substances that occur more frequently in this 
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cluster are the Protein kinase inhibitors, Proton pump inhibitors and Other 






Figure 5.8 Drugs with relatively low enrichment of tcdGenes, which signifies weak 
population differentiation profile. 
 
5.3.4 Genes and SNPs linked to drugs with high population differentiation 
profile 
 
It is postulated that drugs with gene sets enriched by tcdGenes would be more 
likely to have population differences in response. Based on their enrichment z-
scores, the drugs with the strongest tcdGenes enrichment across the six different 
continental population pairs are shown in Table 5.1. In descending order from the 
highest to lowest z-score, the list includes: Penicillamine (z-score = 6.35 – AF-LA 
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/ LWK-CLM; z-score = 3.98 – EA-LA / CHS-MXL), Valdecoxib (z-score = 6.12 
– AF-EA / LWK-JPT), Secobarbital (z-score = 5.69 – EA-EU / JPT-FIN), 
Daunorubicin (z-score = 4.45 – AF-EU / YRI-FIN), and Docetaxel (z-score = 
4.18 – EA-LA / CHS-MXL). The distribution of FST scores in the tcdGenes of 















AF-others Penicillamine 6.35 LWK-CLM AF-LA 
AF-others Valdecoxib 6.12 LWK-JPT AF-EA 
EA-EU Secobarbital 5.69 JPT-FIN EA-EU 
AF-others Daunorubicin 4.45 YRI-FIN AF-EU 
AF-others Docetaxel 4.18 CHS-MXL EA-LA 




Figure 5.9 Distribution of FST scores associated with tcdSNPs residing in genes that 







One primary aim of this work was to accumulate and integrate population 
genomic knowledge that can serve to elucidate the genetic basis of population 
differentiation in drug response. Gene sets containing genes that have previously 
been associated with drug response were collected. These genes are involved in 
pharmacokinetics (PK) and/or pharmacodynamics (PD) pathway. Furthermore, 
the work in this thesis chapter was primarily conducted in parallel to the 
construction of a pharmacogenomics resource containing drug population 
differentiation information. In developing this resource, a total of 10,942 
drug/compound data from four different databases were integrated. Out of this 
total number, 1,511 are approved for therapeutic usage by the FDA. This 
knowledge accumulation is essential in pharmacogenomics, whereby a drug 
potential population differentiation profile is constructed based on its drug-
response gene information. Hence, a comprehensive resource that contains 
information of most if not all known drug-genes relationship is useful, particularly 
for elucidating the drug population genetic profile. 
Traditionally pharmacogenomics studies have adopted a conservative approach. 
Most remain focused on studying specific candidate genes that not only have been 
commonly reported to play significant role in drug response, but also associated 
with variants or SNPs that have high population allele frequency differences [10-
14]. These conventional pharmacogenomics studies had put much emphasis on 
studying absorption, distribution, metabolism, excretion (ADME) genes, which 
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are important to a drug pharmacokinetics. In this thesis however, there is an 
attempt to expand the genes collection to include other possible drug-response 
genes, particularly in a drug pharmacodynamics pathway, where little if any 
information is usually available for most drugs.  
In this thesis chapter, with 4,188 genes in the database, cyclosporine is identified 
as drug with the greatest number of links to drug-response genes. This is then 
followed by tretinoin and estradiol, with 2,861 and 1,899 genes, respectively. The 
inclusion of data from the CTD, a non-conventional pharmacogenomics resource, 
expanded the collection of genes, with those that have been shown to be 
associated with toxic responses. Moreover, the massive compound information 
that is available in the CTD database would also expand the drug collection with 
compounds that are found in food supplements, which may interfere with a 
patient’s response to therapy. It is hoped that the inclusion of these CTD genes 
could increase the possibility in finding more novel pharmacogenomics genes that 
are not only linked to a drug or compound-induced toxicity, but also identified to 
be population-differentiated. Using this novel approach, a significant number of 
drug response genes were collected, many of them are linked to the CTD, a 
toxicogenomics resource [5].  
Several instances of non-drug/compound information that is not found in 
conventional pharmacogenomics resources are copper, selenium and arsenic. For 
example copper, which could be toxic due to its ability in generating reactive 




Subsequently, with this information available, drug-response genes that are 
population-differentiated could be identified. This was done by integrating the 
drug information database with those of tcdSNPs and tcdGenes data that were 
generated in chapter 4. In chapter 4, genes that carry top chromosome 
differentiated SNPs (tcdSNPs) are classified as tcdGenes. A drug 
pharmacogenomics profile, including information on enrichment of tcdGenes that 
could be linked to the drug was generated. Here, it is shown that there are 3,108 
out of 14,166 drug-linked genes that were identified to carry tcdSNPs. This is 
equivalent to 70% of 4,355 tcdGenes in the human genome. One possible reason 
for this high proportion is because of the environmental response role that is 
attributed to the biological function that is associated with these tcdGenes. 
Population differentiation, as estimated by the presence of high FST tcdSNP, could 
arguably be advantageous in genes that are “exposed to environmental” pressures. 
This contributed to our body’s defense mechanism against a wide range of 
xenobiotic substances. 
Furthermore, because different geographic regions would probably exert a 
different range of pressures, human migration and genetic drift may leave a 
distinct population differentiation ‘footprint’ in these tcdGenes. The analysis of 
the top 20 drugs that are enriched by tcdGenes in the two most distant (CHS-YRI) 
and most similar populations (CEU-GBR) shows a different profile. Between the 
CHS and YRI, the proportion of tcdGenes is highest in genes that are linked to 
sincalide, azithromycin and nalidixic acid. On the other hand in the CEU-GBR 
pair, such proportion is highest in genes that are linked to phytonadione, 
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bacitracin and cosyntropin. Due to this population genetic differentiation, the 
drugs that are significantly enriched by these tcdGenes across diverse population 
pairings are believed to carry greater potential in having response differences. 
Nonetheless, one challenge that was encountered in the analysis of 91 population 
pairs and 1,034 drugs/compounds was in finding a method that can delicately 
reveal a novel pattern of population differentiation based on genomic data. In this 
thesis chapter, I presented a two-step hierarchical cluster approach on how we 
could identify a potential drug response pattern using their population genetic 
differentiation profiles. The initial attempt at clustering consisted of 141 drug 
population differentiation profile. In this result, there exist significant presence of 
drugs that are linked to low population differentiation profiles, particularly 
between closely-related populations (populations originated from the same 
continental root). Moreover, because the cluster analysis and heat map generation 
were set to exempt null data, some drugs, more specifically those that have 
insufficient population genetics data for generating z-score using complete 
random sampling analysis in closely-related populations, were not included in this 
initial clustering. For this reason, it was decided to proceed with the second-step 
hierarchical clustering, in which z-score data from closely-related populations 
were excluded. The second tier clustering resulted in the hierarchical grouping of 
173 drugs, 34 of which have strong differentiation profile between Africans and 
other populations. Interestingly, there is a high presence of drugs acting in the 
musculoskeletal system in the cluster that shows population genetic 
differentiation between Africans and other populations. In addition, 28 other 
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drugs were also noted to be in a cluster that is identified to have population 
differences between East Asians and Europeans. Note that the clustering 
methodology itself is not new; however, the application of such approach in 
grouping drugs based on their population differentiation profile is potentially 
novel. Using such technique, we can now identify the drugs that can have 
potential response differences between two different populations.  
In the next step, using their z-scores, drugs with the strongest tcdGenes 
enrichment across six continental pairs were identified. Among these drugs, 
Penicillamine, Daunorubicin and Docetaxel are included in the WHO List of 
Essential Medicines [16]. Whilst both Daunorubicin and Docetaxel serve as 
anticancer agents that work by interfering with mitotic process and DNA 
replication, Penicillamine is a disease modifying anti-rheumatoid drug [17-19]. 
Here, it is identified that the gene set linked to Daunorubicin is enriched by 
tcdgenes that are differentiated between the YRI and FIN populations, which 
belong to the African and European group, respectively. In 2007, Huang et al 
reported that for Daunorubicin, there is significant difference (p-value < 0.05) in 
the effect of drug-induced toxicity between cell lines originated from African and 
European descent as measured by the drug’s  IC50 [20]. Both the African and 
European cell lines were from Yoruban and CEPH populations that participated in 
the HapMap project. These are indeed the same source of populations that were 
later be included in the 1000 Genomes Project, which were also used as the 
primary population genomic data source of this thesis. 
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Furthermore, based on the result presented in this chapter, Docetaxel is identified 
as the drug with the highest enrichment of tcdGenes that are differentiated 
between Southern Chinese (CHS) and Mexicans (MXL). Millward et al had 
previously reported a significant difference in the Docetaxel response rate 
between Asians and Caucasians [21]. Moreover, it was found that ethnicity could 
act as response predictor. In their analysis, it was observed that in contrast to 31% 
Caucasian patients who have had response to Docetaxel, there was significantly 
more Asian patients (65%) who responded to the anticancer drug (P = 0.01). 
When considering the relative genetic closeness between Caucasians and Latin 
Americans (as shown in Chapter 4), the finding that was reported by Millward et 
al is parallel to the z-score analysis involving Docetaxel. 
The results that are presented in this thesis chapter could potentially be applied in 
a drug development pipeline. As discussed in the earlier section of my thesis, 
because a drug that is effective in one individual may not equally be effective in a 
different person, tailoring drug prescription will have an increasing clinical and 
economical benefits in the future. This will be especially more significant in 
certain drug cases that are associated with the occurrence of adverse drug 
reactions (ADRs). It is the long term objective that can be achieved by expanding 
the approach that is developed in this study. Variation in the way patient’s 
response to drug, including ADRs susceptibility has been reported to be a 
significant contributing factor to the increasing cost of healthcare. It was reported 




To the pharmaceutical industry, the occurrence of ADR in several patients or 
clinical trial volunteers could potentially be damaging to a drug portfolio, leading 
to a potential loss of revenue. For the individual patient, suffering an ADR is 
equivalent to adding an extra layer of burden rather than cure. By identifying the 
group of individuals who are more susceptible to an ADR or toxic reaction, using 
their population information as proxy, we could potentially prevent ADR before it 
happens.  
Furthermore, although drug response differences are attributed to various factors, 
genetic polymorphisms are by far still one of the most promising factor that can 
be used to group patient populations. One reason is because of its constant and 
heritable nature, where a person genetic profile is constant for his or her life span. 
Nonetheless, despite the potentially effective utilization of SNPs that are 
associated with drug response differences in developing a more personalized 
medicine, cost is still a hurdle. For instance, if it must tailor new drug 
development to all variant types in different individuals, drug companies would 
incur an even greater price-tag into its already burgeoning cost in developing a 
drug. This translates to higher cost of medicine.  
Nonetheless, the future of applying personalizing medicine still depends on the 
success of clinical or industrial prototyping of this approach, which harnesses an 
up-to-date knowledge of population genomic information. An attempt to address 
this challenge is presented in the next chapter, where I conclude this thesis with a 
presentation of the PharmaSNP resource. It is a prototype of one stop 
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pharmacogenomics portal that is aimed to utilize the results generated in this 
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In this thesis, one key focus is to accumulate new knowledge surrounding human 
population genomic differentiation, particularly those that are important in 
pharmacogenomics. It is also equally important to integrate this data with the 
existing breadh of knowledge, such as SNP, gene and drug information. However 
this alone, would not probably exert much translational significance, especially if 
the information is only stored for the benefits of a specific individual or group. 
Hence in this last chapter, I would like to present the final deliverable of this 
thesis, a pharmacogenomics online resource which publicizes the information that 
has been accumulated in this thesis.  
In delivering translational impact, the results that have been presented in the 
previous chapter are packaged and presented in this 'PharmaSNP' resource, an 
online portal that aims to provide population genetics information of various 
drugs and compounds. The resource, which is currently in its beta format, 
integrated drug, gene and SNPs data that are relevant to elucidating the genomic 





6.2 Developing the PharmaSNP resource 
6.2.1 Data storage 
 
The PharmaSNP resource includes various data that are relevant for profiling 
population differentiation pattern of various drugs/compounds. These data can be 
generally classified or grouped based on the type of information that is stored. 
Similar types of information are stored in a network of tables that are interlinked 
using the relational database approach. For ‘big-data’ computation such as in the 
calculation of FST, the Microsoft SQL Server (Microsoft Corporation, Washington, 
USA) relational database was utilized, where a database connection to the ‘R’ 
statistical programming environment was done. On the other hand, MySQL 
(Oracle Corporation, California, USA) was used for the purpose of publishing the 
data in PharmaSNP website. Table 6.1 summarizes these various data based on 




Table 6.1 Data that are integrated in the PharmaSNP resource. 
Information Class Detail Content 
Drug Population 
Differentiation 
Z-score signifying enrichment of tcdGenes in drug-
response gene set 
Drug Classification Drug classification based on WHO Anatomical Therapeutic Cemical (ATC) classfication system 
Drug-response Genes Drug-response genes data accumulated from PharmGKB, Chembl13, CTD, and Drug Bank 
tcdGenes 
Top chromosome differentiated genes (tcdGenes) 
information including gene name, NCBI geneID, 
chromosome, and population-differentiation status 
tcdSNPs 
Top chromosome differentiated SNPs (tcdSNPs) 
information including SNP rsID, mRNA-based location 
info, and population-pair FST score 
 
6.2.2 Web development 
 
The PharmaSNP website was developed based on a modular basis (Table 6.2). 
Whilst the first part consists of a data storage module as described in the above 
section, the second module involves a PHP-based query and data presentation 
applications, which connects and presents data on the worldwide web. Because 
PHP is a server-side scripting language, all queries that are performed in 
PharmaSNP are done within the NUS server. For the purpose of PharmaSNP, the 
Sriptcase (Netmake, Brazil) web development platform was used to develop the 
PHP applications. This includes the interactive database query functions, 
summary tables, graphical summaries and detailed information tables that are 




Table 6.2 Three major modules that form the PharmaSNP resource. 
Module Platform 
Data Storage Microsoft SQL Server, MySQL 
Server-side Scripting  
(Web database query) PHP 
Web Content Management 




Figure 6.1 The PharmaSNP web resource allows users to query the 





The last module was developed using Wordpress, a content management system 
(CMS) platform that is specially used to manage the PharmaSNP website content, 
allowing the creation of a user-friendly front end (www.wordpress.org). 
Wordpress is built based on MySQL and PHP, hence allowing straight-forward 
structural integration for deploying the PharmaSNP website. This last module, 
which is the most utilized CMS in the world, packages the PharmaSNP resource 
into a presentable website, allowing seamless navigation of the online resource. In 
addition, to serve mobile device users, this module can also adapt to various 
screen resolutions as it implements a responsive frame design. 
6.3 Utilizing PharmaSNP 
 
The prototype release of the PharmaSNP resource is currently accessible through 
the following link http://bit.ly/pharma-snp. When utilizing the beta version of 
PharmaSNP, one could initiate a database query from three different starting 
points (Fig. 6.1). The first one involved querying the PharmaSNP database with a 
drug name, whilst the second entry point would be useful for a database search 
using a gene name. The third initiation point allows PharmaSNP users to obtain 
detailed SNP information that is associated with SNPs linked to drug of interest. 
6.3.1 Search Drug in PharmaSNP Collection 
 
In the first initiation point, one could search the PharmaSNP database using a 
drug name and/or drug type (Fig. 6.2). In addition, information surrounding the 
population pair of interest could also be accounted in the database query by 
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highlighting the relevant population(s). Entering this information into the search 
form would allow one to obtain the population differentiation profile of a drug of 
interest based on the 1000 Genomes data. The following figures that are presented 
in this thesis were captured when a user initiated a database query using the drug 
name that contain the word ‘statin’. The same user was interested to explore the 
population differentiation profile of statin between the Luhya population in 





Figure 6.2 Search drug from PharmaSNP collection. Users are able to search 
the drug collection that is available at the PharmaSNP database. 
 




Following a search initiation, the PharmaSNP interface would then bring the user 
to a summary page, where all drug names containing the word ‘statin’ are 
presented (Figure 6.3). In this example, PharmaSNP summarizes population 
genetics data from six statin drugs: atorvastatin, fluvastatin, lovastatin, pravastatin, 
rosuvastatin, and simvastatin. In each drug, a summary is presented for the 
average number of genes that are associated with the drug, the average proportion 
of extremely population-differentiated genes and the maximum z-score signifying 
enrichment of such genes. In addition, an interactive barchart that summarizes the 
information is provided at the bottom of the summary table. When clicked, the 
individual bar in the chart will direct the user to more detailed population 
differentiation information of the drug of interest. 
Figure 6.4 shows what happened after clicking ‘atorvastatin’ on the bar in the 
chart. Here, the users are taken into a more detailed table view of the population 
genetic differentiation profile of atorvastatin. In this case, PharmaSNP would 
present information that is relevant to atorvastatin including the total number of 
genes associated with atorvastatin and the proportion of extremely population-
differentiated genes, which is alongside the population names. For instance, the 
first row of this search results describes that atorvastatin, as an HMG CoA 
reductase inhibitor, is linked with 128 genes in the PharmaSNP database. Out of 
128 genes, 3% carry SNPs that are extremely differentiated between Luhya 
population (LWK, which belongs to the African continent group) and Mexican 
(MEX, which belongs to the Latin American continent group). Moreover, because 
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the z-score of 2.5993 is above the significant threshold of 1.96, these extremely 
population-differentiated genes are considered to be significantly enriched.  
Both the summary and detailed table results that are generated by the PharmaSNP 
database search could be exported in PDF, table, XML or other text file formats. 
The user is also able to customize the display of the search results, in accordance 
to a more specific requirement. This includes advance results sorting based on a 
chosen field, selecting the columns-to-display and performing a quick search from 





Figure 6.4 Detailed table view of the drugs’ population genetic differentiation 
profile. 
 





6.3.2 Search Gene in PharmaSNP Collection 
 
While the first initiation point allows the user to search using a drug name, the 
second initiation point, will receive a gene name or an NCBI gene ID as input to 
query the PharmaSNP database. The user could also opt to choose to present a 
result only if the gene(s) of interest is extremely population-differentiated (Fig. 
6.5). 
In this particular example, using the PharmaSNP gene query interface, the user 
has attempted to search for pharmacogenomics information that is relevant to any 
gene containing the keyword ‘CYP’ (Fig. 6.5). The user also chose the option to 
show only the genes that are population-differentiated. Figure 6.6 shows what the 
PharmaSNP resource would return when this search was submitted. The table 
summarizes all the CYP genes that are extremely differentiated, in addition to all 
the drug names that are linked to these tcdGenes. For instance in the first row, the 
gene CYP2D6, with an NCBI gene ID of 1565 is extremely differentiated 
between CHB (Han Chinese in Beijing, China) and the CLM (Columbian in 
Medellin, Columbia). Moreover this gene, is linked to the drug bromfenac, which 
is an anti-inflammatory agents, non steroids type; as well as to buspirone, an 
Azaspirodecanedione derivatives (row 2); estrone, a natural and semisynthetic 




Figure 6.6 The search result following submission of the keyword ‘CYP’. 
 
Figure 6.7 To search for the SNPs that are linked to a drug of interest, a user 




6.3.3 Obtaining Pharmacogenomics SNP Details 
 
The third interface of the PharmaSNP resource integrates the drugs, genes and 
SNPs data in the database, which allow users to obtain a comprehensive list of 
genes and detailed SNPs information that could be linked to a drug of interest. In 
this illustration, the same user attempted to search pharmacogenomics information 
that are relevant to the keyword of interest, ‘statin’, which is an HMG CoA 
reductase inhibitors (Fig. 6.7). Note that due to the massive data integration that is 
involved, the interface currently serves as a beta version, in which only a subset of 
the results is shown by the query engine. 
When the user entered statin as the keyword, PharmaSNP beta would present a 
sample result that encompasses the drug named lovastatin. The positive sign next 
to the drug name would allow the user to expand the results in which a sample 
population genetics pair differentiation analysis between Luhyans (LWK) and 
Mexican (MEX) is displayed (Fig. 6.8). In this example, the proportion of 
extremely population-differentiated genes between these two populations is 0.06, 
with a significant enrichment z-score of 5.1832. The user could then further 
expand the table to display the extremely population-differentiated genes that are 
involved in this particular drug, in addition to the population pair information. 
Lastly, clicking the expansion side in the gene would then bring the user to a table 





When the same user expanded the information on the PPARG genes, the SNPs 
within the gene are displayed in addition to their positions in accordance to the 
RNA splicing variants. In the first row instance, a PPARG SNP with reference 
SNP identifier (rs#) of rs709154, is seen to have an FST score of 0.3065 based on 
its allele frequency differentiation between the JPT (Japanese) and YRI (Yoruban) 
populations. Within the PPARG splice variant identified as NM_005037.5, the 
same SNP could be localized in the Intron 5 region, 1,369 away from the 3’ 
intron-exon junction. SNP rs709154 is associated with an A to T nucleotide 
substitution and due to its location, is not considered as a promoter SNP. Using 
this information, a position-centric nomenclature of rs709154 could then be 





Figure 6.8 The summary page presenting the search results. The user could 
expand the results to display the extremely population-differentiated genes that 
are involved in the drug of interest. 
 
Figure 6.9 To view the SNPs in the gene of interest, another expansion step 
could be performed.  
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Significance and Future Direction 
 
Genetic Diversity, a Great Strength 
Genetic diversity is a great strength. Once deciphered, the information stored in 
our genetic sequence could serve as predictor of population differences in 
phenotype. As illustrated in this thesis, genetic diversity in the form of SNPs in 
drug-response genes, could explain and have the potential to predict response 
profile. By identifying the PharmaSNPs that are linked to a set of drug-response 
genes, a drug population differentiation profile could be constructed (Chapter 6).  
The Impact 
For the pharmaceutical industry, ADR occurrence can potentially damage a drug 
portfolio, leading to a potential loss of revenue. For the patient, an ADR 
occurrence can add extra layer of burden rather than cure. The results presented in 
this thesis can hopefully attack these problems from a population genomic 
perspective. By utilizing the PharmaSNP resource, a drug population genetic 
differentiation profile can be obtained. This allows the early implementation of 
ADR prevention strategy, by identifying the group of drugs or individuals that are 
more susceptible to drug toxicity. The aim is to improve treatment quality and 
concurrently reduce the cost of medicine. 
Moreover, in a drug development pipeline, this novel approach may prove useful 
in identifying the population that could potentially be more susceptible to ADR. I 
propose two future approaches that can potentially be employed before 
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conducting a new drug trial. The first relies on structural similarity with an 
existing drug, whilst the second takes into account any existing or new drug-
response genes information that could be linked to the drug in trial. 
In the first approach, a new drug can be linked with a set of drug-response genes 
of an existing drug that is structurally similar. One would be able to obtain the 
population genetic differentiation profile of a new drug using information from its 
existing counterpart. The population genomic differentiation data in PharmaSNP, 
in addition to the drug-response genes information can be used to obtain a drug 
population genetic differentiation profile. The second approach will 
hypothetically yield a more accurate prediction as drug-response genes 
information is derived from in vitro experiment involving the new drug. For 
instance, functional toxicogenomic studies are to be initially conducted, which 
may yield new genes information. The PharmaSNP resource could then provide 
the SNPs that can be linked to these genes. Using this information, drug 
population genetic differentiation profile can then be obtained. 
Therefore, the information that is derived from PharmaSNP could arguably be 
used before considering to test a drug in one or more populations of interest. It 
may also reduce the potential occurrence of ADR during trial, by identifying the 
population group that is potentially more susceptible to ADR. This may also 
increase the probability of success in developing potentially block buster drugs. 
These two proposed approaches can hopefully contribute to improving the drug 
development pipeline, which can reduce the cost that is associated with multi-
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populations drug trial. The next step following the completion of this thesis is to 
continue developing the PharmaSNP prototype, in addition to optimizing new 
algorithm that can better provide a drug population differentiation profile using 
this population genomics information. 
Nonetheless, whilst it is tempting to conduct a census-scale DNA sequencing in 
profiling all individuals in a country, ethical and economic reasons will still 
provide a continuous hindrance. It is for this reason that in this field, there is a 
greater focus on the study of individual representatives that are originated from 
different population backgrounds [1-3]. The availability of population genetic 
data could eventually serve as a proxy to the individuals that belong to that 
population. And this can be used to infer the inter-individual differences that are 
seen across diverse human populations, an approach that was adopted by the 
HapMap [1], Environment Genome Project [3], and more recently, the 1000 
Genomes Project [2]. One primary assumption is that within the same population, 
individuals are likely to carry more similar gene variants compared to those who 
are originated from a different population.  
This study is also associated with limitations, such as in the potential inheritance 
of error from various external data sources. Addressing these concerns would 
require involvement of more data speacialists who would be able to thoroughly 





The Art in Medicine 
I would like to end this thesis with a little bit of history. The word ‘medicine’ is 
derived from ‘medicus’, a latin word that means ‘physicians’ [4]. For centuries, 
the field has touched upon one of the most basic human necessities: to have a 
good health, hence good life. The word ‘Ars medicina’ was then used, which 
means the ‘art of healing’. And more recently, parallel to the accumulation of new 
facts and technology in diagnosing and treating patients, our perception of the 
word ‘medicine’ has been influenced by one important component: science. In 
fact, the current English Oxford Dictionaries recorded medicine as “the science or 
practice of the diagnosis, treatment, and prevention of disease” [5]. I find it 
interesting that the word ‘art’ is not included anymore in today’s decscription. It 
signifies a significant degree of evolution in the field to a more knowledge-based 
method of treating diseases. 
The art component however, shall not be entirely diminished. I believe that as 
medicine progresses, our ability to understand and apply human art can help to 
effectively apply and deliver new scientific discoveries. Therefore, medicine did 
and plausibly still does require a great deal of ‘art’ in its application. In fact, it is 
still arguably a combination between science and art [6]. Indeed, this is what 
provides gravity to my thesis. Here, I presented the scientific accumulation and 
integration of novel knowledge that in the long run, can hopefully be utilized in 
developing new utility for improving therapy. 
As we move forward, pharmacogenomics will and can propel new medical 
innovations; especially in the development of personalized medicine. All in all, 
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the intent is to benefit the consumers, be it the scientists who are investigating, the 
doctors who are applying this knowledge, or the patients who are receiving the 
products. In the last chapter of my thesis, I attempted to package the study results 
into a prototype online resource. It is an art in progress. I believe that the results 
generated from the work presented in this thesis can humbly expand the medicine 
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Appendix 1. SNP centric summary of results from association studies assessing the link between ABCB1 
coding region SNPs and drug pharmacokinetics or response 
No. 








(cohort size)* [Ref] Minor Allele Association Notes^^ 
1 E3/61A>G (N21D) 
Immunosuppressants 
Yes [1] In vitro - cell lines. [1] Modulate CsA intracellular accumulation effect. 
No [2] White (73). [2] No influence on CsA pharmacokinetics. 
Opiate analgesic Yes [3] NS - Switzerland (276). [3] Influence methadone plasma level. 
Others/Mixed 
Substrates 
Yes [1] In vitro- cell lines. [1] Increase of BODIPYL-FL-paclitaxel intracellular accumulation 
No [4] In vitro - cell lines.  [4] N21D, F103L, S400N, A893S, and A998T on the PK of a range of cytotoxic derivatives.  
No report for the 
following drug 
classes/indications 
  Antiepileptic Drugs (AED), Antibiotics, Antidepressants, Anti Cancer Agents, Cardiac Glycoside, Antiretroviral Therapy (HIV), Statins. 
2 E5/266C>T (M89T) Anti Cancer Agents Yes [5] In Vitro - cell lines. 
[5] Increased resistance to daunorubicin, 
doxorubicin, valinomycin, or actinomycin D. 
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No report for the 
following drug 
classes/indications 





Anti Cancer Agents Yes [6] In vitro - multidrug-resistant cell lines.  
[6] G185V confer changes in vinblastine and 
colchicine specificity 
No report for the 
following drug 
classes/indications 
  Antiepileptic Drugs, Antibiotics, Antidepressants, Cardiac Glycoside, Antiretroviral Therapy (HIV), Immunosuppressants, Opiate analgesic, Statins. 
4 E12/1199G>A (S400N) 
Anti Cancer Agents 
Yes 
[7] In vitro, cell lines; 
[8] NS - Sweden (51); 
[9] Taiwanese (59) 
[10] In vitro - cell lines; 
[11] NS - USA (85); 
[12] In vitro cell lines; 
[7] NS - USA. 
[7] 1199G>T, reduced resistance, variety of drugs; 
[8] 1199G>T/A = paclitaxel response; [9] 2677GG 
and 3435CC = docetaxel side effects, no effect from 
-41A>G, -145C>G, 1236C>T; [10] 1199A = 
increased resistance; [11] IVS9 -44A>G = SN-38 PK 
^^ [12] 2005C>T = lower resistance to paclitaxel and 
etoposide;  [7] T allele is associated with reduced 
resistance to vinblastine, vincristine, paclitaxel, and 
doxorubicin in Leukemia patients. Patients carrying 
the A allele exhibited increased resistance. 
No [13] In vitro, cell lines. [13] Does not affect resistance to doxorubicin 
Antiretroviral Therapy 
(HIV) Yes [14] In vitro - cell lines. 
[14] Increased cellular uptake and permeability of 
HIV protease inhibitors 
Immunosuppressants Yes 
[15] Finnish 
Caucasian (103), East 
African (1). 
[15] 1199G>T, 1236C>T, 2677G>T/A, 3435C>T 
haplotypes = CsA PK 
Others/Mixed 
Substrates No [4] In vitro - cell lines.  
[4] N21D, F103L, S400N, A893S, and A998T on the 
PK of a range of cytotoxic derivatives.  
No report for the 
following drug 
classes/indications 




#s6        
E13/1236C>T 
(G412G) 
Antibiotics Yes [16] Chinese (18). [16] 1236CC = lower cloxacillin Cmax, higher oral clearnace, lower urinary excretion. 
Anti Cancer Agents Yes 
[17] African American 
and Caucasian (NA); 
[18] Caucasian (63), 
Asian (2); [19] NS - 
Germany (112). 
[17] MTX toxicity; [18] Irinotecan dose;  [19] 1236CC 
= temozolamide response -assesed with other 
SNPs. 
Immunosuppressants Yes [20] Han Chinese (103). [20] Dose adjusted conc. following renal transplant. 
No report for the 
following drug 
classes/indications 
  Antiepileptic Drugs, Antidepressants, Cardiac Glycoside, Antiretroviral Therapy (HIV), Opiate analgesic, Statins. 
6 E17/1985T>C (L662R) 
Anti Cancer Agents Yes [5] In vitro - cell lines. [5] Increased resistance to daunorubicin, doxorubicin, valinomycin, or actinomycin D. 
No report for the 
following drug 
classes/indications 
  Antiepileptic Drugs, Antibiotics, Antidepressants, Cardiac Glycoside, Antiretroviral Therapy (HIV), Immunosuppressants, Opiate analgesic, Statins. 
7 E17/2005C>T (R669C) 
Anti Cancer Agents Yes [5] In vitro - cell lines; [12] In Vitro - cell lines. 
[5] Increased resistance to daunorubicin, 
doxorubicin, valinomycin, or actinomycin D; [12] 
Decreased paclitaxel and etoposide resistance. 
No report for the 
following drug 
classes/indications 





Antidepressants Yes [21] NS - Croatia (240). [21] Olanzapine efficacy. 
Anti Cancer Agents Yes 
[22] In vitro cell lines; 
[23] NS - Australia 
(309). 
[22] Increased vincristine transport with Ser893 and 
Thr893; [23] Taxane response. 
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No [24] Central European Caucasian (213). [24] MTX efficacy. 
Cardiac Glycoside Yes [25] Caucasian (77). [25] 2677T/A = digoxin stimulated saliva/serum ratio - assessed with other SNPs. 
Immunosuppressants Yes 
[26] NS - Japan (17); 
[27] NS - India (155); 
[28] Han Chinese 
(115). 
[26] TRL induced neurotoxicity; [27] CsA dosage; 
[28] 2677T/A = TRL induced neurotoxicity;  
Statins Yes [29] Caucasian (1507). [29] 2677T/A = Pravastatin Efficacy - assessed other SNPs 
Others/Mixed 
Substrates Yes 
[30] NS - Germany 
(55); [31] Caucasian 
(37), African American 
(23). 
[30] TT/TA = elevated serum concentration-time 
curve values of talinolol; [31] Efflux of digoxin, 
Fexofenadine levels.  
No report for the 
following drug 
classes/indications 
  Antiepileptic Drugs, Antibiotics, Antiretroviral Therapy (HIV), Opiate analgesic.
9 E26/3151C>G (P1051A) 
Others/Mixed 
Substrates Yes [5] In vitro - cell lines. 
[5] Influence resistance to valinomycin when in 
diplotype with E22/2677G>T/A (S893A/T). 




Antiepileptic Drugs, Antibiotics, Antidepressants, Anti Cancer Agents, Cardiac 
Glycoside, Antiretroviral Therapy (HIV), Immunosuppressants, Opiate 
analgesic, Statins 
10 E27/3322T>C (W1108R) 
Anti Cancer Agents No [5] In vitro - cell lines. [5] Decrease resistance to daunorubicin, doxorubicin, valinomycin, or actinomycin D. 
No report for the 
following drug 
classes/indications 
  Antiepileptic Drugs, Antibiotics, Antidepressants, Cardiac Glycoside, Antiretroviral Therapy (HIV), Immunosuppressants, Opiate analgesic, Statins 
11 E27/3421T>A (S1141T) Anti Cancer Agents Yes [5] In vitro - cell lines. 
[5] Increased resistance to daunorubicin, 
doxorubicin, valinomycin, or actinomycin D. 
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Immunosuppressants Yes [1] In vitro - cell lines. [1] Reduced sensitivity to CsA inhibition of BODIPYL-FL-paclitaxel transport. 
No report for the 
following drug 
classes/indications 
  Antiepileptic Drugs, Antibiotics, Antidepressants, Cardiac Glycoside, Antiretroviral Therapy (HIV), Opiate analgesic, Statins 
12 





[32] NS - Turkey (96); 
[33] NS - France 
(2208). 
[32] Pharmacokinetics of phenytoin; [33] TT = side 
effect from clopidogrel (cardiovascular event at 
1yr).^^ 
No 
[34] NS - Turkey (189); 
[35] Meta analysis 
(3371); [36] NS- 
Turkey (104). 
[34] Drug resistance; [35] Drug efficacy; [36] PK of 
valporic acid. 
Antibiotics No 
[37] Mixed - 
Caucasian (12), Asian 
(5), African American 
(1), NS (1); [38] 
Korean (210). 
[37] Dicloxacillin pharmacokinetics. [38] 




Caucasian" (160); [40] 
NS - Sweden (116). 
[39] 3435TT risk factor for nortriptyline-induced 
postural hypotension; [40] Olanzapine efficacy. 
Anti Cancer Agents 
Yes 
[41] Caucasian (191), 
Asian (5) African (2) 
Hindustani (3), 
Surinamese (3) and 
Israeli (1); [42] 
Caucasian (73); [43] 
NS - France (23); [44] 
NS - USA (324) [45] 
Northern Irish (184); 
[46] Caucasian (334). 
[41] T allele assoc with adverse side effect after 6 
months. No assoc with drug efficiacy. ^^ [42] TT = 
risk of side effects encephalopathy; [43] Irinotecan 
PK; [44]  TT = adverse side effect; [45] CT = higher 
survival on vincristine, doxorubicin and 
dexamethasone; [46] lower response to epirubicin 
and doxorubicin. 
No 
[47] Chinese (28), 
Malay (3), Indian (1); 
[48] Japanese (145), 
Japanese (197), NS - 
[47] Docetaxel PK; [48] PK or adverse effects of a 
range of drugs. [49] Imatinib response.^^ 
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[50] Caucasian (21); 
[51] German (461); 
[52] Japanese (15) 
[53] Japanese (11); 
[54] NS - France (12); 
[55] NS - France (32). 
[50] digoxin plasma levels; [51] TT = increased 
intestinal uptake; [52] lower serum concentration; 
[53] suppression of duodenal absorption of drug; 
[54] TT = higher AUC @ 4 and 24hrs. [55] 3435T = 
volume of distribution, Higher conc. for T variants - 
assessed with other SNPs. 
No 
[56] NS - France (12); 
[57] Meta analysis 
(183); [58] Caucasian 
(77). 




[59] Caucasian (123); 
[60] NS - USA (71); 
[61] NS - Spain (74); 
[62] NS - France (32); 
[63] African (22), 
Caucasian (46) Other 
(8); [64] African (156). 
[59] nelfinavir/efavirenz efficacy and plasma drug 
concentrations; [60] higher nelfinavir plasma levels; 
[61] Plasma levels of atazanavir and risk of 
hyperbilirubinemia; [62] absorption constant of 
indinavir; [63] Drug dependent changes in mean 
HDL-c levels; [64] T allele = protective effect from 
nevirapine induced hepatotoxicity. 
No [65] NS - Finland (17). [65] Saquinavir PK. 
Immunosuppressants Yes 
[66] Black (22), White 
(120), Middle Eastern 
(12), South Asian (26); 
[67] NS - USA (10); 
[68] NS - France (44); 
[69] NS - China (50); 
[70] NS - Iran (88); 
[71] Caucasian (75); 
[72] NS - Turkey (92); 
[73] Chinese (66); [74] 
NS - Italy (50); [75] 
Chinese (66), Malay 
(13), Indian (3); [76] 
[66] CC genotype = minor effect on blood conc. of 
TRL; [67 higher CsA oral clearance; [68] CsA C:D 
ratio and dose requirement; [69] TRL dose 
requirement and dose-adjusted trough levels; [70] 
CsA PK and dose requirements; [71] CsA conc; [72] 
CC = lower dose-adjusted trough TRL conc; [73] 
TRL dosage requirements; [74] TT genotype = CsA 
induced gingival overgrowth; [75] CC genotype = 
higher TRL efflux/lower C:D ratio - due to higher 






[77] Caucasian (142); 
[78] NS  - USA (14); 
[79] NS - Japan (69); 
[80] Meta-analysis 
(1036); [81] Chinese - 
(155); [82] NS - Spain 
(53). 
[77] CsA efficacy; [78] CsA PK; [79] TRL C:D 
ratio^^; [80] CsA PK; [81] sirolimus PK; [82] TRL 
dosage requirements. 
Opiate analgesic Yes [83] Caucasian - Italy (145). [83] Morphine efficacy.^^ 
Statins Yes [84] NS - Netherlands (1255). 
[84] 3435T interacts with CYP3A4*1B and 
subsequently simvastatin and atorvastatin PK - 




[85] NS - Croatia (60); 
[86] Caucasian (80); 
[87] Caucasian (31); 
[88] In Vitro - cell lines. 
[85] Phenobarbital conc. in cerebrospinal fluid; [86] 
CC genotype = cannabis dependence; [87] 
Rhodamine 123 efflux; [88] Altered substrate 
specificity (range of compounds). 
No 
[89] Caucasian (16); 
[90] NS - Turkey (58); 
[91] Japanese (12); 
[92] Japanese (80); 
[93] Caucasian (20). 
[89] loperamide disposition or CNS effects; [90] 
Losartan disposition^^; [91] Telmisartan PK^^; [92] 




13 E29/3751G>A (V1251I) 
Immunosuppressants Yes [1] In vitro - cell lines. [1] Modulate CsA effect on the intercellular accumulation of BODIPY-FL-paclitaxel transport. 
No report for the 
following drug 
classes/indications 












[94] In vitro - Cell 
Lines; [95] Caucasian 
(289). 
[94] PK of various AEDs; [95] 3435TT and 2677TT = 
reduced drug resistance. 
No 
[49] Korean (193); [96] 
North Indian (325); 
[97] Caucasian (463); 
[98] Indian (369). 
[49, 96-98] Drug efficacy/response.^^ 
Antibiotics Yes [99] Han Chinese (20). [99] 2677TT and 3435TT = lower azithromycin plasma conc, higher Tmax, lower AUC. 
Antidepressants 
Yes 
[100] NS - Germany 
(15); [101] Japanese 
(68); [102] NS - Italy 
(60). 
[100] 2677G>T influences citalopram plasma and 
CSF conc, 3435C>T does not; [101] Paroxetine 
efficacy; [102] 3435CC = higher clozapine dose 
required to equal plasma conc. 
No [103] NS - Croatia (127). [103] Paroxetine efficacy. 
Anti Cancer Agents Yes 
[104] Japanese (145); 
[105] NS - USA (73); 
[106] NS - Singapore 
(62); [1] In vitro - cell 
lines; [107] Han 
Chinese (69); [108] 
Korean (118); [109] 
Han Chinese (54); 
[110] NS - Germany 
(1047), Spain (49); 
[111] NS - Korea 
[104] TTT = reduced clearance of irinotecan; [105] 
docataxel side effects; [106] doxorubicin PK; [1] 
paclitaxel transport; [107] Vinorelbine outcome; 
[108] 2677 genotype = 
hematological/gastrointestinal toxicities; [109] 
docetaxel-cisplatin efficacy; [110] lower 
mitoxantrone efflux.^^ [111] 3435CT = shorter OS, 
2677GG = paclitaxel/doxorubicin resistance; [112] 
Adverse side effects, 3435CT and TT genotypes = 




(121); [112] Korean 
(161); [113] NS - 
France (90). 
No [114] NS - France (42). [114] Erlotinib PK.^^ 
Cardiac Glycoside Yes 
[115] Caucasian (687); 
[116] NS - Japan (15); 
[117] Caucasian (25), 
African (6), Asian (1); 
[117] NS - 
Netherlands (195); 
[119] Han Chinese 
(20). 
[115] 3435TT = higher Cmax and AUC, 
2677T/3435T = higher AUC, 2677G/3435C = lower 
AUC; [116] 2677GG/3435CC = bioavailability; [117] 
3435T and 2677T = higher conc. [118] TTT 
genotype = higher serum conc in the elderly; [119] 





[120] Caucasian (118); 
[121] African American 
(13), Hispanic (4), 
Asian (1), Caucasian 
(13). 
[120] 3435CT/2677TT = lower atazanavir levels; 
[121] CGC predicts slower oral clearance of 
atazanavir an ritonavir. 
No 
[122] NS - USA (103), 
[123] NS - Belgium 
(53); [124] NS - Spain 
(115). 
[122] atazanavir or lopinavir trough concentrations; 
[123] Lopinavir PK^^; [124] Tenofovir induced 





[125] Chinese (106), 
Malay (92) and Indian 
(91); [126] Caucasian 
(73), African (7), 
Indian (1); [127] NS - 
USA. (65); [54] 
Caucasian (91); [128] 
NS - Canada (69); 
[129] NS - China 
(129); [130] NS - 
Netherlands (104); 
[131] Caucasian - 
Czech Republic (832); 
[132] Chinese (112); 
[133] Caucasian (38), 
Asian (10) and 3 Black 
Caribbean; [134] NS - 
Portugal (30). 
[125] TTT = CsA PK - higher AUC and Cmax; [126] 
2677T allele = TRL PK and dose requirements, 
2677T/3434T = dose requirements; [127] 
2677T/3434T = TRL blood conc. @ 6 and 12 
months; [54]. TRL dosage requirements; [128] 
2677GG/3435CC = CsA exposure @ 1 wk only; 
[129] CsA blood conc. [130] CsA oral bioavailibilty in 
children; [131] TRL/Cyclosporin efficacy - risk of 
acute rejection^^; [132] CGC, TGT and TTC 
genotypes assoc with CsA conc; [133] TTT = TRL 
induced nephrotoxicity, higher dose adjusted pre-
dose conc.; [134] higher TRL conc. with 1236T and 
2677T/A alleles. 
No 
[135] Caucasian (82), 
African (2), South 
Asian (1); [136] 
Korean (29); [137] 
Caucasian (95); [138] 
NS - China (104); 
[139] NS - Norway 
(25); [140] NS - 
Switzerland (19);[141] 
NS - France (136); 
[142] NS - Belgium 
(29); [143] Japanese 
(63); [144] Korean 
(568); [145] Caucasian 
(32); [146] Caucasian 
(50); [147] Caucasian 
(192). 
[135] Sirolimus and TRL PK and dose 
requirements^^; [136] TRL PK; 24. TRL PK; [137] 
TRL PK; [138] TRL PK^^; [139] CsA PK; [140] CsA 
PK in PBMCs; [141] TRL efficacy^^; [142] 
TRL/Fluconazole PK; [143] TRL PK^^; [144] TRL 
PK^^; [145] TRL dosage requirements^^; [146] TRL 




Opiate analgesic Yes 
[148] (138) Sephardic 
(Western Europe, 
Balkans and Morocco) 
(39%), Ashkenazi 
(Central and Eastern 
Europe) (22%), 
Oriental (Iraq, Iran, 
Yemen and Syria) 
(16%), mixed (13%) 
and unknown (10%); 
[149] Japanese (32). 
[148] Methadone dose requirement; [149] 2677G 
and 3435C = reduced chance of vomiting. 
Statins 
Yes 
[150] Finnish (534); 
[151] Caucasian (85); 
5. Korean (28). 
[150] Simvastatin and Atorvastatin PK; [151] TTT 
and CGT = Simvastatin Efficacy; 5. 2677TT/3435TT 
= atorvastatin lactone, 2-hydroxyatorvastatin and 2-
hydroxyatorvastatin lactone PK. 




[153] Caucasians (46); 
[154] Han Chinese 
(24); [155] In vitro - 
cell lines; [156] Korean 
(33). 
[153] TTT haplotype = lower plasma concentration 
of the active metabolite of risperidone, 9-
hydroxyrisperidone; [154] TT/TT and GT/CT = lower 
AUC, TT/TT = higher oral clearnce of Verapamil; 
[155] 2677G>T assoc. with Ibutilide resistance. 
3435T associated with disrupted protein trafficking - 
reversed with fexofenadine; [156] 2677AA/3435CC 
= lower plasma conc. of fexofenadine. 
No 
[157] Korean (104); 
[158] Korean (30); 
[159] Han Chinese 
(24); [160] Korean 
(10); [161] Japanese 
(95); [162] Japanese 
(65); [163] In vitro - 
cell lines.  
[157] Cilostazol PK^^; [158] Rebamipide PK; [159] 
Valacyclovir absorption; [160] verapamil PK; [161] 
Prednisolone efficacy; [162] Prednisolone PK; [163] 




Studies are grouped according to the substrates investigated. *The racial background of the cohort population is indicated. In the event that the 
study did not specify the racial background, an NS (Not Specified) is stated along with the country in which the study was conducted. ^^ 
Indicates that SNPs or SNP haplotypes located in other genes, including CYP3A4, CYP3A5 or other ABC proteins were associated with drug 
pharmacokinetics/response to an equal or greater extent than those of ABCB1. 
Notes on drug classes: 
Antiepileptic Drugs (AED)  Includes phenytoin, carbamazepine, lamotrigine, phenobarbital, valproic acid, levetiracetam, and gabapentin. 
Antibiotics  Includes dicloxacillin, amoxicillin, clarithromycin and azithromycin 
Antidepressants  Includes citalopram, clozapine, paroxetine, venlafaxine, mirtazapine. 
Anti Cancer Agents                                              
(antimetabolite, general cytotoxics, tyrosine 
kinase inhibitors)   
Includes methotrexate (MTX), docetaxel, irinotecan, doxorubicin, daunorubicin, vincristine, 
dexamethasone, epirubicin, imatinib, temozolamide, paclitaxel, cisplatin, mitoxantrone, and 
erlotinib. 
Cardiac Glycoside Includes digoxin 
Antiretroviral Therapy (HIV) Includes nelfinavir, efavirenz, atazanavir, indinavir, nevirapine, saquinavir, ritonavir, lopinavir, and tenofovir. 
Immunosuppressants Includes tacrolimus (TRL), cyclosporin A (CsA), and sirolimus.  
Opiate analgesic  Includes Methadone and Morphine. 
Statins Includes simvastatin, atorvastatin, pravastatin, fluvastatin, pravastatin, lovastatin, and rosuvastatin. 
Others/Mixed Substrates  
Includes telmisartan, phenobarbital, cannabis, rhodamine 123, loperamide, losartan, 






The reference numbers in Appendix 1 are in accordance to the reference list provided Steven J. Wolf*, Maulana Bachtiar*, Jingbo 
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Appendix 2. Drug pathways curated by the PharmGKB database 
ID Drug-response Pathway 
Total 
Genes PharmGKB Pathway 
No. 
Genes 
Associated Tissue(s) of 
Expression Associated Drug(s) 
1 ACE inhibitor  19 ACE inhibitor pathway 19 Non-tissue specific Ace Inhibitors, Plain 
2 Anti diabetic 33 
Anti diabetic drug pathway (Nateglinide PK) 3 Liver Nateglinide 
Anti diabetic drug pathway (Potassium 





Anti diabetic drug pathway (Repaglinide PK) 3 Liver Repaglinide 
3 Anti estrogen  19 
Anti estrogen pathway (Aromatase inhibitor) 5 
Adrenals, ovary, peripheral 
tissues, liver & circulation, 
breast  
Anti estrogen drugs 
inhibiting aromatase-
mediated synthesis 
Anti estrogen pathway (Estrogen 
metabolism) 11 Liver and peripheral tissues Anti estrogen 






Anti estrogen pathway (Tamoxifen PK) 6 Liver and breast tissues Raloxifene, tamoxifen, toremifene 
4 Antiarrhythmic 59 Antiarrhythmic Drug Pathways 59 Cardiomyocyte 
Amiodarone, 
antiarrhythmics, class i 














5 Antiplatelet 9 Antiplatelet Drug Clopidogrel Pathway (PK) 9 Liver, intestine, platelet Clopidogrel 
6 Benzodiazepine  25 
Benzodiazepine pathway (PD) 14 Presynaptic/postsynaptic neurons Benzodiazepine  



































10 Citalopram 4 Citalopram (PK) 4 Liver, intestine Citalopram 
11 Codeine and morphine 9 Codeine and Morphine Pathway (PK) 9 Liver Codeine, morphine 
12 Cyclophosphamide  24 
 
Cyclophosphamide Pathway 17 
Non-tissue specific cancer 
cells Cyclophosphamide 
Cyclophosphamide Pathway (PK) 7 Liver 
13 Doxorubicin 74 
Doxorubicin (Cancer PD) 18 Cancer cells Doxorubicin 
Doxorubicin (Cardio PD) 15 Cardiomyocyte Dexrazoxane, doxorubicin 
Doxorubicin Pathway 56   
Doxorubicin 
Doxorubicin (PK) 22   




15 Erlotinib  8 Erlotinib Pathway (PK) 8 Erlotinib 




17 Fluoropyrimidine 33 
Fluoropyrimidine (PD) 10 Non-tissue specific cancer cells Capecitabine, 
fluorouracil, tegafur Fluoropyrimidine (PK) 24   
18 Gefitinib 8 Gefitinib Pathway (PK) 8   Gefitinib 
19 Gemcitabine  10 Gemcitabine Pathway 10 Non-tissue specific cancer cells 
Antineoplastic agents, 
gemcitabine 
20 Glucocorticoid and inflammatory 16 
Glucocorticoid and Inflammatory genes 








Glucocorticoid and Inflammatory genes 
Pathway (PD) 9 
CNS and peripheral tissues 






Glucocorticoid and Inflammatory genes 
Pathway (Regulation) 0
#     
21 Ifosfamide  19 
Ifosfamide Pathway 13 Non-tissue specific cancer cells 
Antineoplastic agents, 
ifosfamide 
Ifosfamide Pathway (PK) 6 Liver Ifosfamide 
22 Imatinib 12 Imatinib 12 Blood, intestine, liver Dasatinib, imatinib 
23 Imipramine desipramine 4 Imipramine Desipramine Pathway (PK) 4 Liver 
Desipramine, imipramine 
24 Irinotecan  23 
Irinotecan pathway 14 Antineoplastic agents, irinotecan 
Irinotecan Pathway (Cancer) 19 Non-tissue specific cancer cells Irinotecan 
25 Losartan 5 Losartan (PK) 5 Liver Losartan 





27 Nicotine 34 
Nicotine Pathway 10 Liver 
Nicotine Nicotine PD Pathway (Chromaffin Cell) 4 chromaffin cells 
Nicotine PD Pathway (Dopaminergic 
Neuron) 21 dopaminergic neurons 
28 Phenytoin 10 Phenytoin PK Pathway 10 Liver Phenytoin 




30 Platinum  45 Platinum Pathway 45   
Antineoplastic agents, 
cisplatin, oxaliplatin,  
platinum 






Proton Pump Inhibitor (PK) 3   Omeprazole 
32 RAAS 20 Renin-Angiotensin-Aldosterone-System-acting Drug Pathway 20   
Ace Inhibitors, Plain, 
Aldosterone antagonists, 













33 SSRI 33 
Selective Serotonin Reuptake Inhibitors 





SSRI Fluoxetine Pathway (PK) 5 Liver Fluoxetine 
34 Statin   46 
Statin Pathway (Atorvastatin Lovastatin and 
Simvastatin PK) 14 Liver, intestine 
Atorvastatin, lovastatin, 
simvastatin 
Statin Pathway (Cholesterol and Lipoprotein 
Transport PD) 27 
Liver, enterocyte, peripheral 
tissue 
Atorvastatin, fluvastatin, 




Statin Pathway (Fluvastatin PK) 13 Liver, intestine Fluvastatin 
Statin Pathway (PK) 19 
Liver, intestine, kidney 
Atorvastatin, fluvastatin, 




Statin Pathway (Pravastatin PK) 9 Pravastatin 
Statin Pathway (Rosuvastatin PK) 4 Liver, intestine Rosuvastatin 
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35 Sympathetic nerve   31 
Sympathetic Nerve Pathway (Neuroeffector 
Junction) 22 Neuroeffector junction 
Acebutolol, atenolol, 






















Sympathetic Nerve Pathway (Pre- and Post-




36 Taxane  16 Taxane Pathway 16   Docetaxel, paclitaxel 
37 Tenofovir adefovir  7 Tenofovir Adefovir pathway 7 Kidney Adefovir dipivoxil, tenofovir 
38 Thiopurine  33 Thiopurine Pathway 33   
Antineoplastic agents, 
azathioprine, folic acid, 
mercaptopurine, 
thioguanine 






40 Vinca alkaloids 10 Vinca Alkaloids (PK) 10 
Liver 
Vincristine 
41 Warfarin   24 
Warfarin Pathway (PD) 15 
Warfarin 
Warfarin Pathway (PK) 9 
#The Glucocorticoid and Inflammatory genes Pathway (Regulation) of the PharmGKB did not have gene index that could be 




Appendix 3. SNP density of the drug-response pathways 
ID Drug Response Pathway 































1 ACE inhibitor  8.81 10.13 9.40 8.06 6.46 4.53
2 Anti diabetic 8.42 8.50 8.45 12.09 6.76 3.71
3 Anti estrogen 11.44 12.46 12.72 11.53 14.45 7.08
4 Antiarrhythmic 8.61 7.87 10.85 11.26 6.31 4.11
5 Antiplatelet 10.79 12.32 25.83 18.76 17.18 5.52
6 Benzodiazepine 10.60 9.62 9.14 9.07 9.55 4.47
7 Beta-agonist and beta-blocker 7.83 7.78 5.65 11.77 3.88 3.68
8 Bisphosphonate 8.74 9.90 9.13 11.18 8.51 4.13
9 Celecoxib 10.24 11.55 12.43 15.10 10.39 5.35
10 Citalopram 14.00 16.32 17.55 11.92 28.01 7.91
11 Codeine and morphine 11.98 13.65 10.57 16.16 18.59 6.24
12 Cyclophosphamide 10.27 11.01 11.82 14.27 12.05 5.69
13 Doxorubicin 10.04 10.30 12.66 16.81 11.52 5.44
14 EGFR inhibitors 7.77 8.23 6.11 9.84 3.98 3.34
15 Erlotinib 12.32 10.87 18.22 16.54 15.72 3.40
16 Etoposide 10.50 10.45 15.86 16.59 10.57 4.78
17 Fluoropyrimidine 9.72 11.38 18.39 14.18 6.78 4.55
18  Gefitinib 
 
 
14.39 13.33 19.68 14.71 21.51 5.92
19 Gemcitabine 10.46 9.59 32.46 12.18 6.71 3.60
20 Glucocorticoid and inflammatory 8.02 8.69 9.54 9.55 4.08 3.23
21 Ifosfamide 10.28 11.20 13.26 16.70 12.43 5.73
22 Imatinib 12.00 12.45 16.21 16.37 16.40 5.93
23 Imipramine desipramine 13.77 18.44 12.77 7.53 29.79 8.19
24 Irinotecan 10.43 10.59 19.33 19.64 13.94 4.27
25 Losartan 12.51 11.66 7.16 21.98 16.58 5.89
26 Methotrexate 9.62 10.07 12.73 10.42 5.64 4.03
27 Nicotine 9.17 10.51 4.07 15.31 8.86 6.13
28 Phenytoin 10.98 11.20 12.67 13.96 18.82 4.16
29 Platelet aggregation 8.61 10.18 7.01 13.22 9.08 4.62
30 Platinum 8.96 8.96 10.69 14.86 10.65 3.64
31 Proton pump inhibitor 8.46 8.49 6.45 11.71 4.73 3.18







33 SSRI 8.20 8.62 9.56 8.01 7.56 4.52
34 Statin 10.92 11.36 14.67 12.99 12.65 4.65
35 Sympathetic nerve 9.77 7.50 9.04 14.08 7.00 5.06
36 Taxane 10.57 12.55 16.88 15.73 8.97 4.38
37 Tenofovir adefovir 8.21 8.18 17.72 9.89 7.21 4.34
38 Thiopurine 9.27 9.55 11.44 11.47 6.48 4.28
39 VEGF 8.53 9.40 7.56 11.00 4.39 3.90
40 Vinca alkaloids 8.67 9.79 15.91 13.83 8.21 3.39
41 Warfarin 9.91 10.22 9.67 12.75 10.38 4.55
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Appendix 4. Common DRP genes housing one or more expression-associated functional SNPs 
 
ID Pathway 
Expression-associated potentially functional SNPs in Common Genes 





























































































































































































1 ACE inhibitor  
 
 
    RYR2 (rs2275288)           
2 Anti diabetic 
 
 
                
3 Anti estrogen UGT1A1 (rs10929302)                 
4 Antiarrhythmic                   
5 Antiplatelet ABCB1 (rs3747802)                 
6 Benzodiazepine                   
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8 Bisphosphonate                   










          
10 Citalopram ABCB1 (rs3747802)                 









































          



















































          
17 Fluoropyrimidine SLC29A1 (rs3734701) 
TYMS 










          
18 Gefitinib ABCB1 (rs3747802)                
19 Gemcitabine SLC29A1 (rs3734701)     
SLC29A1 
(rs1128930)         
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    AKR1A1 (rs2088102)           
22 Imatinib ABCB1 (rs3747802)                 






    XRCC1 (rs762507)   
XRCC1 
(rs3547)       








































  MTRR (rs12347) 
MTRR 
(rs10380)   
MTRR 
(rs10380) 
27 Nicotine                   
28 Phenytoin  UGT1A1 (rs10929302)                 










          




















  XRCC1 (rs3547)       
31 Proton pump inhibitor 
ABCB1 




          
32 RAAS                   
















    SLCO1B3 (rs60140950)     
35 Sympathetic nerve                   




    SLCO1B3 (rs60140950)     






























  MTRR (rs12347) 
MTRR 
(rs10380)   
MTRR 
(rs10380) 
































          
40 Vinca alkaloids ABCB1 (rs3747802)                 
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Appendix 5. Common DRP genes housing one or more highly-differentiated  functional SNPs 
 
ID Pathway 
Highly-differentiated Potentially Functional SNPs in Common Genes 





























































































































































































1 ACE inhibitor  
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5 Antiplatelet       CYP3A5 (rs776746)           
6 Benzodiazepine       CYP3A5 (rs776746)           






























  ADCY8 (rs13278912) 
















          
10 Citalopram                   
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23 Imipramine desipramine                   







          
25 Losartan                   
   
263 
 







          





          
28 Phenytoin       CYP3A5 (rs776746)           















  ADCY8 (rs13278912) 




          

























  ADCY8 (rs13278912) 





32 RAAS                   
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37 Tenofovir adefovir       SLC22A8 (rs4149181)           


















          
40 Vinca alkaloids RALBP1 (rs7245045)     
CYP3A5 
(rs776746)           
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Appendix 6. Studies describing drug-response variation   
          
























































































































































inhibitors ASW_CEU  CEU ASW   
Whites had greater BP 
reduction with enalapril 
than blacks 
Exner et al  







inhibitors ASW_CEU  CEU ASW   
Lesser Response to 
Angiotensin-
Converting–Enzyme 
Inhibitor Therapy in 
Black as Compared 
with White Patients 
with Left Ventricular 
Dysfunction 
Exner et al  





pathway Enalapril ASW_CEU  CEU ASW    Exner et al  





pathway Angiotensin I ASW_CEU  CEU ASW   
Black subjects required 
twice as much 
angiotensin I as 
Caucasian subjects to 
achieve similar DBP 
elevations 
Joubert  







inhibitors CHB_CEU    CHB 
The high incidence and 
greater odds ratio of Woo et al  
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cough among Chinese 
patients taking ACE 
inhibitors 
raises the possibility of 
an enhanced 
susceptibility to this 
adverse effect among 
the Chinese. 
ACE inhibitor 
pathway Captopril ASW_CEU  CEU ASW   
Antihypertensive effect greater in 
Whites  





pathway Enalapril CHS_MAS      
Ethnic distribution of ADR reports 
showed statistically significant 
difference with the general population 
 
ACE inhibitor 
pathway Enalapril CHS_INS      
Ethnic distribution of ADR reports 
showed statistically significant 
difference with the general population 
 
ACE inhibitor 
pathway Enalapril MAS_INS      
Ethnic distribution of ADR reports 
showed statistically significant 


















Insulin CHB_GIH  GIH CHB   
The time of onset of 
insulin effect was 
approximately 10 
minutes earlier in the 
Indian subjects 













Nigeria, Singapore, Sri Lanka, and 
United States   
Sex hormone 
concentrations were 
reported as being 
highest in women from 
Southeast Asia 
Bennink HJ  
Eur J Contracept 
Reprod Health 
Care. 2000 Sep;5 
Suppl 2:12-20. 
Anti estrogen Estrogen CHB_CEU CEU CHB   Caucasians more Massart F  Gynecol 














Estrogen CEU_MEX  CEU MEX   
Caucasians more 
estrogen-sensitive than 
other human races 








Estrogen CEU_YRI  CEU YRI   
Caucasians more 
estrogen-sensitive than 
other human races 










Nigeria, Singapore, Sri Lanka, and 
United States   
Sex hormone 
concentrations were 
reported as being 
highest in women from 
Southeast Asia
Bennink HJ  
Eur J Contracept 
Reprod Health 






Estrogen CHB_CEU  CEU CHB   
Caucasians more 
estrogen-sensitive than 
other human races 








Estrogen CEU_MEX  CEU MEX   
Caucasians more 
estrogen-sensitive than 
other human races 








Estrogen CEU_YRI  CEU YRI   
Caucasians more 
estrogen-sensitive than 
other human races 









Nigeria, Singapore, Sri Lanka, and 
United States   
Sex hormone 
concentrations were 
reported as being 
highest in women from 
Southeast Asia 
Bennink HJ  
Eur J Contracept 
Reprod Health 





Estrogen CHB_CEU  CEU CHB   
Caucasians more 
estrogen-sensitive than 
other human races 




Anti estrogen Estrogen CEU_MEX CEU MEX   Caucasians more Massart F  Gynecol 












Estrogen CEU_YRI  CEU YRI   
Caucasians more 
estrogen-sensitive than 
other human races 










Haloperidol CHB_CEU/ASW CHB CEU/ASW   
These results suggest 
that the metabolism and 
disposition of 
haloperidol and reduced 
haloperidol could differ 
among ethnic 
populations 








Haloperidol CHB_"Other populations" CHB 
"Other 
populations" 
The Chinese group 
differed from the other 
ethnic populations 











Haloperidol ASIAN_CEU CHB CEU   
The results were similar 
between the two Asian 
groups but significantly 
different between 
Caucasians and Asians. 










Haloperidol CHB_CEU  CHB CEU   
Chinese schizophrenic 
patients (in the People's 
Republic of China) had 














Haloperidol CHB_ASW  CHB ASW   
Chinese patients were 
shown to produce 40–




Poolsup et al  













Haloperidol CHB_CEU  CHB CEU   
Chinese patients were 
shown to produce 40–





(Caucasians and blacks) 
Poolsup et al  








Haloperidol CHB_CEU  CHB CEU   
Chinese patients were 
shown to produce 40–





(Caucasians and blacks) 
Poolsup et al  








Haloperidol CHB_CEU  CHB CEU   
The higher haloperidol 
levels noted in Chinese 
may be explained by 
the lower clearance in 
this population 
(6·17 ml/min/kg) ( 120) 
compared with 




Poolsup et al  












ASW_CEU  ASW CEU   
Different reduction of 
blood pressure Brewster et al  









Adinazolam CHB_ASW  CHB ASW   
Greater exposure of 
adinazolam in Asians Ajir et al  
Psychopharmaco
logy (Berl). 1997 
Feb;129(3):265-
70. 




pathway (PD) Adinazolam CHB_CEU  CHB CEU   
Greater exposure of 
adinazolam in Asians Ajir et al  
Psychopharmaco




pathway (PD) Adinazolam JPT_ASW  JPT ASW   
Greater exposure of 
adinazolam in Asians Ajir et al  
Psychopharmaco




pathway (PD) Adinazolam JPT_CEU  JPT CEU   
Greater exposure of 
adinazolam in Asians Ajir et al  
Psychopharmaco














pathway (PD) Triazolam CEU_GIH  GIH CEU   
Higher Cmax was 
observed in Asians Kinirons et al  




pathway (PD) Diazepam CHB_CEU  CHB CEU   
Greater volume of 
distribution and 
clearance in Caucasians 
than Chinese 
Kumana et al  





pathway (PD) Alprazolam CHB_CEU  CHB CEU   
Lower CLo, CLs in 






pathway (PD) Alprazolam CHB_CEU  CHB CEU   
Ethnic pharmacokinetic 
differences between 
Caucasians and Asians 
(30% greater AUC after 
oral dosing and 25% 
after IV in Asians) 






pathway (PD) Midazolam JPT_CEU  JPT CEU   
25% lower systemic 
clearance of midazolam 
in Japanese as 
compared to Caucasians 









pathway (PD) Midazolam ASW_CEU 
ASW_
CEU     
Similar CL, CL/F, F in 
African- and Caucasian 
Americans 





pathway (PD) Diazepam CHB_CEU  CHB CEU   
Lower clearance for 
diazepam in Chinese of 
the EM phenotype for 
S-mephenytoin versus 
historical controls 






pathway (PD) Triazolam CEU_GIH      
Similar CLo, CLm in 
Asian Indians and 
Caucasians 
Kinirons et al  

















Triazolam CEU_GIH  GIH CEU   
Higher Cmax was 
observed in Asians Kinirons et al  






Diazepam CHB_CEU  CHB CEU   
Greater volume of 
distribution and 
clearance in Caucasians 
than Chinese 
Kumana et al  







Alprazolam CHB_CEU  CHB CEU   
Lower CLo, CLs in 








Alprazolam CHB_CEU  CHB CEU   
Ethnic pharmacokinetic 
differences between 
Caucasians and Asians 
(30% greater AUC after 
oral dosing and 25% 
after IV in Asians) 








Midazolam JPT_CEU  JPT CEU   
25% lower systemic 
clearance of midazolam 
in Japanese as 
compared to Caucasians 





Benzo- Midazolam ASW_CEU ASW_   Similar CL, CL/F, F in Wandel et al  Clin Pharmacol 












Diazepam CHB_CEU  CHB CEU   
Lower clearance for 
diazepam in Chinese of 
the EM phenotype for 
S-mephenytoin versus 
historical controls 








Triazolam CEU_GIH      
Similar CLo, CLm in 
Asian Indians and 
Caucasians 
Kinirons et al  











Propranolol MAS_CHS  MAS CHS   
Malays to have 
significantly greater 
propranolol responses 
compared to Chinese 
healthy male subjects 
Rasool et al  









propranolol CHB_CEU  CHB CEU   
Altered sensitivity to 
and clearance of 
propranolol in men of 
Chinese descent as 
compared with 
American whites 
Zhou et al  







propranolol CHB_CEU  CHB CEU   
Chinese men had a 2- to 
3-fold greater 
sensitivity to 
propranolol's effect on 
heart rate and a 10-fold 
greater sensitivity to the 
BP effect than 
Caucasian men. 
Zhou et al  







Propranolol ASW_CEU  CEU ASW   
Antihypertensive effect greater in 
Whites  







Propranolol CHB_CEU  CHB CEU   
Chinese twice as sensitive to effects on 
blood pressure and heart rate  
JAMA. 1982 Oct 
22;248(16):1996
-2003. 







Propranolol ASW_CEU  CEU ASW   
As evidenced by these results, 
propranolol is as efficacious as HCTZ in 
whites, but HCTZ is more effective than 
propranolol in African Americans 24 
 










CEU_YRI  CEU YRI   
Recovery of 
mercapturic acid and 
cysteine conjugates of 
acetaminophen was 
found to be 9.3% in 
Caucasians compared 
With only 5.2% and 
4.4% in Ghanaians and 
Kenyans, respectively 
Critchley et al  










ASW_CEU  ASW CEU   
Approximately 40% 
higher AUC and 11% 
lower apparent 
clearance in Blacks 
compared to Whites 









Caffeine CHB_CEU      
The 7-demethylation 
and 8-hydroxylation 
activities were found to 
be different between 
Asians and Caucasians 









(Ibuprofen) ASW_CEU    ASW 
Suggested that Black
patients should be 
monitored for an 
increase in adverse 
effects of NSAIDs in 
the presence of 
histamine H2 receptor 
antagonists 







Diclofenac CHS_MAS      
Ethnic distribution of ADR reports 
showed statistically significant 





Diclofenac CHS_INS      
Ethnic distribution of ADR reports 
showed statistically significant 
difference with the general population 
 






Diclofenac MAS_INS      
Ethnic distribution of ADR reports 
showed statistically significant 





Naproxen CHS_MAS      
Ethnic distribution of ADR reports 
showed statistically significant 





Naproxen CHS_INS      
Ethnic distribution of ADR reports 
showed statistically significant 





Naproxen MAS_INS      
Ethnic distribution of ADR reports 
showed statistically significant 












CHB_CEU    CHB 













Codeine CHB_CEU  CEU CHB   
Chinese were less able 





Yue et al  






Codeine CHB_JPT  JPT CHB   
Chinese metabolized 
codeine less effectively 
than Japanese and 
Koreans 







Codeine CHB_JPT  JPT CHB   
Chinese metabolized 
codeine less effectively 
than Japanese and 
Koreans 







Morphine CHB_CEU  CEU CHB   
Caucasians more 
sensitive to the 
cardiovascular and 
rerespiratory effects of 
morphine than Chinese. 
Chinese less sensitive 
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Morphine CHB_CEU  CHB CEU   
Apparent clearance of 
morphine significantly 
higher in Chinese than 
in Caucasians 











amide ASW_CEU  CEU ASW   
Renal survival was 
significantly worse in 
blacks compared with 
white patients. 
Dooley et al  















amide ASW_CEU  CEU ASW   
Renal survival was 
significantly worse in 
blacks compared with 
white patients. 
Dooley et al  







































Erlotinib JPT_CEU  JPT CEU   
Higher response to 
gefitinib and erlotinib 
in patients of Asian 
origin 
Calvo et al  







Gefitinib JPT_CEU  JPT CEU   
Higher response to 
gefitinib and erlotinib 
in patients of Asian 
origin 
Calvo et al  




EGFR EGFR JPT_CEU JPT CEU   The response rates to Fukuoka et  J Clin Oncol. 








treatment with these 
agents are higher in 
Asians than Caucasians, 
but highest in Asian 
females with tumours 
of adenocarcinoma 
histology who have 
never smoked. 
al; Kris et al 2003 Jun 
15;21(12):2237-
46. Epub 2003 








inhibitors JPT_CEU  JPT CEU    Thatcher et al  









JPT_CEU      
The response rates to 
treatment with these 
agents are higher in 
Asians than Caucasians, 
but highest in Asian 
females with tumours 
of adenocarcinoma 
histology who have 
never smoked. 
Fukuoka et 
al; Kris et al  
J Clin Oncol. 
2003 Jun 
15;21(12):2237-
46. Epub 2003 








JPT_CEU    JPT 
Much greater toxicity is 
experienced by 
Japanese patients 
treated with cisplatin 
and either irinotecan or 
etoposide as Compared 
to similarly treated 
Caucasian patients 










5-fluorouracil ASW_CEU    ASW 
Hematologic toxicities 




J Natl Cancer 





5-fluorouracil ASW_CEU    CEU 
Overall incidence of 
any toxicity was 





J Natl Cancer 
Inst. 2002 Aug 
7;94(15):1160-7. 
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ASW_CEU    ASW 
Response rate and 
adverse events vary 
considerably by race 
Sanoff et al  
J Clin Oncol. 
2009 Sep 
1;27(25):4109-











ASW_CEU    ASW 
Response rate and 
adverse events vary 
considerably by race 
Sanoff et al  
J Clin Oncol. 
2009 Sep 
1;27(25):4109-











ASW_CEU    ASW 
Response rate and 
adverse events vary 
considerably by race 
Sanoff et al  
J Clin Oncol. 
2009 Sep 
1;27(25):4109-











ASW_CEU    ASW 
Response rate and 
adverse events vary 
considerably by race 
Sanoff et al  
J Clin Oncol. 
2009 Sep 
1;27(25):4109-































ASW_CEU  ASW CEU   
Almost 50% lower 










X  ASW CEU   
Blacks have a higher 
exposure to nicotine 
Caraballo et 
al  
JAMA. 1998 Jul 
8;280(2):135-9. 














Nicotine ASW_CEU  ASW MEX   
Blacks have a higher 
exposure to nicotine 
































ASW_CEU  ASW CEU   
Almost 50% lower 












Nicotine ASW_MEX  ASW CEU   
Blacks have a higher 
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Pathway Ifosfamide JPT_CEU      
CYP2C19 is involved 





antidepressants, all of 
which are commonly 
used in cancer patients. 






Pathway (PK) Ifosfamide JPT_CEU      
CYP2C19 is involved 





antidepressants, all of 
which are commonly 
used in cancer patients. 





Imatinib Imatinib pathway Desatinib Asians_CEU
Asian-
CEU     
Results from 55 Asian 
and 615 non-Asian 
patients demonstrated 
that the efficacy and 
safety of dasatinib was 
comparable. Dasatinib 
was well tolerated, with 
no observed toxicities 
exclusive to Asian 
patients. A higher 
incidence of adverse 
events and lower rate of 
response observed 
among Asian patients 
with myeloid blast 
phase CML reflected 
the aggressive nature of 
the disease. 
Kim et al  












Barbados and Saudi 
Arabia     
Higher plasma levels 
for tricyclic 
antidepresantidepressan
ts in patients from 
Barbados 
(clomipramine) or 
Saudi Arabia (doxepin 
or imipramine) 
in patients from 
Barbados 
(clomipramine)102 or 










Barbados and Saudi 
Arabia     
Higher plasma levels 
for tricyclic 
antidepresantidepressan
ts in patients from 
Barbados 
(clomipramine) or 
Saudi Arabia (doxepin 
or imipramine) 
in patients from 
Barbados 
(clomipramine)102 or 
Mahy  GE  






Desipramine CHB_CEU      
Mean total clearance of 
DMI ( CLDMI ) from 
plasma was 
significantly (P less 
than 0.05) higher in the 
Caucasians (123 +/- 57 
l/h) than in the Chinese 
(73.5 +/- 38.8 l/h). 
Rudorfer et al  








JPT_CEU    JPT 
Much greater toxicity is 
experienced by 
Japanese patients 
treated with cisplatin 
and either irinotecan or 
etoposide as compared 
to similarly treated 

















ASW_CEU    ASW 
Response rate and 
adverse events vary 
considerably by race 
Sanoff et al  
J Clin Oncol. 
2009 Sep 
1;27(25):4109-
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JPT_CEU    JPT 
Neutropenia in patients 
receiving a combination 
of platinum and 
antimicrotubule agents 
may be more severe in 
Japanese than in 
Europeans and 
Americans 
Sekine et al  
Br J Cancer. 
2008 Dec 
2;99(11):1757-
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JPT_CEU    JPT 
Neutropenia in patients 
receiving a combination 
of platinum and 
antimicrotubule agents 
may be more severe in 
Japanese than in 
Europeans and 
Americans 
Sekine et al  
Br J Cancer. 
2008 Dec 
2;99(11):1757-
62. Epub 2008 
Nov 4. 
Irinotecan Irinotecan JPT_CEU JPT Different grade of Sekine et al  Br J Cancer. 





toxicity 2008 Dec 
2;99(11):1757-




Methotrexate Methotrexate ASW_CEU    ASW 
The presence of the C 
allele at the 
exon 7 rs4846051 SNP 
was associated with a 
higher mean 
toxicity score among 
African-Americans than 
Caucasians 
(0.371 v 0.078, 
p=0.050). The presence 
of at least one copy 
of haplotype 4 (which 
contains the rs4846051 
C allele) was 
also associated with a 
higher toxicity score 
among the African- 
Americans (p=0.03). 
Hughes et al  
Ann Rheum Dis. 
2006 
Sep;65(9):1213-
8. Epub 2006 Jan 
26. 




their effects on MTX 
toxicity in Caucasian 














X  ASW CEU   
Blacks have a higher 
exposure to nicotine 





JAMA. 1998 Jul 
8;280(2):135-9. 
Nicotine 
Pathway Nicotine ASW_CEU  ASW MEX   
Blacks have a higher 
exposure to nicotine 
Caraballo et 
al  
JAMA. 1998 Jul 
8;280(2):135-9. 
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Pathway Nicotine ASW_CEU  ASW CEU   
Total clearance of 
cotinine, the fractional 
conversion of nicotine 
to cotinine, and the 
metabolic clearance of 
nicotine to cotinine 
were all significantly 






on of nicotine 
and cotinine. 
 





Pathway Nicotine JPT_ASW  ASW JPT   
Decrease nicotine-to-
cotinine metabolism in 









Pathway Nicotine JPT_CEU  CEU JPT   
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cotinine metabolism in 









Pathway Nicotine JPT_KOREAN 
KOREA
N JPT   
Decrease nicotine-to-
cotinine metabolism in 
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Cell) to cotinine, and the 
metabolic clearance of 
nicotine to cotinine 
were all significantly 
lower in Blacks than in 
Caucasians 
glucuronidati
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Pathway Phenytoin JPT_CEU  JPT CEU   
Approximately  four- to 
fivefold more Asians 









Pathway Phenytoin ASW_CEU  ASW CEU   
Phenytoin metabolism 
is slowed in Black as 
compared to Caucasian 
individuals 
Edeki et al  











ASW_CEU  ASW CEU   
Different reduction of 
blood pressure Brewster et al  


















and paclitaxel JPT_CEU    JPT 
To support this 
approach, they have 
published data 
comparing toxicity and 
response for similar 
chemotherapy regimens 
used in Asian and 
Caucasian cohorts 




64. Epub 2006 
Jun 15. 
Platinum Carboplatin, JPT_CEU JPT Neutropenia in patients Sekine et al  Br J Cancer. 







receiving a combination 
of platinum and 
antimicrotubule agents 
may be more severe in 





62. Epub 2008 
Nov 4. 
Platinum 
Pathway Paclitaxel JPT_CEU  JPT CEU   
Paclitaxel sensitivity in 










Inhibitor (PD) Omeprazole CHB_CEU  CHB CEU   
The AUC values noted 
in the Chinese group 
were significantly 
higher than those in the 
Caucasian group 






Inhibitor (PK) Omeprazole CHB_CEU  CHB CEU   
The AUC values noted 
in the Chinese group 
were significantly 
higher than those in the 
Caucasian group 











Enalapril ASW_CEU  CEU ASW   
Hypertension and 
hospitalization for heart 
failure reduced in 
Whites but not in 
Blacks with left 
ventricular dysfunction 
Exner et al  










desartan ASW_CEU  CEU ASW   
White individuals 
demonstrated a strong, 
significant correlation 
between responses to 
these drugs (r = 0.78, P 
= 0.008) and a 
significantly greater 
increase in the renal 
plasma flow in response 
Forman et al  











Enalapril CHS_MAS      
Ethnic distribution of ADR reports 
showed statistically significant 







Enalapril CHS_INS      
Ethnic distribution of ADR reports 
showed statistically significant 







Enalapril MAS_INS      
Ethnic distribution of ADR reports 
showed statistically significant 









Fluoxetine Latinos-ASW-CEU CEU ASW   
Attrition was greater 
among Latinos than 
either blacks or whites. 
Black patients were 
more likely than whites 
to be nonresponders to 
fluoxetine. Latinos 
were more likely to 
respond to placebo 
compared with blacks 
and whites. 










Statins CHB_CEU  CHB CEU   
Higher plasma levels of 
statins in Asians 
compared with 
Caucasians 
Liao JK  
Am J Cardiol. 
2007 Feb 
1;99(3):410-4. 
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Higher plasma levels of 
statins in Asians 
compared with 
Liao JK  
Am J Cardiol. 
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Epub 2006 Dec 
15. 
Statin Pathway 
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Isoproterenol ASW_CEU  CEU ASW   
Vasodilation response 
to isoproterenol 
markedly lower in 
Blacks 









Propranolol MAS_CHS  MAS CHS   
Malays to have 
significantly greater 
propranolol responses 
compared to Chinese 
healthy male subjects 
Rasool et al  










Nitroglycerin ASW_CEU  CEU ASW   
Lower transdermal 
availability of 
nitroglycerin in 4 Black 
subjects as opposed to 
12 Caucasian and Asian 
subjects 






Nitroglycerin ASW_CEU  CHB ASW   
Lower transdermal 
availability of 
nitroglycerin in 4 Black 
subjects as opposed to 
12 Caucasian and Asian 
subjects 
Williams et al  Pharm Res. 1991 Jun;8(6):744-9. 








Nitroglycerin ASW_CEU  JPT ASW   
Lower transdermal 
availability of 
nitroglycerin in 4 Black 
subjects as opposed to 
12 Caucasian and Asian 
subjects 






Propranolol CHB_CEU  CHB CEU   
Chinese men had a 2- to 
3-fold greater 
sensitivity to 
propranolol's effect on 
heart rate and a 10-fold 
greater sensitivity to the 
BP effect than 
Caucasian men. 
Zhou et al  








Beta-blockers ASW_CEU  ASW CEU   Different reduction of blood pressure  








Beta-blockers ASW_CEU  ASW CEU   Different reduction of blood pressure  








Propranolol ASW_CEU  CEU ASW   
Antihypertensive effect greater in 
Whites  








Propranolol CHB_CEU  CHB CEU   
Chinese twice as sensitive to effects on 
blood pressure and heart rate  






Nicotine ASW_MEX  ASW CEU   
Blacks have a higher 
exposure to nicotine 
and cotinine than 
Caraballo et 
al  
JAMA. 1998 Jul 
8;280(2):135-9. 














Nicotine ASW_CEU  ASW MEX   
Blacks have a higher 
exposure to nicotine 













Nicotine ASW_CEU  ASW CEU   
Total clearance of 
cotinine, the fractional 
conversion of nicotine 
to cotinine, and the 
metabolic clearance of 
nicotine to cotinine 
were all significantly 






on of nicotine 
and cotinine. 
 










Nicotine JPT_ASW  ASW JPT   
Decrease nicotine-to-
cotinine metabolism in 
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Decrease nicotine-to-
cotinine metabolism in 














Nicotine JPT_KOREAN KOREAN JPT   
Decrease nicotine-to-
cotinine metabolism in 








Taxane  Taxane Docetaxel ASW_CEU CEU-   Docetaxel clearance Lewis et al  Clin Cancer Res 
   
294 
 











and paclitaxel JPT_CEU    JPT 
To support this 
approach, they have 
published data 
comparing toxicity and 
response for similar 
chemotherapy regimens 
used in Asian and 
Caucasian cohorts 













JPT_CEU    JPT 
Neutropenia in patients 
receiving a combination 
of platinum and 
antimicrotubule agents 
may be more severe in 
Japanese than in 
Europeans and 
Americans 
Sekine et al  
Br J Cancer. 
2008 Dec 
2;99(11):1757-
62. Epub 2008 
Nov 4. 
Taxane 
Pathway Paclitaxel JPT_CEU  JPT CEU   
paclitaxel sensitivity in 














CEU     
There were no 
significant differences 
in treatment response 
between Asians and 
Caucasians. Adefovir 
dipivoxil was well 
tolerated and no 
resistance developed up 
to week 48 in both 
racial groups 
Lim et al  





Pathway Azathioprine ASW_CEU  ASW CEU   
Racial differences are 
likely to be a minor 
determinant in 
concentrations; 
however, a greater 




Chocair et al  




Pathway Azathioprine JPT_CEU  JPT CEU   
Racial differences are 
likely to be a minor 
determinant in 
concentrations; 
however, a greater 




Chocair et al  






Alkaloids (PK) Vincristine ASW_CEU    CEU 
Neurotoxicity more 
common in CAU 







Warfarin   
Warfarin 
Pathway (PD) Warfarin 
Afro_Caribbeans, non_Far East Asians 
and Caucasians   
Greater daily warfarin 
dose requirements in 
Afro-Caribbeans 
compared with non–Far 
East Asians and 
Caucasians 
Blann et al  
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Warfarin 
Pathway (PD) Warfarin CHB_CEU  CHB CEU   
Asians might require a 
lower INR for 
protection from 
thromboembolism and 
might be at increased 
risk of bleeding at 
lower INRs 






Pathway (PD) R-warfarin JPT_CEU  JPT CEU   
CYP2C19 is involved 
in the metabolism of Phan et al  
Expert Opin 
Drug Metab 







antidepressants, all of 
which are commonly 




Pathway (PD) Warfarin CHB_CEU  CHB CEU   
Chinese patients have 
been reported to have 
lower daily warfarin 
dose requirements than 
what has been reported 
for similarly 
anticoagulated patients 
in the United States and 
the United Kingdom 
Yu et al  
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which are commonly 
used in cancer patients.
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Chinese patients have 
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 Exon Intron 
NA Grand Total 
1 2 3 4 5 6 7 8 9 10 1 2 3 4 5 6 7 8 9 10 11 13 14 19 
ATAT1       1                               3                   4 
  NM_001031722.2                                       1                   1 
  NM_001254952.1                                       1                   1 
  NM_014046.3       1                                                   1 
  NM_024909.2                                       1                   1 
C6orf136 3 1   11                       2                           17 
  NM_001031722.2       3                                                   3 
  NM_001109938.2 1                             1                           2 
  NM_001161376.1 1                             1                           2 
  NM_001164239.1       3                                                   3 
  NM_001254952.1       1                                                   1 
  NM_003587.4       3                                                   3 
  NM_024909.2       1                                                   1 
  NM_145029.3 1 1                                                       2 
C6orf15 8     9 3                                                 20 
  NM_001264.4       8                                                   8 
  NM_014068.2 8                                                         8 
  NM_014070.2       1 3                                                 4 
CCHCR1                                               3           3 
  NM_001105563.1                                               1           1 
   
301 
 
  NM_001105564.1                                               1           1 
  NM_019052.3                                               1           1 
CDSN 37 12 18 1   10                 30                             108 
  NM_001264.4   12 18 1   10                                               41 
  NM_014068.2 2                           30                             32 
  NM_014070.2 35                                                         35 
DDR1 18                               3 1 1 1       2 2 2       30 
  NM_001202521.1 2                               1             1           4 
  NM_001202522.1 2                               1             1           4 
  NM_001202523.1 4                                 1             1         6 
  NM_001954.4 4                                     1           1       6 
  NM_013993.2 4                                   1             1       6 
  NM_013994.2 2                               1               1         4 
DHX16 4     9                                 2             2   17 
  NM_001109938.2       1                                                   1 
  NM_001134870.1       3                                                   3 
  NM_001161376.1       1                                                   1 
  NM_001164239.1 2                                       1             1   4 
  NM_003587.4 2                                       1             1   4 
  NM_133471.3       3                                                   3 
  NM_145029.3       1                                                   1 
DPCR1 3 2 1   2                   4                             12 
  NM_080870.3 3 2 1   2                   4                             12 
FLOT1                                   5       15               20 
  NM_005803.2                                   5       15               20 
GTF2H4 1     6                                                   7 
  NM_001202521.1       1                                                   1 
  NM_001202522.1       1                                                   1 
  NM_001202523.1       1                                                   1 
   
302 
 
  NM_001517.4 1                                                         1 
  NM_001954.4       1                                                   1 
  NM_013993.2       1                                                   1 
  NM_013994.2       1                                                   1 
HCG18 27                                                         27 
  NM_001199119.1 3                                                         3 
  NM_021253.3 12                                                         12 
  NM_172016.2 12                                                         12 
HLA-C 16   2 6     6 10 4   4         9 12 14 27 6 6               1 123 
  NM_001243042.1 8   1 2     3 5 2   2         4 6 7 13 3 3                 59 
  NM_002117.5 8   1 4     3 5 2   2         5 6 7 14 3 3               1 64 
MDC1 2     1                     1                       1     5 
  NM_014641.2       1                     1                       1     3 
  NM_178014.2 2                                                         2 
MRPS18B 1                                 1                       2 
  NM_002714.3 1                                                         1 
  NM_014046.3                                   1                       1 
MUC21 1   3     1                                               5 
  NM_001010909.2     3     1                                               4 
  NM_001198815.1 1                                                         1 
MUC22                             1 6                           7 
  NM_001198815.1                             1 6                           7 
POU5F1       4                     1 2                           7 
  NM_001077511.1       2                                                   2 
  NM_001173531.1                               1                           1 
  NM_002701.4                               1                           1 
  NM_007109.2       2                                                   2 
  NM_203289.4                             1                             1 
PPP1R10                               1           1               2 
   
303 
 
  NM_002714.3                               1           1               2 
PPP1R11 2     14                                                   16 
  NM_001278785.1       2                                                   2 
  NM_001278786.1       2                                                   2 
  NM_014596.5       2                                                   2 
  NM_021959.2 2                                                         2 
  NM_025236.3       3                                                   3 
  NM_170769.2       3                                                   3 
  NM_170783.3       2                                                   2 
PPP1R18       15 3                   3                             21 
  NM_001134870.1                             3                             3 
  NM_001270707.1       3                                                   3 
  NM_001270708.1       3                                                   3 
  NM_001270709.1       3                                                   3 
  NM_001270710.1       3                                                   3 
  NM_007243.2       3                                                   3 
  NM_133471.3         3                                                 3 
PRR3 1                             1 1                         3 
  NM_001077497.2                               1                           1 
  NM_005275.3 1                                                         1 
  NM_025263.3                                 1                         1 
PSORS1C1 1   1 18                         4                         24 
  NM_001105563.1       5                                                   5 
  NM_001105564.1       5                                                   5 
  NM_014068.2     1                           4                         5 
  NM_014069.2 1     3                                                   4 
  NM_019052.3       5                                                   5 
PTMAP1                                       9                   9 
  NM_001031722.2                                       3                   3 
   
304 
 
  NM_001254952.1                                       3                   3 
  NM_024909.2                                       3                   3 
RNF39       2                     2                             4 
  NM_021959.2       2                                                   2 
  NM_025236.3                             1                             1 
  NM_170769.2                             1                             1 
RPP21 6   7 40         14     1   5     6 3       2 1             85 
  NM_001199119.1     1 1               1   5               2 1             11 
  NM_001199120.1 2   1 1         7               2 1                       14 
  NM_001199121.1 2   4 1                         2 1                       10 
  NM_021253.3       18                                                   18 
  NM_024839.2 2   1 1         7               2 1                       14 
  NM_172016.2       18                                                   18 
SFTA2 5                                                         5 
  NM_205854.2 5                                                         5 
TRIM10 6 2 26 21                                                   55 
  NM_006778.3   1 13 1                                                   15 
  NM_033229.2 6                                                         6 
  NM_052828.2   1 13 1                                                   15 
  NM_138700.3       19                                                   19 
TRIM15 12                           1       1                     14 
  NM_006778.3 6                                                         6 
  NM_033229.2                             1       1                     2 
  NM_052828.2 6                                                         6 
TRIM26   6 2 2       4             2 6 4 1 11 10                   48 
  NM_001242783.1   6 1 1                     1 4   1 10                     24 
  NM_003449.4     1 1       4             1 2 4   1 10                   24 
TRIM31                                     3 7                   10 
  NM_007028.3                                     3 7                   10 
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TRIM39 31 4   6           1   1 1       3   6 4                   57 
  NM_001199119.1 8                 1             3     4                   16 
  NM_001199120.1 5                                                         5 
  NM_001199121.1 5                                                         5 
  NM_021253.3 4 2   3                 1           3                     13 
  NM_024839.2 5                                                         5 
  NM_172016.2 4 2   3               1             3                     13 
TRIM39-RPP21 12   3 16         14 1   2 1 5                               54 
  NM_001199119.1                   1   1   5                               7 
  NM_001199120.1 4               7                                         11 
  NM_001199121.1 4   3                                                     7 
  NM_021253.3       8                 1                                 9 
  NM_024839.2 4               7                                         11 
  NM_172016.2       8               1                                   9 
TRIM40 6 29 1 22         1           8 2   1                       70 
  NM_006778.3       10                                                   10 
  NM_052828.2       10                                                   10 
  NM_138700.3 6 29 1 2         1           8 2   1                       50 
VARS2   2   2   4                                       1 2     11 
  NM_001167733.1   2                                               1       3 
  NM_001167734.1           2                                         1     3 
  NM_001517.4       2                                                   2 
  NM_020442.4           2                                         1     3 
ZNRD1 2                               1 3                       6 
  NM_001278785.1                                   1                       1 
  NM_001278786.1                                   1                       1 
  NM_014596.5                                   1                       1 
  NM_021959.2 2                                                         2 
  NM_170783.3                                 1                         1 
   
306 
 
License Agreement from Springer 
 
 


















   
310 
 




   
311 
 
 
